ID,GeneID,SeqNo,Drug,GeneName,ApprovalLevel,AddedByUser,PrimaryReference,ReviewReferece,SecondaryReference,NucleotidePosition,Polymorphism,EstimatedCodonPosition,ReportedCodonPosition,AminoAcid,Note,TimePeriod,StudyPopulation,Country,MolecularDetectionMethod,GeneCoverage,ResistancePattern,MIC,SusceptibilityTestingMethod,RTotalIsolates,RSIsolatesWMutation,AdditionalMutations,HighQuality,PMID,OverallSequentialNumber,NoHC,Temp1,Temp2,Temp3,Temp4,Temp5,MutationType
1,Rv3795,76,EMB,embB,,,Srivastava S JMM 2009,,,1109-1110,CTG/CGT,370,370,Leu/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB V377M  E378A  F398H  N399H  E405P  G406A,0,19010731,955,0,,,,,,
2,Rv3795,77,EMB,embB,,,Srivastava S JMM 2009,,,1112-1113,CCG/CGT,371,371,Pro/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  A356S  E378K; embR R230W  L292M  L303E,0,19010731,956,0,,,,,,
3,Rv3795,78,EMB,embB,,,Srivastava S JMM 2009,,,1121-1122,GGC/GTG,374,374,Gly/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,4ug/ml,Proportion method  E-Test,44/44,1/0,embC W395C  N400P; embC G288W  V303G; embR A187V  R230W  I369T,0,19010731,957,0,,,,,,
4,Rv3795,79,EMB,embB,,,Srivastava S JMM 2009,,,1123-1124,CCG/GCG,375,375,Pro/Ala,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  V309G  A310R  D311R  V369A  F398Y  P461S; embC T270I; embR G240R,0,19010731,958,0,,,,,,
5,Rv3795,80,EMB,embB,,,Srivastava S JMM 2009,,,1129,GTG/ATG,377,377,Val/Met,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB L370R  E378A  F398H  N399H  E405P  G406A,0,19010731,959,0,,,,,,
6,Rv3795,81,EMB,embB,,,Srivastava S JMM 2009,,,1130-1131,GTG/GGC,377,377,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,256ug/ml,Proportion method  E-Test,44/44,1/0,embB L239P  Y315L  N318S  E378A  Y384N  N400K  V452L,0,19010731,960,0,,,,,,
7,Rv3795,82,EMB,embB,,,Srivastava S JMM 2009,,,1132,GAA/AAA,378,378,Glu/Lys,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  A356S  P371R; embR R230W  L292M  L303E,0,19010731,961,0,,,,,,
8,Rv3795,83,EMB,embB,,,Srivastava S CurrMicro 2006,,,1103-1104,GAA/GCG,378,378,Glu/Ala,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,2ug/ml,Proportion method,23/23,2/0,Both of these isolates were mutated at embB Asp299Glu. One was also mutated at embB Pro446His and Ile465Asp  as well as embC Thr270Ile and 254 Synonymous (GCC/GCG). The other isolate was mutated at embBArg469Pro and Arg 471Pro. R/Tot and R/S calculated fr,0,16972132,962,0,,,,,,
9,Rv3795,84,EMB,embB,,,Srivastava S JMM 2009,,,1135-1137,GCG/ACC,379,379,Ala/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S; embC V287F  Y309N; embR L320V S326N  V350G  H351Q  R356G  I369T,0,19010731,963,0,,,,,,
10,Rv3795,85,EMB,embB,,,Srivastava S JMM 2009,,,1136-1137,GCG/GAT,379,379,Ala/Asp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,8ug/ml,Proportion method  E-Test,44/44,1/0,embB A356F  A357V  L359I  E378A  Y384N  A388G  N399D  G406P; embC A247P  T270I  I297T,0,19010731,964,0,,,,,,
11,Rv3795,86,EMB,embB,,,Srivastava S CurrMicro 2006,,,1138-1140,AGC/CGT,380,380,Ser/Arg,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,32ug/ml,Proportion method,23/23,1/0,Met306Val  Glu368Ala  and Pro397Gln on embB. R/Tot and R/S calculated from Table 1.,0,16972132,965,0,,,,,,
12,Rv3795,87,EMB,embB,,,Srivastava S JMM 2009,,,1139,AGC/AAC,380,380,Ser/Asp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,3ug/ml,Proportion method  E-Test,44/44,1/0,embB G358V  E368Q  P397T  G406D  G448V; embC I287L  W326R,0,19010731,966,0,,,,,,
13,Rv3795,88,EMB,embB,,,Srivastava S JMM 2009,,,1150-1152,TAT/AAC,384,384,Tyr/Asn,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,256ug/ml,Proportion method  E-Test,44/44,1/0,embB L239P  Y315L  N318S  V377G  E378A   N400K  V452L,0,19010731,967,0,,,,,,
14,Rv3795,89,EMB,embB,,,Srivastava S JMM 2009,,,1163-1164,GCG/GGC,388,388,Ala/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,8ug/ml,Proportion method  E-Test,44/44,1/0,embB A356F  A357V  L359I  E378A  A379D  Y384N  N399D  G406P; embC A247P  T270I  I297T,0,19010731,968,0,,,,,,
15,Rv3795,90,EMB,embB,,,Srivastava S JMM 2009,,,1183-1185,TGG/CGT,395,395,Trp/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  A356V  S366P  A434G  V435G  V436G  T437A; embC T270I,0,19010731,969,0,,,,,,
16,Rv3795,91,EMB,embB,,,Srivastava S JMM 2009,,,1185,TGG/TGC,395,395,Trp/Cys,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,4ug/ml,Proportion method  E-Test,44/44,1/0,embC G374V  N400P; embC G288W  V303G; embR A187V  R230W  I369T,0,19010731,970,0,,,,,,
17,Rv3795,92,EMB,embB,,,Srivastava S JMM 2009,,,1189-1190,CCG/ACC,397,397,Pro/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,3ug/ml,Proportion method  E-Test,44/44,1/0,embB G358V  E368Q  S380D  G406D  G448V; embC I287L  W326R,0,19010731,971,0,,,,,,
18,Rv3795,93,EMB,embB,,,Srivastava S CurrMicro 2006,,,1190,CCG/CAG,397,397,Pro/Gln,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,32ug/ml,Proportion method,23/23,1/0,Met306Val  Glu368Ala  and Ser380Arg on embB. R/Tot and R/S calculated from Table 1.,0,16972132,972,0,,,,,,
19,Rv3795,94,EMB,embB,,,Srivastava S JMM 2009,,,1192-1193,TTT/CAT,398,398,Phe/His,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB L370R  V377M  E378A  N399H  E405P  G406A,0,19010731,973,0,,,,,,
20,Rv3795,95,EMB,embB,,,Srivastava S JMM 2009,,,1193,TTT/TAT,398,398,Phe/Tyr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  V309G  A310R  D311R  V369A  P375A  P461S; embC T270I; embR G240R,0,19010731,974,0,,,,,,
21,Rv3795,96,EMB,embB,,,Srivastava S JMM 2009,,,1195-1196,TTT/GAT,399,399,Asn/Asp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,8ug/ml,Proportion method  E-Test,44/44,1/0,embB A356F  A357V  L359I  E378A  A379D  Y384N  A388G  G406P; embC A247P  T270I  I297T,0,19010731,975,0,,,,,,
22,Rv3795,97,EMB,embB,,,Srivastava S JMM 2009,,,1195-1196,TTT/CAT,399,399,Asn/His,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB L370R  V377M  E378A  F398H  E405P  G406A,0,19010731,976,0,,,,,,
23,Rv3795,98,EMB,embB,,,Srivastava S JMM 2009,,,1198-1200,AAC/CCG,400,400,Asn/Pro,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,4ug/ml,Proportion method  E-Test,44/44,1/0,embC G374V  W395C; embC G288W  V303G; embR A187V  R230W  I369T,0,19010731,977,0,,,,,,
24,Rv3795,99,EMB,embB,,,Srivastava S JMM 2009,,,1200,AAC/AAA,400,400,Asn/Lys,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,256ug/ml,Proportion method  E-Test,44/44,1/0,embB L239P  Y315L  N318S  E378A  Y384N  V452L,0,19010731,978,0,,,,,,
25,Rv3795,100,EMB,embB,,,Srivastava S JMM 2009,,,1203,ACG/ACA,401,401,Gly/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,ER,16ug/ml,Proportion method  E-Test,44/44,1/0,embB G331R  G374V  G374V; embC I297T; embR D223E,0,19010731,979,0,,,,,,
26,Rv3795,101,EMB,embB,,,Srivastava S JMM 2009,,,1213-1214,GAA/CCG,405,405,Glu/Pro,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB L370R  V377M  E378A  F398H  N399H  G406A,0,19010731,980,0,,,,,,
27,Rv3795,102,EMB,embB,,,Srivastava S JMM 2009,,,1216,GGC/CCG,406,406,Gly/Pro,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,8ug/ml,Proportion method  E-Test,44/44,1/0,embB A356F  A357V  L359I  E378A  A379D  Y384N  A388G  N399D; embC A247P  T270I  I297T,0,19010731,981,0,,,,,,
28,Rv3795,103,EMB,embB,,,Ramaswamy SV AAC 2000,,,1216,GGC/AGC,406,406,Gly/Ser,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,-43 CG deletion in embA.,1,10639358,982,13,,,,,,
29,Rv3795,104,EMB,embB,,,Ramaswamy SV AAC 2000,,,1216,GGC/TGC,406,406,Gly/Cys,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30-50ug/ml,BACTEC 460  agar diffusion method,75/108,2/0,,0,10639358,983,0,,,,,,
30,Rv3795,105,EMB,embB,,,Srivastava S JMM 2009,,,1217,GGC/GAT,406,406,Gly/Asp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,3ug/ml,Proportion method  E-Test,44/44,1/0,embB G358V  E368Q  S380D  P397T  G448V; embC I287L  W326R,0,19010731,984,0,,,,,,
31,Rv3795,106,EMB,embB,,,Ramaswamy SV AAC 2000,,,1217,GGC/GAC,406,406,Gly/Asp,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,40ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Asp4Asn in embA,1,10639358,985,13,,,,,,
32,Rv3795,107,EMB,embB,,,Ramaswamy SV AAC 2000,,,1217,GGC/GCC,406,406,Gly/Ala,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,20ug/ml,BACTEC 460  agar diffusion method,75/108,2/0,In one of the isolates  -11 C/A in embA and Met306Ile in embB.,0,10639358,986,0,,,,,,
33,Rv3795,108,EMB,embB,,,Srivastava S CurrMicro 2006,,,1190,GGC/GCG,406,406,Gly/Ala,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,32ug/ml,Proportion method,23/23,1/0,Met306Val  Glu368Ala  and Ser380Arg on embB. R/Tot and R/S calculated from Table 1.,0,16972132,987,0,,,,,,
34,Rv3795,109,EMB,embB,,,Lee AS AAC 2004,,,1269,ATG/ATA,423,423,Met/Ile,,Published 2004,EMB-R (n=25) and EMB-S (n=20) isolates. Total N=45.,Singapore,Sequencing,Whole gene,EI,N.S.,BACTEC 460,25/45,1/0,None in region amplified (see Gene coverage).,0,15504879,988,13,,,,,,
35,Rv3795,110,EMB,embB,,,Srivastava S JMM 2009,,,1289,CCG/CTG,430,430,Pro/Leu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB G406D  A431T; embC I297T,0,19010731,989,0,,,,,,
36,Rv3795,111,EMB,embB,,,Srivastava S JMM 2009,,,1291-1293,GCG/ACC,431,431,Ala/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB G406D P430L; embC I297T,0,19010731,990,0,,,,,,
37,Rv3795,112,EMB,embB,,,Srivastava S JMM 2009,,,1301-1302,GCG/GGC,434,434,Arg/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  A356V  S366P  W395R  V435G  V436G  T437A; embC T270I,0,19010731,991,0,,,,,,
38,Rv3795,113,EMB,embB,,,Srivastava S JMM 2009,,,1304-1305,GTG/GGC,435,435,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  A356V  S366P  W395R  A434G  V436G  T437A; embC T270I,0,19010731,992,0,,,,,,
39,Rv3795,114,EMB,embB,,,Srivastava S JMM 2009,,,1307-1308,GTG/GGC,436,436,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  A356V  S366P  W395R  A434G  V435G  T437A; embC T270I,0,19010731,993,0,,,,,,
40,Rv3795,115,EMB,embB,,,Srivastava S JMM 2009,,,1309-1311,ACC/GCG,437,437,Thr/Ala,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  A356V  S366P  W395R  A434G  V435G  V436G; embC T270I,0,19010731,994,0,,,,,,
41,Rv3795,116,EMB,embB,,,Srivastava S CurrMicro 2006,,,1337-1338,CCG/CAT,446,446,Pro/His,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,2ug/ml,Proportion method  E-Test,23/23,1/0,Asp299Glu  Glu378Ala  and Ile465Asp in embB; Thr270Ile and 254 Synonymous (GCC/GCG) in embC. R/T and R/S calculated from Table 1.,0,16972132,995,0,,,,,,
42,Rv3795,117,EMB,embB,,,Srivastava S JMM 2009,,,1343-1344,GGC/GTG,448,448,Gly/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,3ug/ml,Proportion method  E-Test,44/44,1/0,embB G358V  E368Q  S380D  P397T  G406D; embC I287L  W326R,0,19010731,996,0,,,,,,
43,Rv3795,118,EMB,embB,,,Srivastava S JMM 2009,,,1354,GTG/CTG,452,452,Val/Leu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,256ug/ml,Proportion method  E-Test,44/44,1/0,embB L239P  Y315L  N318S  E378A  Y384N  N400K,0,19010731,997,0,,,,,,
44,Rv3795,119,EMB,embB,,,Srivastava S JMM 2009,,,1376-1377,GGC/GCG,459,459,Gly/Ala,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,32ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  N318K  N368A  S380R  P397Q   R460C; embR T32P  D53H,0,19010731,998,0,,,,,,
45,Rv3795,120,EMB,embB,,,Srivastava S JMM 2009,,,1378-1380,CGT/TGC,460,460,Arg/Cys,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB E368A  S380R  P397Q; embC A244T  G288W  V303G embR L172R,0,19010731,999,0,,,,,,
46,Rv3795,121,EMB,embB,,,Srivastava S JMM 2009,,,1379-1380,CGT/CTG,460,460,Arg/Leu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB S347I  E368D; embC I297T; embR R230W  I396T,0,19010731,1000,0,,,,,,
47,Rv3795,122,EMB,embB,,,Srivastava S JMM 2009,,,1381-1383,CCG/AGC,461,461,Pro/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  V309G  A310R  D311R  V369A  P375A  F398Y; embC T270I; embR G240R,0,19010731,1001,0,,,,,,
48,Rv3795,123,EMB,embB,,,Srivastava S CurrMicro 2006,,,1393-1394,ATT/GAT,465,465,Ile/Asp,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,2ug/ml,Proportion method  E-Test,23/23,1/0,Asp299Glu  Glu378Ala  and Pro446His in embB; Thr270Ile and 254 Synonymous (GCC/GCG) in embC. R/T and R/S calculated from Table 1.,0,16972132,1002,0,,,,,,
49,Rv3795,124,EMB,embB,,,Srivastava S CurrMicro 2006,,,1406-1407,CGT/CCG,469,469,Arg/Pro,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,2ug/ml,Proportion method  E-Test,23/23,1/0,Asp299Glu  Glu378Ala  and Arg471Pro in embB. R/T and R/S calculated from Table 1.,0,16972132,1003,0,,,,,,
50,Rv3795,125,EMB,embB,,,Srivastava S CurrMicro 2006,,,1412-1413,CGT/CCG,471,471,Arg/Pro,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,2ug/ml,Proportion method  E-Test,23/23,1/0,Asp299Glu  Glu378Ala  and Arg469Pro in embB. R/T and R/S calculated from Table 1.,0,16972132,1004,0,,,,,,
51,Rv3795,126,EMB,embB,,,Ramaswamy SV AAC 2000,,,1490,CAG/CGG,497,497,Gln/Arg,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30-50ug/ml,BACTEC 460  agar diffusion method,75/108,3/0,In one of the isolates: -12 C/T in embA  Ser501Trp in iniA.,1,10639358,1005,13,,,,,,
52,Rv3795,127,EMB,embB,,,Ramaswamy SV AAC 2000,,,1490,CAG/AAG,497,497,Gln/Lys,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30-50ug/ml,BACTEC 460  agar diffusion method,75/108,2/0,-12 C/T in embA at MIC=30ug/ml; -89 C/T in iniB at MIC>50ug/ml.,0,10639358,1006,0,,,,,,
53,Rv3795,128,EMB,embB,,,Sreevatsan S AAC 1997,,,1889,ACC/ATC,630,630,Thr/Ile,Found in two epidemiologically related resistant strains.,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,>40ug/ml,BACTEC 460  agar diffusion method,69/99,2/0,,0,9257740,1007,0,,,,,,
54,Rv3795,129,EMB,embB,,,Lee AS AAC 2004,,,1975,GCG/ACG,659,659,Ala/Thr,,Published 2004,EMB-R (n=25) and EMB-S (n=20) isolates. Total N=45.,Singapore,Sequencing,Whole gene,ES,N.S.,BACTEC 460,25/45,0/1,None in region amplified (see Gene coverage).,0,15504879,1008,0,,,,,,
55,Rv3795,130,EMB,embB,,,Ramaswamy SV AAC 2000,,,2234,GGC/GAC,745,745,Gly/Asp,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,40ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Gly308Arg in iniA,0,10639358,1009,13,,,,,,
56,Rv3795,131,EMB,embB,,,Ramaswamy SV AAC 2000,,,2876,GAC/GCC,959,959,Asp/Ala,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,1010,0,,,,,,
57,Rv3795,132,EMB,embB,,,Ramaswamy SV AAC 2000,,,2999,ATG/AGG,1000,1000,Met/Arg,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,1011,0,,,,,,
58,Rv3795,133,EMB,embB,,,Ramaswamy SV AAC 2000,,,3070,GAC/AAC,1024,1024,Asp/Asn,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,1012,0,,,,,,
59,Rv1267c,1,EMB,embR,,,Ramaswamy SV AAC 2000,,,-273,ins A,-273,-273,intergenic,Hypothesis cited in paper: if embR is a transcription regulator for embAB  then an over-active mutant form will produce enough arabinosyltransferase to compensate for given level of ethambutol  resulting in de facto resistance. Needs more evidence.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,20-40ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,1013,0,,,,,,
60,Rv1267c,2,EMB,embR,,,Srivastava S JMM 2009,,,20-21,GTG/GGC,7,7,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,48ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M; embC A247P  I297L  W326R,0,19010731,1014,0,,,,,,
61,Rv1267c,3,EMB,embR,,,Srivastava S JMM 2009,,,94-96,ACC/CCG,32,32,Thr/Pro,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,32ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  N318K  E368A  S380R  P397Q  G459A  R460C; embR D53H,0,19010731,1015,0,,,,,,
62,Rv1267c,4,EMB,embR,,,Srivastava S JMM 2009,,,157,GAT/CAT,53,53,Asp/His,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,32ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  N318K  E368A  S380R  P397Q  G459A  R460C; embR T32P,0,19010731,1016,0,,,,,,
63,Rv1267c,5,EMB,embR,,,Srivastava S JMM 2009,,,329-330,TGC/TAT,110,110,Cys/Tyr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,8ug/ml,Proportion method  E-Test,44/44,1/0,embC G288W  V303G,0,19010731,1017,0,,,,,,
64,Rv1267c,6,EMB,embR,,,Srivastava S JMM 2009,,,515-516,CTG/CGT,172,172,Leu/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB E368A  S380R  P397Q  R460C; embC A244T  G288W  V303G,0,19010731,1018,0,,,,,,
65,Rv1267c,7,EMB,embR,,,Srivastava S JMM 2009,,,527,GCG/GTG,176,176,Ala/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M  A431T; embC G272S  H285Y  M300R  A307T; embR I369T,0,19010731,1019,0,,,,,,
66,Rv1267c,8,EMB,embR,,,Srivastava S JMM 2009,,,556-558,CGT/GGC,186,186,Arg/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,24ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  E368A  S380R  P397Q  R460C; embC I297T; embR S188R  E200A  L211M,0,19010731,1020,0,,,,,,
67,Rv1267c,9,EMB,embR,,,Srivastava S JMM 2009,,,559-560,GCG/GTG,187,187,Ala/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB G374V  W395C  N400P; embC G288W  V303G; embR R230W  I369T,0,19010731,1021,0,,,,,,
68,Rv1267c,10,EMB,embR,,,Srivastava S JMM 2009,,,541-543,AGC/CGT,188,188,Ser/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  E378A  R469P  R471P; embR L211M  L320V,0,19010731,1022,0,,,,,,
69,Rv1267c,11,EMB,embR,,,Srivastava S JMM 2009,,,599-600,GAA/GCG,200,200,Glu/Ala,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,24ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  E368A  S380R  P397Q  R460C; embC I297T; embR S186G  S188R  L211M,0,19010731,1023,0,,,,,,
70,Rv1267c,12,EMB,embR,,,Srivastava S JMM 2009,,,631,CTG/ATG,211,211,Leu/Met,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  E378A  R469P  R471P; embR S188R  L320V,0,19010731,1024,0,,,,,,
71,Rv1267c,13,EMB,embR,,,Srivastava S JMM 2009,,,669,GAT/GAA,223,223,Asp/Glu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,16ug/ml,Proportion method  E-Test,44/44,1/0,embB G331R  V360M  G374V  G401S; embC I297T,0,19010731,1025,0,,,,,,
72,Rv1267c,14,EMB,embR,,,Srivastava S JMM 2009,,,688-690,CGT/TGG,230,230,Arg/Trp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB S347I  E368D  R460L; embC I297T; embR I396T,0,19010731,1026,0,,,,,,
73,Rv1267c,15,EMB,embR,,,Srivastava S JMM 2009,,,718-720,GGC/CGT,240,240,Gly/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  V309G  A319R  D311R  V369A  P375A  F398Y  P461S;  embC T270I,0,19010731,1027,0,,,,,,
74,Rv1267c,16,EMB,embR,,,Srivastava S JMM 2009,,,874,CTG/ATG,292,292,Leu/Met,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  A356S  P371R  E378K;  embR R230W  L303E,0,19010731,1028,0,,,,,,
75,Rv1267c,17,EMB,embR,,,Srivastava S JMM 2009,,,907-909,CTG/GAA,303,303,Leu/Glu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  A356S  P371R  E378K;  embR R230W  L292M,0,19010731,1029,0,,,,,,
76,Rv1267c,18,EMB,embR,,,Srivastava S JMM 2009,,,958,CTG/GTG,320,320,Leu/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  E378A  R469P  R471P; embR S188R  L211M,0,19010731,1030,0,,,,,,
77,Rv1267c,19,EMB,embR,,,Srivastava S JMM 2009,,,977,AGC/AAC,326,326,Ser/Asn,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S  A379T; embC V287F  Y309N; embR L320V  V350G  H351Q  R356G  I369T,0,19010731,1031,0,,,,,,
78,Rv1267c,20,EMB,embR,,,Srivastava S JMM 2009,,,1049-1050,GTG/GGC,350,350,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S  A379T; embC V287F  Y309N; embR L320V  S326N  H351Q  R356G  I369T,0,19010731,1032,0,,,,,,
79,Rv1267c,21,EMB,embR,,,Srivastava S JMM 2009,,,1053,CAT/CAG,351,351,His/Glu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S  A379T; embC V287F  Y309N; embR L320V  S326N  V350G  R356G  I369T,0,19010731,1033,0,,,,,,
80,Rv1267c,22,EMB,embR,,,Srivastava S JMM 2009,,,1066-1068,CGT/GGC,356,356,Arg/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S  A379T; embC V287F  Y309N; embR L320V  S326N  V350G  H351Q  I369T,0,19010731,1034,0,,,,,,
81,Rv1267c,23,EMB,embR,,,Srivastava S JMM 2009,,,1106-1107,ATT/ACC,369,369,Ile/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S  A379T; embC V287F  Y309N; embR L320V  S326N  V350G  H351Q  R356G,0,19010731,1035,0,,,,,,
82,Rv1267c,24,EMB,embR,,,Ramaswamy SV AAC 2000,,,1136,CAG/CGG,379,379,Gln/Arg,(If proposed mechanism is correct  would we expect to see synergistic action between resistance-conferring mutations in embR and in embAB? Look for evidence.),Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,20-40ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,1036,0,,,,,,
83,Rv1267c,25,EMB,embR,,,Srivastava S JMM 2009,,,1187-1188,ATT/ACC,396,396,Ile/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB S347I  E368D  R460L; embC I297T; embR R230W,0,19010731,1037,0,,,,,,
84,Rv3124,1,EMB,Rv3124,,,Ramaswamy SV AAC 2000,,,-16,A/G,-16,-16,intergenic,Role of change unclear  due to additional mutations.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Met306Ile in embB.,0,10639358,1038,0,,,,,,
85,Rv3125c,2,EMB,Rv3125c,,,Ramaswamy SV AAC 2000,,,,,54,54,Pro/Ser,Role of change unclear  due to additional mutations. This proline residue is conserved in the homologous region of EmbR. (Look for Pro mutations in embR?),Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,40ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Arg728Gln in embC  -16 C/T in embA  and  Met306Ile in embB.,0,10639358,1039,0,,,,,,
86,Rv3126,3,EMB,Rv3126,,,Ramaswamy SV AAC 2000,,,,,276,276,Leu/Arg,Role of change unclear  due to additional mutations.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Asn396Asp in embC  Gly350Asp and Pro913Ser in embA and -12 G deletion in Rv0340.,0,10639358,1040,0,,,,,,
87,Rv0340,1,EMB,Rv0340,,,Ramaswamy SV AAC 2000,,,-24,del G,-24,-24,Frameshift,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,N.S.,BACTEC 460  agar diffusion method,75/108,1/0,Asn396Asp in embC  Gly350Asp and Pro913Ser in embA  and Leu276Arg in Rv3124.,0,10639358,1041,0,,,,,,
88,Rv0340,2,EMB,Rv0340,,,Ramaswamy SV AAC 2000,,,,,173,173,Thr/Met,Probably does not confer resistance  but appears in association with additional mutations.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,N.S.,BACTEC 460  agar diffusion method,75/108,1/0,All three resistant isolates also had resistance-associated mutations in embC (n=1) or embB (n=3); see Note.,0,10639358,1042,0,,,,,,
89,Rv0341,1,EMB,iniB,,,Ramaswamy SV AAC 2000,,,-89,C/T,-89,-89,,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,>50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Gln497Lys in embB.,0,10639358,1043,0,,,,,,
90,Rv0341,2,EMB,iniB,,,Ramaswamy SV AAC 2000,,,,,47,47,Ala/Thr,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,1044,0,,,,,,
91,Rv0342,1,EMB,iniA,,,Ramaswamy SV AAC 2000,,,,,308,308,Gly/Arg,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,>50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Gly745Asp in embB,0,10639358,1045,0,,,,,,
92,Rv0342,2,EMB,iniA,,,Ramaswamy SV AAC 2000,,,,,501,501,Ser/Trp,Mutation found exclusively in resistant strains  though 5/7 also had mutations in other genes. Computer model says mutation hits the middle of a transmembrane helix (could change shape significantly; similar to proposed model of action for embB codon 306,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,>50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Two of the seven isolates had the single mutation only  with MICs>50ug/ml; the other five strains each had one or more of the following mutations  with MICs of 5-30ug/ml: one with -12 C/T in embA and Gln497Arg in embB; one with -16 C/G in embA; one with M,0,10639358,1046,0,,,,,,
93,Rv0343,1,EMB,iniC,,,Ramaswamy SV AAC 2000,,,,,248,248,Pro/Ala,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,5ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Ser501Trp in iniA.,0,10639358,1047,0,,,,,,
94,Rv0343,2,EMB,iniC,,,Ramaswamy SV AAC 2000,,,,,351,351,Gln/STOP,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,40ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Pro913Ser in embA.,0,10639358,1048,0,,,,,,
95,Rv3264c,1,EMB,manB,,,Ramaswamy SV AAC 2000,,,,,152,152,Asp/Asn,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,>50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Met305Ile in embB.,0,10639358,1049,0,,,,,,
96,Rv3266c,1,EMB,rmlD,,,Ramaswamy SV AAC 2000,,,-71,G/T,-71,-71,,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,>50ug/ml,BACTEC 460  agar diffusion method,75/108,2/0,,0,10639358,1050,0,,,,,,
97,Rv3266c,2,EMB,rmlD,,,Ramaswamy SV AAC 2000,,,,,257,257,Ser/Pro,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,>50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,No other resistance-associated mutations in the other 11 genes sequenced in the paper.,0,10639358,1051,0,,,,,,
98,Rv1484,1,ETH,inhA,,,Lee H Int J Tuberc Lung Dis 2000,,,280,TCG/GCG,94,94,Ser/Ala,This study was designed to examine the upstream regulatory sequences and the coding region of inhA  especially the 94 codon. 14 (58%) of the 24 isolates sequenced contained mutations in the regulatory region; in all of them  the mutation was a C/T substit,Published 2000,Clinical M.tb isolates; 12 INH-R only and 12 INH-R + ETH-R; none were involved in a single major outbreak of the disease (and so less likely to be related). N=24,Korea,Sequencing,nt 174-384,HEth  HREth,N.S.,Proportion method.,40171,0/0,Mutations in the regulatory region (mabA) were found.,0,10815738,1052,0,,,,,,
99,Rv1484,2,ETH,inhA,,,Ristow M Lancet 1995,,,304-305,AT/CC,95,95,Ile/Pro,The authors designed this study as a rapid PCR-based restriction-analysis screen  with the purpose of looking for the inhA94 mutation described in previous papers; however  they did not detect this mutation. All 5 sensitive and 35 of the resistant isolate,Published 1995,Clinical M.tb isolates  including pan-susceptible (n=5)  INH-R only (n=10)  ETH-R only (n=4)  INH-R and ETH-R (n=6)  and resistant to INH and two or more other drugs (n=22). Total N=47,Germany  Nepal,Sequencing,region around inhA 94,MDR,N.S.,Proportion method.,32/47,7/0,None found in the fragment analyzed.,0,7637495,1053,0,,,,,,
100,Rv3854c,1,ETH,ethA,,,DeBarber AE PNAS 2000,,,65,del 1bp,22,,Frameshift,Out of 14 MDR isolates  11 were ETH-R; all 11 (100%) had a mutation in the ethA gene. The nt65 deletion mutation was found in 1 (7%) of 15 isolates analyzed.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,Eth,N.S.,Proportion method.,40132,1/0,None found in region analyzed.,0,10944230,1054,0,,,,,,
101,Rv3854c,2,ETH,ethA,,,Morlock GP AAC 2003,,,110,del A,37,,Frameshift,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr,0,14638486,1055,0,,,,,,
102,Rv3854c,3,ETH,ethA,,,DeBarber AE PNAS 2000,,,127,GGC/TGC,43,43,Gly/Cys,This mutation was found in 1 (7%) of 15 isolates.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,HEth,N.S.,Proportion method.,40132,1/0,None found in region analyzed.,0,10944230,1056,0,,,,,,
103,Rv3854c,4,ETH,ethA,,,Morlock GP AAC 2003,,,127,GGC/AGC,43,43,Gly/Ser,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr,0,14638486,1057,0,,,,,,
104,Rv3854c,5,ETH,ethA,,,DeBarber AE PNAS 2000,,,152,CCC/CTC,51,51,Pro/Leu,This mutation was found in 1 (7%) of 15 isolates.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,EthL,N.S.,Proportion method.,40132,1/0,None found in region analyzed.,0,10944230,1058,0,,,,,,
105,Rv3854c,6,ETH,ethA,,,Morlock GP AAC 2003,,,167,GAC/GCC,55,55,Asp/Ala,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,katG Gly279Asp  mabA -15 C/T,0,14638486,1059,0,,,,,,
106,Rv3854c,7,ETH,ethA,,,DeBarber AE PNAS 2000,,,173,GAC/GCC,58,58,Asp/Ala,This mutation was found in 1 (7%) of 15 isolates.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,Eth,N.S.,Proportion method.,40132,1/0,None found in region analyzed.,0,10944230,1060,0,,,,,,
107,Rv3854c,8,ETH,ethA,,,DeBarber AE PNAS 2000,,,250,TAC/GAC,84,84,Tyr/Asp,This mutation was found in 1 (7%) of 15 isolates.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,Eth,N.S.,Proportion method.,40132,1/0,None found in region analyzed.,0,10944230,1061,0,,,,,,
108,Rv3854c,9,ETH,ethA,,,Morlock GP AAC 2003,,,338,ins A,113,,Frameshift,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,100ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr,0,14638486,1062,0,,,,,,
109,Rv3854c,10,ETH,ethA,,,DeBarber AE PNAS 2000,,,557,ACG/AAG,186,186,Thr/Lys,This was the only mutation found in the laboratory-generated ETH-R strain.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,Eth,N.S.,Proportion method.,40132,1/0,None found in region analyzed.,0,10944230,1063,0,,,,,,
110,Rv3854c,11,ETH,ethA,,,Morlock GP AAC 2003,,,667,GAG/AAG,223,223,Glu/Lys,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,50ug/ml,Microplate almar blue assay,41/41,1/0,mabA -15 C/T,0,14638486,1064,0,,,,,,
111,Rv3854c,12,ETH,ethA,,,Morlock GP AAC 2003,,,703,del T,234,,Frameshift,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr,0,14638486,1065,0,,,,,,
112,Rv3854c,13,ETH,ethA,,,Morlock GP AAC 2003,,,736,CAG/TAG,246,246,Gln/STOP,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,mabA -15 C/T,0,14638486,1066,0,,,,,,
113,Rv3854c,14,ETH,ethA,,,Morlock GP AAC 2003,,,768,del G,256,,Frameshift,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr,0,14638486,1067,0,,,,,,
114,Rv3854c,15,ETH,ethA,,,DeBarber AE PNAS 2000,,,811,ins 1 bp,270,,Frameshift,This mutation was found in 1 (7%) of 15 isolates.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,HEth,N.S.,Proportion method.,40132,1/0,None found in region analyzed.,0,10944230,1068,0,,,,,,
115,Rv3854c,16,ETH,ethA,,,DeBarber AE PNAS 2000,,,1025,ACG/AAG,342,342,Thr/Lys,This mutation was found in 3 (20%) of 15 isolates.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,HEth,N.S.,Proportion method.,40132,3/0,None found in region analyzed.,0,10944230,1069,0,,,,,,
116,Rv3854c,17,ETH,ethA,,,Morlock GP AAC 2003,,,1013,ATC/AGC,338,338,Ile/Ser,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,200ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr  mabA -15 C/T,0,14638486,1070,0,,,,,,
117,Rv3854c,18,ETH,ethA,,,DeBarber AE PNAS 2000,,,1141,GCC/CCC,381,381,Ala/Pro,This mutation was found in 2 (13%) of 15 isolates.,Published 2000,Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15.,South Africa,Sequencing,Whole gene,HEth,N.S.,Proportion method.,40132,2/0,None found in region analyzed.,0,10944230,1071,0,,,,,,
118,Rv3854c,19,ETH,ethA,,,Morlock GP AAC 2003,,,1154,GGC/GAC,385,385,Gly/Asp,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr  mabA -15 C/T,0,14638486,1072,0,,,,,,
119,Rv3854c,20,ETH,ethA,,,Morlock GP AAC 2003,,,1174,ACG/GCG,392,392,Thr/Ala,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr,0,14638486,1073,0,,,,,,
120,Rv3854c,21,ETH,ethA,,,Morlock GP AAC 2003,,,1238,GGT/GAT,413,413,Gly/Asp,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,50ug/ml,Microplate almar blue assay,41/41,1/0,None found in region analyzed.,0,14638486,1074,0,,,,,,
121,Rv3854c,22,ETH,ethA,,,Morlock GP AAC 2003,,,1290,del C,430,,Frameshift,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,50ug/ml,Microplate almar blue assay,41/41,1/0,katG Ser315Thr,0,14638486,1075,0,,,,,,
122,Rv3854c,23,ETH,ethA,,,Morlock GP AAC 2003,,,1322-1323,del GC,441,,Frameshift,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,>200ug/ml,Microplate almar blue assay,41/41,1/0,None found in region analyzed.,0,14638486,1076,0,,,,,,
123,Rv3854c,24,ETH,ethA,,,Morlock GP AAC 2003,,,1387,CGT/AGT,463,463,Arg/Ser,An ethA mutation was identified in 15 (37%) of the 41 isolates analyzed. All 15 mutations were unique and had not been reported previously; 6 (40%) of the ethA mutants also had a mutation in the regulatory region of inhA. (Note: no susceptible controls we,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole gene,HEth,50ug/ml,Microplate almar blue assay,41/41,1/0,katG Trp341Ser  mabA -15 C/T,0,14638486,1077,0,,,,,,
124,Rv1483,1,ETH,fabG1,,,Lee H Int J Tuberc Lung Dis 2000,,,-15,C/T,-15,-15,,This C/T mutation was found in all 12 (100%) of the INH-R and ETH-R isolates  and in 2 (17%) of the 12 INH-R isolates. This region is believed to be the regulatory region for the inhA gene.,Published 2000,Clinical M.tb isolates; 12 INH-R only and 12 INH-R + ETH-R; none were involved in a single major outbreak of the disease (and so less likely to be related). N=24,South Korea,Sequencing,Whole,HEth  HREth,40-80ug/ml,Proportion method.,40171,40149,No mutation in inhA94 found.,0,10815738,1078,0,,,,,,
125,Rv1483,2,ETH,fabG1,,,Morlock GP AAC 2003,,,-17,G/T,-17,-17,,This is the only mutation found in this region other than the -15 C/T substitution.,Published 2003,ETH-R clinical isolates. N=41,USA  Russia  Brazil,Sequencing,Whole,EthH,100ug/ml,Microplate almar blue assay,41/41,1/0,inhA Ile21Thr,0,14638486,1079,0,,,,,,
126,Rv0006,1,FLQ,gyrA,,,Shi R JCM 2006,,,220,GCC/TCC,74,74,Ala/Ser,,2002-2003,,China,Sequencing,227bp QRDR gyrA,OFX,OFL 2-32,Absolute concentration method,87/109,10/0,gyrA: Asp94Gly,1,17035499,1080,13,,,,,,
127,Rv0006,2,FLQ,gyrA,,,Aubry A AAC 2006,,,238,ACC/GCC,80,80,Thr/Ala,,Published 2006,,France,Sequencing,QRDRs on gyrA and gyrB,The Thr80Ala mutants are resistant to all 5 drugs. The Thr80Ala + Ala90Gly double mutants are hypersusceptible to all 5 drugs  with MICs significantly lowered compared to H37Rv.,,Proportion method,14/15,Single mutants: 2/0. Double mutants: 0/4.,gyrA: Ala90Val,0,16377674,1081,0,,,,,,
128,Rv0006,3,FLQ,gyrA,,,Matrat S AAC 2006 Dec,,,263,GGC/GCC,88,88,Gly/Ala,,Published 2006,,N.S.,Sequencing,nt 247-282 of gyrA,Resistant to: sparfloxacin  gemifloxacin  gatifloxacin  moxifloxacin  levofloxacin  ofloxacin  enoxacin  temafloxacin  flumequine  oxolinic acid  nalidixic acid  pipemidic acid; and to coumarin.,2x to 16x higher than WT (H37Rv) MICs for the same drugs.,Proportion method,39938,5/0,N.S.,0,17015626,1082,0,,,,,,
129,Rv0006,4,FLQ,gyrA,,,Von Groll A AAC 2009,,,265,GAC/AAC,89,89,Asp/Asn,,Published 2006,,N.S.,Sequencing,nt 247-282 of gyrA,Resistant to: sparfloxacin  gemifloxacin  gatifloxacin  moxifloxacin  levofloxacin  ofloxacin  enoxacin  temafloxacin  flumequine  oxolinic acid  nalidixic acid  pipemidic acid; and to coumarin.,2x to 16x higher than WT (H37Rv) MICs for the same drugs.,Proportion method,39938,5/0,N.S.,0,17015626,1083,13,,,,,,
130,Rv0006,5,FLQ,gyrA,,,Takiff HE AAC 1994,,,269,GCG/GTG,90,90,Ala/Val,,Published 1994,,N.S.,PCR-SSCP  Sequencing,320-bp QRDR of gyrA,CIP,CIP: 4-8,BACTEC 460,3/54,3/0,gyrA: Ser95Thr,1,8031045,1084,13,,,,,,
131,Rv0006,6,FLQ,gyrA,,,Aubry A AAC 2006,,,269,GCG/GGG,90,90,Ala/Gly,,Published 2006,,France,Sequencing,QRDRs on gyrA and gyrB,Hypersusceptible to all 5 drugs  with MICs significantly lowered compared to H37Rv.,GAT 0.12-0.5  MOX 0.12-0.25  LVX 0.25-1  OFX 0.25-1  and ENX 2-8 ug/ml.,Proportion method,14/15,0/4,gyrA: Thr80Ala,0,16377674,1085,0,,,,,,
132,Rv0006,7,FLQ,gyrA,,,Takiff HE AAC 1994,,,271,TCG/CCG,91,91,Ser/Pro,,Published 1994,,N.S.,PCR-SSCP  Sequencing,320-bp QRDR of gyrA,CIP,CIP: 4,BACTEC 460,1/54,1/0,gyrA: Ser95Thr,1,8031045,1086,13,,,,,,
133,Rv0006,8,FLQ,gyrA,,,Takiff HE AAC 1994,,,280,GAC/AAC,94,94,Asp/Asn,,Published 1994,,N.S.,PCR-SSCP  Sequencing,320-bp QRDR of gyrA,CIP,CIP: 8,BACTEC 460,1/54,1/0,gyrA: Ser95Thr,1,8031045,1087,13,,,,,,
134,Rv0006,9,FLQ,gyrA,,,Takiff HE AAC 1994,,,280,GAC/CAC,94,94,Asp/His,,Published 1994,,N.S.,PCR-SSCP  Sequencing,320-bp QRDR of gyrA,CIP,CIP: 4,BACTEC 460,1/54,1/0,gyrA: Ser95Thr,1,8031045,1088,13,,,,,,
135,Rv0006,10,FLQ,gyrA,,,Bravao LTC JCM 2009,,,280-281,GAC/GTC,94,94,Asp/Phe,,Published 2009,,Phillipines,Sequencing,225-bp gyrA QRDR,HROfx,N.S.,Proportion method,9/102,1/0,gyrA: Ser95Thr,0,19846642,1089,0,,,,,,
136,Rv0006,11,FLQ,gyrA,,,Takiff HE AAC 1994,,,280,GAC/TAC,94,94,Asp/Tyr,,Published 1994,,N.S.,PCR-SSCP  Sequencing,320-bp QRDR of gyrA,CIP,CIP: 8,BACTEC 460,2/54,2/0,gyrA: Ser95Thr,1,8031045,1090,13,,,,,,
137,Rv0006,12,FLQ,gyrA,,,Takiff HE AAC 1994,,,281,GAC/GGC,94,94,Asp/Gly,,Published 1994,,N.S.,PCR-SSCP  Sequencing,320-bp QRDR of gyrA,CIP,CIP: 8,BACTEC 460,5/54,5/0,gyrA: Ser95Thr,1,8031045,1091,13,,,,,,
138,Rv0006,13,FLQ,gyrA,,,Takiff HE AAC 1994,,,281,GAC/GCC,94,94,Asp/Ala,,Published 1994,,N.S.,PCR-SSCP  Sequencing,320-bp QRDR of gyrA,CIP,CIP: 4,BACTEC 460,1/54,1/0,gyrA: Ser95Thr,1,8031045,1092,13,,,,,,
139,Rv0006,14,FLQ,gyrA,,,Sulochana S J Chemother 2007,,,281,GAC/GTC,94,94,Asp/Val,,Published 2007,,India,Sequencing,320-bp gyrA QRDR  360-bp gyrB QRDR,Moderately resistant to OFX.,OFX: 16-64,Absolute concentration method,71/118,7/0,gyrA: Ser95Thr,0,17434825,1093,0,,,,,,
140,Rv0006,15,FLQ,gyrA,,,Kapur V Arch PathLabMEd 1995,,,284,AGC/ACC,95,95,Ser/Thr,,,,,,,,,,,,,0,7848059,1094,0,,,,,,
141,Rv0006,16,FLQ,gyrA,,,Kam KM Microb Drug Res 2006,,,305,CCC/CAC,102,102,Pro/His,,,,,,,,,,,,,1,16584301,1095,13,,,,,,
142,Rv0006,17,FLQ,gyrA,,,Sulochana S J Chemother 2007,,,325,CTG/GTG,109,109,Leu/Val,,Published 2007,,India,Sequencing,320-bp gyrA QRDR  360-bp gyrB QRDR,Moderately susceptible to OFX.,OFX: 2,Absolute concentration method,71/118,0/1,,0,17434825,1096,0,,,,,,
143,Rv0005,1,FLQ,gyrB,,,Feuerriegel S AAC 2009,,,1369,CGT/TGT,457,457,Arg/Cys,This mutation was originally reported as R485C  this correpond to R457C using the Takiff et al start codon (= nucleotide 5207 in the NCBI sequence H37Rv  NC_000962.2),2003-2006,Isolates from a program for the treatment of MDR in Karakalpakstan,Uzbekistan,Sequencing,QRDRs on gyrA and gyrB,OFX,N.S.,BACTEC 460 and MGIT 960,26/49,1/0,,0,19470505,1097,0,,,,,,
144,Rv0005,2,FLQ,gyrB,,,Duong DA AAC 2009,,,1373,TCC/TTC,458,458,Ser/Phe,Mutation reported as S486F,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,No other mutation in gyrA or gyrB,0,19721073,1098,0,,,,,,
145,Rv0005,3,FLQ,gyrB,,,Duong DA AAC 2009,,,1414,GAC/CAC,472,472,Asp/His,Mutation reported as D500H,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,No other mutation in gyrA or gyrB,0,19721073,1099,0,,,,,,
146,Rv0005,4,FLQ,gyrB,,,Aubry A AAC 2006,,,1414,GAC/CAC,472,472,Asp/His,,Published 2006,,France,Sequencing,QRDRs on gyrA and gyrB,Strongly resistant to OFX,OFX: 60ug/ml,N.S.,14/15,1/0,Ala90Val in gyrA; no other mutations in QRDR of gyrB.,0,16377674,1100,0,,,,,,
147,Rv0005,5,FLQ,gyrB,,,Pitaksajjakul P Southeast Asian J Trop Med Public Health 2005,,,1414,GAC/AAC,472,472,Asp/Asn,Mutation reported as D495N,Published 2005,,Thailand,PCR-SSCP  Sequencing,320-bp QRDR of gyrA; 429-bp QRDR of gyrB.,INH+RIF+STR+EMB+OFX,N.S.,Absolute concentration method,35/35,1/0,No further mutations in gyrA or gyrB QRDRs found.,0,16438215,1101,0,,,,,,
148,Rv0005,6,FLQ,gyrB,,,Duong DA AAC 2009,,,1414,GAC/AAC,472,472,Asp/Asn,Mutation reported as D500N,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,gyrA D94A,0,19721073,1102,0,,,,,,
149,Rv0005,7,FLQ,gyrB,,,Duong DA AAC 2009,,,1415,GAC/GCC,472,472,Asp/Ala,Mutation reported as D500A,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,gyrA A90V,0,19721073,1103,0,,,,,,
150,Rv0005,8,FLQ,gyrB,,,Duong DA AAC 2009,,,1442,GGT/GCT,481,481,Gly/Ala,Mutation reported as G509A,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,No other mutation in gyrA or gyrB,0,19721073,1104,0,,,,,,
151,Rv0005,9,FLQ,gyrB,,,Lee AS Int J Infect Dis 2002,,,1514,GAC/GCC,505,505,Asp/Ala,,,,,,,,,,,,,0,12044302,1105,0,,,,,,
152,Rv0005,10,FLQ,gyrB,,,Aubry A AAC 2006,,,1528,AAC/GAC,510,510,Asn/Asp,This mutation is frequently referred to as N538D  these reports are using the NCBI start codon (nucleotide 5123 of NCBI sequence H37Rv NC_000962.2). This database report mutations based on the Takiff et al 1994 proposed start codon (corresponding to nucleotide 5207 of NCBI sequnce H37Rv NC_000962.2). Tuberculist report on yet another alternative start codon (corresponding to nucleotide 5240 of NCBI sequence H37Rv NC_000962.2),Published 2006,,France,Sequencing,QRDRs on gyrA and gyrB,GAT  MOX  LVX  and OFX; strongly resistant to ENX.,GAT: >1  MOX and LVX: 2  OFX: 4  and ENX: 64,Proportion method,14/15,1/0,No other mutations in QRDR of gyrA or gyrB.,1,16377674,1106,13,,,,,,
153,Rv0005,11,FLQ,gyrB,,,Duong DA AAC 2009,,,1529,AAC/ACC,510,510,Asn/Thr,Mutation reported as N538T,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,gyrA A90V,0,19721073,1107,0,,,,,,
154,Rv0005,12,FLQ,gyrB,,,Mokrousov I AAC 2008,,,1530,AAC/AAA,510,510,Gln/Lys,,2004 - 2005,,Taiwan,Sequencing,QRDRs on gyrA and gyrB,OFX  CIP  LVX  and MOX. Out of the 14 FQ-R isolates  6 (42.9%) were resistant to at least one 1st-line drug  while 4 (28.6%) were multidrug-resistant.,OFX: 8  CIP: 5  LVX: 1  and MOX: 1,Modified proportion method,14/420,1/0,No further mutations in gyrA or gyrB QRDRs found.,0,18559646,1108,0,,,,,,
155,Rv0005,13,FLQ,gyrB,,,Duong DA AAC 2009,,,1531,ACC/CCC,511,511,Thr/Pro,Mutation reported as T539P,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,gyrA A90V,0,19721073,1109,0,,,,,,
156,Rv0005,14,FLQ,gyrB,,,Duong DA AAC 2009,,,1535,GAA/GTA,512,512,Glu/Val,Mutation reported as E540V,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,No other mutation in gyrA or gyrB,0,19721073,1110,0,,,,,,
157,Rv0005,15,FLQ,gyrB,,,Duong DA AAC 2009,,,1536,GAA/,512,512,Glu/Asp,Mutation reported as E540D,2005-2007,,Vietnam,Sequencing,QRDRs on gyrA and gyrB,,,Proportion method,109/218,1/0,No other mutation in gyrA or gyrB,0,19721073,1111,0,,,,,,
158,Rv0005,16,FLQ,gyrB,,,Mokrousov I AAC 2008,,,1543,GCG/ACG,515,515,Ala/Thr,,2004 - 2005,,Taiwan,Sequencing,QRDRs on gyrA and gyrB,OFX  CIP  LVX  and MOX. Out of the 14 FQ-R isolates  6 (42.9%) were resistant to at least one 1st-line drug  while 4 (28.6%) were multidrug-resistant.,OFX: 8  CIP: 5  LVX: 1  and MOX: 1,Modified proportion method,14/420,1/0,No further mutations in gyrA or gyrB QRDRs found.,0,18559646,1112,0,,,,,,
159,Rv0005,17,FLQ,gyrB,,,Mokrousov I AAC 2008,,,1544,GCG/GTG,515,515,Ala/Val,,2004 - 2005,,Taiwan,Sequencing,QRDRs on gyrA and gyrB,OFX  CIP  LVX  and MOX. Out of the 14 FQ-R isolates  6 (42.9%) were resistant to at least one 1st-line drug  while 4 (28.6%) were multidrug-resistant.,OFX: 8  CIP: 5  LVX: 1  and MOX: 1,Modified proportion method,14/420,1/0,No further mutations in gyrA or gyrB QRDRs found.,0,18559646,1113,0,,,,,,
160,Rv0005,18,FLQ,gyrB,,,Mokrousov I AAC 2008,,,1647,CAA/CAT,549,549,Gln/His,,2004 - 2005,,Taiwan,Sequencing,QRDRs on gyrA and gyrB,OFX  CIP  LVX  and MOX. Out of the 14 FQ-R isolates  6 (42.9%) were resistant to at least one 1st-line drug  while 4 (28.6%) were multidrug-resistant.,OFX: 8  CIP: 5  LVX: 1  and MOX: 1,Modified proportion method,14/420,1/0,No further mutations in gyrA or gyrB QRDRs found.,0,18559646,1114,0,,,,,,
161,Rv1694,1,AMI,tlyA,,,Maus CE AAC 2005,,,7,CGA/TGA,3,3,Arg/STOP,Mutations in tlyA were found in 28 (93%) spontaneous mutants selected for CAP resistance  and in clinical isolates. None of the 30 laboratory-produced isolates had mutations in the rrs gene. This mutation was found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap Vio,Cap 40ug/ml  Vio 20ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1115,0,,,,,,
162,Rv1694,2,AMI,tlyA,,,Maus CE AAC 2005,,,26,del C,9,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1116,0,,,,,,
163,Rv1694,3,AMI,tlyA,,,Maus CE AAC 2005 Feb,,,40,CGG/TGG,14,14,Arg/Trp,Out of 18 clinical isolates tested  14 had A1401G mutations in rrs  while 5 were mutated in the tlyA gene; 4 (80%) were K-R. The Arg/Trp was a double mutant). Mutants with both tlyA mutations and an rrs A1401G mutation had enhanced resistance for CAP an,Published 2005,Mutagenized M.smeg; also M.tb strains H37Rv  CDC1551  Beijing F2  and 18 clinical isolates obtained from CDC. N=18,USA,Sequencing,Whole gene,HRESEthKCapVioAmi,K >80ug/ml,Proportion method,16/18,1/0,Also mutated at rrs A1401G.,0,15673735,1117,0,,,,,,
164,Rv1694,4,AMI,tlyA,,,Maus CE AAC 2005,,,52,CGA/TGA,18,18,Arg/STOP,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1118,0,,,,,,
165,Rv1694,5,AMI,tlyA,,,Maus CE AAC 2005,,,64,CAG/TAG,22,22,Gln/STOP,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,Cap 40ug/ml  Vio <10ug/ml,Proportion method,30/30,3/0,None identified specifically.,0,15673735,1119,0,,,,,,
166,Rv1694,6,AMI,tlyA,,,Maus CE AAC 2005,,,23,del A,8,,Frameshift,Mutation found in the clinical group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,RESKCapVio Ami,Cap 80ug/ml,Proportion method,18/18,1/0,None found in region analyzed.,0,15673735,1120,0,,,,,,
167,Rv1694,7,AMI,tlyA,,,Maus CE AAC 2005 Feb,,,67-69,del GCC,23,23,del A,,Published 2005,Mutagenized M.smeg; also M.tb strains H37Rv  CDC1551  Beijing F2  and 18 clinical isolates obtained from CDC. N=18,USA,Sequencing,Whole gene,HRESKCapVioAmi,K 20ug/ml,Proportion method,16/18,1/0,None found in region analyzed.,0,15673735,1121,0,,,,,,
168,Rv1694,8,AMI,tlyA,,,Maus CE AAC 2005,,,200,GCG/GAG,67,67,Ala/Glu,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1122,0,,,,,,
169,Rv1694,9,AMI,tlyA,,,Maus CE AAC 2005,,,205,AAA/GAA,69,69,Lys/Glu,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1123,0,,,,,,
170,Rv1694,10,AMI,tlyA,,,Maus CE AAC 2005,,,218,ins C,73,,Frameshift,Mutation found in the clinical group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,HRESKCapVioAmi,Cap 80ug/ml,Proportion method,18/18,1/0,None found in region analyzed.,0,15673735,1124,0,,,,,,
171,Rv1694,11,AMI,tlyA,,,Maus CE AAC 2005,,,272,GCA/GAA,91,91,Ala/Glu,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,Cap 40ug.ml  Vio <10ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1125,0,,,,,,
172,Rv1694,12,AMI,tlyA,,,Maus CE AAC 2005,,,310,del G,103,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1126,0,,,,,,
173,Rv1694,13,AMI,tlyA,,,Maus CE AAC 2005,,,353,CTG/CCG,118,118,Leu/Pro,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,CapVio,Cap 40ug/ml  Vio 40ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1127,0,,,,,,
174,Rv1694,14,AMI,tlyA,,,Maus CE AAC 2005,,,383,GTG/GAG,128,128,Val/Glu,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1128,0,,,,,,
175,Rv1694,15,AMI,tlyA,,,Maus CE AAC 2005,,,397,ins C,132,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,CapVio,Cap 40ug/ml  Vio 20ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1129,0,,,,,,
176,Rv1694,16,AMI,tlyA,,,Maus CE AAC 2005,,,400,del A,133,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1130,0,,,,,,
177,Rv1694,17,AMI,tlyA,,,Maus CE AAC 2005 Feb,,,449,CTG/CCG,150,150,Leu/Pro,,Published 2005,Mutagenized M.smeg; also M.tb strains H37Rv  CDC1551  Beijing F2  and 18 clinical isolates obtained from CDC. N=18,USA,Sequencing,Whole gene,HRSCap,K <5ug/ml Cap 40ug/ml,Proportion method,16/18,0/1,None found in region analyzed.,0,15673735,1131,0,,,,,,
178,Rv1694,18,AMI,tlyA,,,Maus CE AAC 2005,,,477,del G,159,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,Cap 40ug/ml  Vio <10ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1132,0,,,,,,
179,Rv1694,19,AMI,tlyA,,,Maus CE AAC 2005,,,548,C/T,183,183,Pro/Leu,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,CapVio,Cap 40ug/ml  Vio 20ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1133,0,,,,,,
180,Rv1694,20,AMI,tlyA,,,Maus CE AAC 2005,,,550,C/T,184,184,Gln/STOP,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,Cap 40ug/ml  Vio <10ug/ml,Proportion method,30/30,5/0,None identified specifically.,0,15673735,1134,0,,,,,,
181,Rv1694,21,AMI,tlyA,,,Maus CE AAC 2005,,,555,T/G,185,185,Phe/Leu,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1135,0,,,,,,
182,Rv1694,22,AMI,tlyA,,,Maus CE AAC 2005,,,586,del G,195,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,CapVio,Cap 40ug/ml  Vio 20ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1136,0,,,,,,
183,Rv1694,23,AMI,tlyA,,,Maus CE AAC 2005,,,653,del T,218,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1137,0,,,,,,
184,Rv1694,24,AMI,tlyA,,,Maus CE AAC 2005 Feb,,,,ins C,218,218,Frameshift,,Published 2005,Mutagenized M.smeg; also M.tb strains H37Rv  CDC1551  Beijing F2  and 18 clinical isolates obtained from CDC. N=18,USA,Sequencing,Whole gene,HRESKCapVioAmI,K 20ug/ml,Proportion method,16/18,1/0,None found in region analyzed.,0,15673735,1138,0,,,,,,
185,Rv1694,25,AMI,tlyA,,,Maus CE AAC 2005,,,673-674,del GT,224,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1139,0,,,,,,
186,Rv1694,26,AMI,tlyA,,,Maus CE AAC 2005 Feb,,,708,AAT/AAG,236,236,Asn/Lys,,Published 2005,Mutagenized M.smeg; also M.tb strains H37Rv  CDC1551  Beijing F2  and 18 clinical isolates obtained from CDC. N=18,USA,Sequencing,Whole gene,HSCapVio,K <5ug/ml Cap 80ug/ml,Proportion method,16/18,0/1,None found in region analyzed.,0,15673735,1140,0,,,,,,
187,Rv1694,27,AMI,tlyA,,,Maus CE AAC 2005,,,712,G/A,238,238,Glu/Lys,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,Cap,N.S.,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1141,0,,,,,,
188,Rv1694,28,AMI,tlyA,,,Maus CE AAC 2005,,,758,del C,253,,Frameshift,Mutation found in the lab-produced group.,Published 2005,Resistance-selected M.tb strains H37Rv (n=11)  CDC1551 (n=11)  and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48,USA,Sequencing,Whole gene,CapVio,Cap 40ug/ml  Vio 20ug/ml,Proportion method,30/30,1/0,None identified specifically.,0,15673735,1142,0,,,,,,
189,Rv2764c,1,PAS,thyA,,,Rengarajan J MolMicro 2004,,,604,ACC/GCC,202,202,Thr/Ala,Three (37.5%) of the 8 PAS-R isolates had mutations in thyA  while all 10 (100%) PAS-S isolates were WT in the gene. The thyX region (250bp upstream of thyA) was also sequenced; all isolates were WT in it  showing that thyX mutations did not account for r,Published 2004,PAS-resistant (n=8) and PAS-sensitive (n=10) clinical M.tb isolates. Total N=18,Russia,Sequencing,Whole gene,PAS,N.S.,N.S.,40043,2/0,None in region analyzed.,0,15225321,1143,0,,,,,,
190,Rv2764c,2,PAS,thyA,,,Rengarajan J MolMicro 2004,,,664,CGC/GGC,222,222,Arg/Gly,,Published 2004,PAS-resistant (n=8) and PAS-sensitive (n=10) clinical M.tb isolates. Total N=18,Russia,Sequencing,Whole gene,PAS,N.S.,N.S.,40043,1/0,None in region analyzed.,0,15225321,1144,0,,,,,,
191,MTB000019,1,SM,rrs,,,Ramaswamy SV J Med Micro 2004,,,189,G/A,189,,,only 44% mutations not found in susceptible isoLates; genes other than rpsL and rrs confer STR resistance. Isolates in same cluster had diff. drug susceptiblities; indicates indep. mutation,1996-1998,patients from Jose E. Gonzalez Univ. Hosp,Mexico,Sequencing,Whole rrs,RHS,N.S,Proportion method,39838,1/0,15 ups; C/T (inhA),0,14729930,1145,0,,,,,,
192,MTB000019,2,SM,rrs,,,Ramaswamy SV J Med Micro 2004,,,426,G/T,426,,,,1996-1998,patients from Jose E. Gonzalez Univ. Hosp,Mexico,Sequencing,Whole rrs,RHS,N.S,Proportion method,39838,1/0,315  AGC/ACC  Ser/Thr (katG); 450  TCG/TTG  Ser/Leu (rpoB),0,14729930,1146,0,,,,,,
193,MTB000019,3,SM,rrs,,,Spies FS AAC 2008,,,426,G/C,426,,,,Published 2008,Rio Grande do Sul,Brazil,Sequencing,530 loop  912 region,RHSE,>31 5ug/ml,Resazurin microtiter assay,47/32,1/0,gidB: CCT/CGT; L16R,0,18541729,1147,0,,,,,,
194,MTB000019,4,SM,rrs,,,Brzostek A IntJ TubLungDis 2004,,,461,C/T,461,,,v. likely a natural polymorphism  not responsible for drug resistance,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,530 loop  912 region,S,N.S,Proportion method,4/88,4/0,none,0,15305490,1148,42,,,,,,
195,MTB000019,5,SM,rrs,,,Meier A AAC 1994,,,491,C/T,491,,,,,,,Sequencing,Whole rrs,HS,N.S,Proportion method,3/38,1/0,,1,8192472,1149,42,,,,,,
196,MTB000019,6,SM,rrs,,,Meier A AAC 1994,,,512,C/T,512,,,,,,,Sequencing,505 bp gene fragment; complete S12 gene,RHS,N.S,Proportion method,3/38,1/0,,0,8192472,1150,42,,,,,,
197,MTB000019,7,SM,rrs,,,Honore N AAC 1995,,,512,ins C,512,,Frameshift,,,,,,,N.S,N.S,,,,,1,7540819,1151,0,,,,,,
198,MTB000019,8,SM,rrs,,,Dobner P MolCellProbes  1997,,,513,A/C,513,,,one of two isolates (out of 25 from Germany) with mutations in rrs and rpsL,1996,Germans  Eastern European immigrants in Germany  Sierra Leone,Germany  Sierra Leone,Sequencing,530 loop  912 region,S,N.S,,1/50,1/0,AAG/AGG  43 Lys/Arg (rpsL),1,9160326,1152,28,,,,,,
199,MTB000019,9,SM,rrs,,,Katsukawa C J Appl Micro 1997,,,513,A/T,513,,,11/36 Str-res isolates had one of following rrs sub.: 513  906  907  907-908 ins (T),1992-1994,172 clinical isolates from Japanese institutions,Japan,Sequencing,450-944,S,20-200ug/ml,Absolute concentration method,95/172,9/0,,1,9418025,1153,14,,,,,,
200,MTB000019,10,SM,rrs,,,Dobner P MolCellProbes  1997,,,516,C/T,516,,,aggregated data comparing mutations in isolates from Germany and Sierra Leone. Mutations in rrs infrequent: Germany (20%)  Sierra Leone (12%),1996,Germans  Eastern European immigrants in Germany  Sierra Leone,Germany  Sierra Leone,Sequencing,530 loop  912 region,S,N.S,,1/50,1/0,none,0,9160326,1154,42,,,,,,
201,MTB000019,11,SM,rrs,,,Brzostek A IntJ TubLungDis 2004,,,627,G/C,627,,,G627C mutation cannot be ruled out as conferring STR res.  but mutation is also in M. shottsii rrs gene,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,530 loop  912 region,S,N.S,Proportion method  BACTEC 460,1/88,1/0,none,0,15305490,1155,0,,,,,,
202,MTB000019,12,SM,rrs,,,Sreevatsan S AAC 1996,,,798,C/T,798,,,novel mutation in 915 region. Data aggregated by country of origin,1995,139 strains of mtb from various geographical localities,USA,Sequencing,530 loop  912 region,S,N.S,Proportion method  BACTEC 460,39814,1/0,only NY isolate with both rrs and rpsL (AAG/AGG; K43-->R) mutations,0,8849220,1156,42,,,,,,
203,MTB000019,13,SM,rrs,,,Cooksey RC  AAC 1996,,,865,C/G,865,,,all 24 isolates with high level STR-res. had this common substitution; mutation not present among any isolates w/ low level Str-res.,1994,New Yorkers,USA,Sequencing,306 bp,RHS,10,Agar dilution method,45/367,1/0,none,0,8723463,1157,0,,,,,,
204,MTB000019,14,SM,rrs,,,Okamoto S MolMicro 2007,,,887,G/A,887,,,Annotated wrongly as nt 888,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,,R  H  S  E  K  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,A276C  T563G (gidB),0,17238915,1158,0,,,,,,
205,MTB000019,15,SM,rrs,,,Honore N AAC 1994,,,904,C/A,904,,,*notes that primary structure of S12 protein is well conserved among mycobacteria  even those naturally res. to Str; permeability barriers may be responsible for resistance,1994,mtb strains from various sources,N.S.,PCR-SSCP,530 loop  912 region,SH,>1280,Agar dilution method,39974,1/0,none,0,8192450,1159,0,,,,,,
206,MTB000019,16,SM,rrs,,,Honore N AAC 1994,,,904,C/G,904,,,,,,,PCR-SSCP,530 loop  912 region,SHR,160,Agar dilution method,39974,1/0,none,0,8192450,1160,0,,,,,,
207,MTB000019,17,SM,rrs,,,Dobner P MolCellProbes  1997,,,905,A/G,905,,,one of two isolates (out of 25 from Germany) with mutations in rrs and rpsL,1996,Germans  Eastern European immigrants in Germany  Sierra Leone,Germany  Sierra Leone,Sequencing,530 loop  912 region,S,N.S,,1/50,1/0,AAG/CAG  88 Lys/Thr (rpsL),0,9160326,1161,0,,,,,,
208,MTB000019,18,SM,rrs,,,Dobner P MolCellProbes  1997,,,906,A/T,906,,,aggregated data comparing mutations in isolates from Germany and Sierra Leone. Mutations in rrs infrequent: Germany (20%)  Sierra Leone (12%),1996,Germans  Eastern European immigrants in Germany  Sierra Leone,Germany  Sierra Leone,Sequencing,530 loop  912 region,S,N.S,,1/50,1/0,none,0,9160326,1162,14,,,,,,
209,MTB000019,19,SM,rrs,,,Katsukawa C J Appl Micro 1997,,,906,A/C,906,,,novel mutation,1992-1994,172 clinical isolates from Japanese institutions,Japan,Sequencing,450-944,S,20-200ug/ml,Absolute concentration method,95/172,1/0,,1,9418025,1163,28,,,,,,
210,MTB000019,20,SM,rrs,,,Katsukawa C J Appl Micro 1997,,,907,A/G,907,,,novel mutation,1992-1994,172 clinical isolates from Japanese institutions,Japan,Sequencing,450-944,S,20-200ug/ml,Absolute concentration method,95/172,1/0,,0,9418025,1164,0,,,,,,
211,MTB000019,21,SM,rrs,,,Katsukawa C J Appl Micro 1997,,,907-908,ins T,907,,Frameshift,novel mutation,1992-1994,172 clinical isolates from Japanese institutions,Japan,Sequencing,450-944,S,20-200ug/ml,Absolute concentration method,95/172,1/0,,0,9418025,1165,0,,,,,,
212,MTB000019,22,SM,rrs,,,Sekigushi J JCM 2007,,,1061,ins C,1061,,Frameshift,*novel mutaiton **aggregated data,2006,TB patients in Japan and Poland,Japan,Multiplex PCR,530 loop  912 region,N.S,N.S,Proportion method  Rapid broth method,55/138,1/0,Lys121Lys (rpsL)  silent mutation  not assoc w/ STR-res.,0,17596354,1166,0,,,,,,
213,MTB000019,23,SM,rrs,,,Ramaswamy SV J Med Micro 2004,,,1238,T/C,1238,,,,1996-1998,patients from Jose E. Gonzalez Univ. Hosp,Mexico,Sequencing,Whole rrs,RHSE,N.S,Proportion method,39897,3/0,315  AGC/ACC  Ser/Thr (katG); 435  GAC/GTC  Asp/Val (rpoB); 43  AAG/AGG  Lys/Arg (rpsL); 306  ATG/CTG  Met/Leu (embB),0,14729930,1167,0,,,,,,
214,MTB000019,24,SM,rrs,,,Sekigushi J JCM 2007,,,1400,A/G,1400,,,aggregated data,2006,TB patients in Japan and Poland,Japan,Multiplex PCR,428-1737,N.S,N.S,Proportion method  Rapid broth method,55/138,1/0,Lys121Lys (rpsL)  silent mutation  not assoc w/ STR-res.,0,17596354,1168,0,,,,,,
215,MTB000019,25,SM,rrs,,,Sekigushi J JCM 2007,,,1539,A/G,1539,,,aggregated data,2006,TB patients in Japan and Poland,Japan,Multiplex PCR,428-1737,N.S,N.S,Proportion method  Rapid broth method,55/138,1/0,A1400G (rrs); Lys121Lys (rpsL)  silent mutation  not assoc w/ STR-res.,0,17596354,1169,0,,,,,,
217,MTB000019,2,AMI,rrs,,,Sander P MolMicro 1996,,,1401,A/G,1401,,rRNA gene,,Published 1996,8 Kanamycin and amikacin resistant Mtb isolates,N.S.,Sequencing,N.S,Kami,N.S.,N.S.,8/8,8/0,none,0,8971706,1171,0,,,,,,
218,MTB000019,3,AMI,rrs,,,Suzuki Y JCM 1998,,,1402,C/T,1402,,rRNA gene,(1401 in ref),Published 1998,K-S (n=71) isolates  K-R (n=43) isolates  and 4 laboratory strains of M.Tb. Total N=118,Japan,Sequencing,300 bp containing the 3' one-fifth of the rrs gene,K,K >100ug/ml,Proportion method,43/118,1/0,None found in gene analyzed.,0,9574680,1172,0,,,,,,
219,MTB000019,4,AMI,rrs,,,Suzuki Y JCM 1998,,,1402,C/A,1402,,rRNA gene,(1401 in ref),Published 1998,K-S (n=71) isolates  K-R (n=43) isolates  and 4 laboratory strains of M.Tb. Total N=118,Japan,Sequencing,300 bp containing the 3' one-fifth of the rrs gene,K,K >100ug/ml,Proportion method,43/118,2/0,Both isolates also mutated at rrs G1484T.,0,9574680,1173,0,,,,,,
220,MTB000019,5,AMI,rrs,,,Taniguchi H JB 1997,,,1408,A/G,1408,,rRNA gene,(1400 in ref) All M.smegmatis strains with high-level K resistance had an A/G nucleotide substitution in gene rrs  at a position equivalent to 1408 in E.coli.  3 out of 4 (75%) of M.tuberculosis strains with high-level K resistance had a mutation of A/G at the equi,Published 1997,Kamycin- and viomycin-resistant M.smegmatis isolated from standard strains in the laboratory (n=15); MDR-M.tb clinical isolates (N=10)  out of which 4 were K-R.,Japan,Sequencing,nt 431 to the 3' end,RSEKVio,K >200ug/ml,N.S.,39913,3/0,Lys43Arg mutation in S12 protein in one isolate; Lys88Gln mutation in S12 protein in second isolate.,0,9244267,1174,0,,,,,,
221,MTB000019,6,AMI,rrs,,,Suzuki Y JCM 1998,,,1484,G/T,1484,,rRNA gene,(1483 in ref),Published 1998,K-S (n=71) isolates  K-R (n=43) isolates  and 4 laboratory strains of M.Tb. Total N=118,Japan,Sequencing,300 bp containing the 3' one-fifth of the rrs gene,K,K >100ug/ml,Proportion method,43/118,2/0,Both isolates also mutated at rrs C1402A.,0,9574680,1175,0,,,,,,
222,Rv1908c,103,INH,katG,,,Baker LV AAC 2005,,,701,GGG/GAG,234,234,Gly/Glu,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,,0,15793126,238,0,,,,,,
223,Rv1908c,104,INH,katG,,,Chan RCY JAC 2007,,,700,GGG/AGG,234,234,Gly/Arg,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,239,0,,,,,,
224,Rv1908c,105,INH,katG,,,Chan RCY JAC 2007,,,707,AAC/ACC,236,236,Asn/Thr,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,240,0,,,,,,
225,Rv1908c,106,INH,katG,,,Hai Hua Lin TubercRespirDis 2007,,,714,AAC/AAG,238,238,Asn/Lys,,2004,,South Korea,Sequencing,Whole gene,MDR,N.S.,N.S,29/29,1/0,katG S140R,0,2007582629,241,0,,,,,,
226,Rv1908c,107,INH,katG,,,Baker LV AAC 2005,,,723,CCC/CCG,241,241,Pro/Pro,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,2/0,,0,15793126,242,0,,,,,,
227,Rv1908c,108,INH,katG,,,Cockerill FR JID 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,727,GCC/TCC,243,243,Ala/Ser,no consistent correlation b/w loss of catalase activity and increasing INH inhibitory concentration,1995,clinical strains of mtb,USA  Japan,Sequencing,Whole gene,,0.12; catalase 28mm,Middlebrook 7H11 agar; 1% Proportion method,,1/0,Pro2Ser  Ser17Asn  Gly19Asp  Gln224Glu  Ala550Asp,0,7798673,243,0,,,,,,
228,Rv1908c,109,INH,katG,,,Ramaswamy SV J Med Micro 2004,,,745,CGC/TGC,249,249,Arg/Cys,,1996-1998,Jose Gonzalez hospital Mexico,Mexico,Directed Oligonucleotide array   Sequencing,codon 228-357,HRSE,>=1% growth 0.2ug/ml I  40ug/ml R  4ug/ml S  2ug/ml E,Proportion method,37/50,2/0,His445Tyr rpoB  Lys43Arg rpsL  Met306Ile embB,0,14729930,244,0,,,,,,
229,Rv1908c,110,INH,katG,,,Gagneux S PLOS Path 2006,,,752,ACG/ATG,251,251,Thr/Met,,,,,,,,,,,,,0,16789833,245,0,,,,,,
230,Rv1908c,111,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998  ?,,754,TTT/CTT,252,252,Phe/Leu,,,,,,,,,,,,,0,10645439,246,0,,,,,,
231,Rv1908c,112,INH,katG,,,Sekigushi J JCM 2007,,,770,ATG/ACG,257,257,Met/Thr,,2007,Japan & Polan,Japan  Poland,Multiplex  Sequencing,Whole gene,,,Middlebrook 7H10 agar medium method Ogawa egg based medium method  Rapid broth method(BACTEC),38/138,1/0,R463L V780P katG  -15C/T upstream of mabA,0,17596354,247,0,,,,,,
232,Rv1908c,113,INH,katG,,,Lavender C AAC 2005,,,771,ATG/ATT,257,257,Met/Ile,,2001-2003,Victorian Inf DiseaseReference Lab,Australia,Multiplex allele specific PCR Assay,Whole gene,HR,0.1ug/ml I  1ug/ml R,BACTEC MGIT960,52/104,1/0,,0,16189082,248,0,,,,,,
233,Rv1908c,114,INH,katG,,,Cockerill FR JID 1995,,,773,AAC/AGC,258,258,Asn/Ser,,1995,Isolates from the Mayo Clinic,USA,Sequencing.,Whole gene,H,0.25ug/ml,Proportion method,,0/1,Pro2Ser  Ala65Thr  Ala66Pro  Met126Ile  Ala243Ser  Ala264Thr  Tyr337Phe,0,7798673,249,0,,,,,,
234,Rv1908c,115,INH,katG,,,Rouse DA AAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,785,ACA/AGA,262,262,Thr/Arg,site directed mutagenesis,1995,washington DC  Bethesda  South Korea ,USA  South Korea,PCR-SSCP  Sequencing,Whole gene,H,1 ug/ml,Absolute concentration method,26/26,1/0,,0,8585728,250,0,,,,,,
235,Rv1908c,116,INH,katG,,,Cockerill FR JID 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,790,GCG/ACG,264,264,Ala/Thr,no consistent correlation b/w loss of catalase activity and increasing INH inhibitory concentration,1995,clinical strains of mtb,USA  Japan,Sequencing,Whole gene,,0.25; catalase 14mm,Middlebrook 7H11 agar; 1% Proportion method,,1/0,Pro2Ser  Ala65Thr  Ala66Pro  Met126Ile  Ala243Ser  Asn258Ser  Tyr337Phe,0,7798673,251,0,,,,,,
236,Rv1908c,117,INH,katG,,,Chan RCY JAC 2007,,,,del G,268,268,Frameshift,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,252,0,,,,,,
237,Rv1908c,118,INH,katG,,,Pretorius GS AAC 1995,,,820,ACC/GCC,275,275,Thr/Ala,,1995,South Africa Switzerland  USA,South Africa  Switzerland,PCR-SSCP  Sequencing,Whole gene?,HR HRSEEryB,10 & >2.5 ug/ml,Agar dilution method,39/69,2/0,,0,8619582,253,0,,,,,,
238,Rv1908c,119,INH,katG,,,Heym B MolMicro 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,823,ACC/CCC,275,275,Thr/Pro,,1995,Isolates from patients of Pitie Salpietre hospital in France during 1991-92,France,PCR-SSCP  Sequencing,Whole gene,HMDR,> 10 ug/ml,Proportion method,34/37,1/0,,0,7746145,254,0,,,,,,
239,Rv1908c,120,INH,katG,,,Ramaswamy SV J Med Micro 2004,,,823,ACC/TCC,275,275,Thr/Ser,,1996-1998,Jose Gonzalez hospital Mexico,Mexico,Directed Oligonucleotide array  Sequencing,codon 228-357,HR,>=1% growth 0.2ug/ml I  40ug/ml R  4ug/ml S  2ug/ml E,Proportion method,37/50,1/0,His445Asp rpoB ,0,14729930,255,0,,,,,,
240,Rv1908c,121,INH,katG,,,Morlock GP AAC 2003,,,836,GGC/GAC,279,279,Gly/Asp,,2003,United States  Russia  Brazil,Brazil,Sequencing,fragment encompassing codons 249 to 342,HEth,>32 I  >200 Eth,Microplate alamar blue assay,17/41,1/0,D55/A ethA L44L inhA ORF  C(-15)T inhA regulator,1,14638486,256,10,,,,,,
241,Rv1908c,122,INH,katG,,,Gagneux S PLOS Path 2006,,,839-840,CCG/CAT or CCG/CAC,280,280,Pro/His,,,,,,,,,,,,,0,16789833,257,0,,,,,,
242,Rv1908c,123,INH,katG,,,Cockerill FR JID 1995,,,842,GCC/GTC,281,281,Ala/Val,,1995,Isolates from the Mayo Clinic,USA,Sequencing,Whole gene,H,1ug/ml,Proportion method,,1/0,Pro2Ser  Ser17Asn  Met126Ile  Gly169Ala  Gln224Glu  Ala264Val  Try337Cys  Arg463Leu,0,7798673,258,0,,,,,,
243,Rv1908c,124,INH,katG,,,Abe C JCM 2008,,,854,GGC/GAC,285,285,Gly/Asp,,Published in 2008,,Japan,Sequencing,Whole gene,H,,MGIT 960,96/96,1/0,,0,18508939,259,10,,,,,,
244,Rv1908c,125,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,ins,289,289,Frameshift?,Primary paper not found.,,,,,,,,,,,,0,10645439,260,0,,,,,,
245,Rv1908c,126,INH,katG,,,Chan RCY JAC 2007,,,867,GAG/GAC,289,289,Glu/Asp,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,261,0,,,,,,
246,Rv1908c,127,INH,katG,,,Fang Z JCM 1999,,,871,GCT/CCT,291,291,Ala/Pro,,1990-1997,Scottish Mycobacterial refererence lab,United Kingdom,PCR-SSCP  Sequencing,,HR,,BACTEC,10/715,1/0,His 526Tyr rpoB,0,10074516,262,0,,,,,,
247,Rv1908c,128,INH,katG,,,Sekigushi J JCM 2007,,,884,CAG/CCG,295,295,Gln/Pro,,2007,Japan & Poland,Poland,Sequencing,Whole gene,,,Proportion method  BACTEC,38/138,1/0,,0,17596354,263,0,,,,,,
248,Rv1908c,129,INH,katG,,,Sekigushi J JCM 2007,,,890,GGC/GTC,297,297,Gly/Val,,2007,Japan & Poland,Poland,Sequencing,Whole gene,,,Proportion method  BACTEC,38/138,1/0,,0,17596354,264,0,,,,,,
249,Rv1908c,130,INH,katG,,,Chan RCY JAC 2007,,,895,GGC/TGC,299,299,Gly/Cys,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,265,0,,,,,,
250,Rv1908c,131,INH,katG,,,Huang WL JCM 2009,,,896,GGC/GCC,299,299,Gly/Ala,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,266,0,,,,,,
251,Rv1908c,132,INH,katG,,,Lee ASG AAC 1999,,,,TGG/TAA or TGG/TAG or TGG/TGA,300,300,Trp/STOP,Multiple mutations possible,1994-1996,Central Tuberculosis Lab  Singapore,Singapore,Sequencing,Whole gene,H,0.1 ug/ml,BACTEC 460,160/192,,,0,10428945,267,0,,,,,,
252,Rv1908c,133,INH,katG,,,Marttila HJ AAC 1996,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,898,TGG/GGG,300,300,Trp/Gly,,1989-1995,Finland,Finland,Sequencing,Whole gene,H,1 ug/ml,Disk elution method,54/56,1/0,,0,8878604,268,0,,,,,,
253,Rv1908c,134,INH,katG,,,Gagneux S PLOS Path 2006,,,901-902,ins T,301,301,Frameshift,,,,,,,,,,,,,0,16789833,269,0,,,,,,
254,Rv1908c,135,INH,katG,,,Cockerill FR JID 1995,Hazbon MH AAC 2006,,906,AGC/AGG,302,302,Ser/Arg,,1995,Isolates from the Mayo Clinic,USA,Sequencing,Whole gene,H,8ug/ml,Proportion method,40071,1/0,Ser315Thr and Arg463Leu in katG.,0,7798673,270,0,,,,,,
255,Rv1908c,136,INH,katG,,,Bolotin S JAC 2009,,,911,TAT/TCT,304,304,Tyr/Ser,,1999-2001,Ontario Agency for Health Protection and Promotion,Canada,Sequencing,codon 250-500,H  HR,,MGIT 960,154/504,1/0,,0,19520719,271,0,,,,,,
256,Rv1908c,137,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,913,GGC/GCC,305,305,Gly/Ala,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,3/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,272,0,,,,,,
257,Rv1908c,138,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,919,GGA/CGA,307,307,Gly/Arg,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,1/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,273,0,,,,,,
258,Rv1908c,139,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,920,GGA/GCA,307,307,Gly/Ala,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,274,0,,,,,,
259,Rv1908c,140,INH,katG,,,Ramaswamy SV J Med Micro 2004,,,920,GGA/GAA,307,307,Gly/Glu,,1996-1998,Jose Gonzalez hospital Mexico,Mexico,Directed Oligonucleotide array  Sequencing,codon 228-357,HRSE,>=1% growth 0.2ug/ml I  40ug/ml R  4ug/ml S  2ug/ml E,Proportion method,37/50,1/0,Ser450Leu rpoB ,0,14729930,275,0,,,,,,
260,Rv1908c,141,INH,katG,,,Khadka DK Southest Asian J Trop Med Public Health 2007,,,922,ACC/CCC,308,308,Thr/Pro,,2007,Sirirraj hospital Bangkok  Chest Disease Institute  Nonthaburi,Bangkok,PCR-SSCP  Sequencing,894 bp fragment encompassing codons 254 to 549,HRSEO,,,29/30,1/0,Arg463Leu katG  C(-15)T inhA,0,17539290,276,0,,,,,,
261,Rv1908c,142,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,926,GGT/GTT,309,309,Gly/Cys,GTT gives Val  see also ref Zakerbostanabad S IngGenEvol 2008,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,277,0,,,,,,
262,Rv1908c,143,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,926,GGT/GCT,309,309,Gly/Ser,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,278,0,,,,,,
263,Rv1908c,144,INH,katG,,,Kim SY Diagn Micro Inf Dis 2003,,,926,GGT/GAT,309,309,Gly/Asp,,200-2002,Korean Institute of TB  Neodin Medical instittue  Kangman st Mary hosptial in South Korea,South Korea,PCR-SSCP  Sequencing,210 bp fragment spanning codon 315,HR,0.2 ug/ml I 40 ug/ml R,Proportion method,71/97,2/0,inhA Ribosomal binding site C/T,0,14596968,279,0,,,,,,
264,Rv1908c,145,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,926-927,GGT/GTC,309,309,Gly/Phe,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,280,0,,,,,,
265,Rv1908c,146,INH,katG,,,Huang WL JCM 2009,,,928-929,del A,310,310,Frameshift,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,281,0,,,,,,
266,Rv1908c,147,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,931,GAC/TAC,311,311,Asp/Tyr,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,282,0,,,,,,
267,Rv1908c,148,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,931-932,GAC/TTC,311,311,Asp/Phe,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,283,0,,,,,,
268,Rv1908c,149,INH,katG,,,Chan RCY JAC 2007,,,932,GAC/GGC,311,311,Asp/Gly,,2007,Grantham Hosptial and Public Health Lab  Hongkong,Hong Kong,PCR-SSCP  Sequencing,703 bp fragment,HEP,1ug/ml I  4ug/ml E  100ug/ml P,Absolute concentration method  BACTEC MGIT 960,241/302,1/0,574Ser/Leu rpoB,0,17360809,284,0,,,,,,
269,Rv1908c,150,INH,katG,,,Zenteno-Cuevas R MemInstOswaldCruz 2009,,,933,GAC/GAG,311,311,Asp/Glu,,2007,,Mexico,Sequencing,codon 240-390 of katG,HREZ,N.S.,BACTEC 460,17/25,1/0,katG S315T,0,19547874,285,0,,,,,,
270,Rv1908c,151,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,941,ACC/AAC,314,314,Ser/Asn,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,286,0,,,,,,
271,Rv1908c,152,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,941-942,ACC/ACG,314,314,Ser/Thr,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,287,0,,,,,,
272,Rv1908c,153,INH,katG,,,Haas WA AAC 1997,Hazbon MH AAC 2006,,943,AGC/CGC,315,315,Ser/Arg,,1997,NationalTuberculosis Research program South Africa  Sierra Leone  Uganda,South Africa,PCR-RFLP,894 bp central fragment of katG?,H,,,124/212,1/0,,0,9210694,288,0,,,,,,
273,Rv1908c,154,INH,katG,,,Marttila HJ AAC 1996,Hazbon MH AAC 2006,,943,AGC/CTA,315,315,Ser/Leu,,1989-1995,Clinical isolates.,Finland,Sequencing,Whole gene,HS,>1ug/ml,Disk elution method.,17/19,1/0,katG Pro501Ala.,0,8878604,289,0,,,,,,
274,Rv1908c,155,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,943,AGC/GGC,315,315,Ser/Gly,,,,,,,,,,,,,0,10645439,290,0,,,,,,
275,Rv1908c,156,INH,katG,,,Musser JM JID 1996,,,944,AGC/ACC,315,315,Ser/Thr,,,,,,,,,,,,,0,8537659,291,10,,,,,,
276,Rv1908c,157,INH,katG,,,Haas WA AAC 1997,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,944,AGC/ATC,315,315,Ser/Ile,,1997,NationalTuberculosis Research program South Africa  Sierra Leone  Uganda,Sierra Leone  Lesotho,PCR-RFLP,892 bp central fragment,HRSEth H,,,124/212,4/0,,1,9210694,292,10,,,,,,
277,Rv1908c,158,INH,katG,,,Haas WA AAC 1997,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,944,AGC/AAC,315,315,Ser/Asn,,1997,NationalTuberculosis Research program South Africa  Sierra Leone  Uganda,Free state  Gauteng  Sierra leone,PCR-RFLP,890 bp fragment,H HRE HR,,,124/212,9/0,,1,9210694,293,10,,,,,,
278,Rv1908c,159,INH,katG,,,Heym B MolMicro 1995,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,944,AGC/ACC,315,315,Ser/Thr,,1995,Isolates from patients of Pitie Salpietre hospital in France during 1991-92,Mali Ivory coast  France,PCR-SSCP  Sequencing,Whole gene,H,1 in 4 and >5 in 1,Proportional method,34/37,5/0,,1,7746145,294,10,,,,,,
279,Rv1908c,160,INH,katG,,,Marttila HJ AAC 1996,Hazbon MH AAC 2006,,944-945,AGC/ACA,315,315,Ser/Thr,,1989-1995,Finland,Finland,Sequencing,Whole gene,HS HRS,1 ug/ml for I,Disk elution method.,54/56,2/0,nt1501G/C katG in one,1,8878604,295,10,,,,,,
280,Rv1908c,161,INH,katG,,,Gagneux S PLOS Path 2006,,,944-945,AGC/ACG,315,315,Ser/Thr,,,,,,,,,,,,,0,16789833,296,0,,,,,,
281,Rv1908c,162,INH,katG,,,Lipin MY CMI 2007,,,945,AGC/AGA,315,315,Ser/Arg,,1998-2001,Tula & Serpokov district  Moscow,Russia,Sequencing,nt 872-1568,HRS,1 ug/ml I  5 ug/ml S  20ug/ml R,Absolute concentration method,217/217,2/0,335 /GTC katG in one,1,17403134,297,10,,,,,,
282,Rv1908c,163,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,945,AGC/AGG,315,315,Ser/Arg,,,,,,,,,,,,,0,16870753,298,0,,,,,,
283,Rv1908c,164,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,Hazbon MH AAC 2006,,946,GGC/AGC,316,316,Gly/Ser,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,18/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,299,0,,,,,,
284,Rv1908c,165,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,947,GGC/GAC,316,316,Gly/Asp,,,,,,,,,,,,,0,16870753,300,10,,,,,,
285,Rv1908c,166,INH,katG,,,Chan RCY JAC 2007,,,949,ATC/CTC,317,317,Ile/Leu,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,2,0,17360809,301,0,,,,,,
286,Rv1908c,167,INH,katG,,,Zenteno-Cuevas R MemInstOswaldCruz 2009,,,953-954,GAG/GTA,318,318,Gly/Val,,2007,,Mexico,Sequencing,codon 240-390 of katG,HRSEZ,N.S.,BACTEC 460,17/25,1/0,katG S315T,0,19547874,302,0,,,,,,
287,Rv1908c,168,INH,katG,,,Chan RCY JAC 2007,,,961,TGG/CGG,321,321,Trp/Arg,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,3,0,17360809,303,0,,,,,,
288,Rv1908c,169,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,961,TGG/TAG,321,321,Trp/STOP,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,304,0,,,,,,
289,Rv1908c,170,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,962,TGG/TTG,321,321,Trp/Leu,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,305,0,,,,,,
290,Rv1908c,171,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,962-963,TGG/TCC,321,321,Trp/Ser,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,1/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,306,0,,,,,,
291,Rv1908c,172,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,963,TGG/TGT,321,321,Trp/Cys,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,1/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,307,0,,,,,,
292,Rv1908c,173,INH,katG,,,No publication listed,,,970,ACC/CCC,324,324,Thr/Pro,see zakerbostanabad IGE 2008,,,,,,,,,,,,0,,308,0,,,,,,
293,Rv1908c,174,INH,katG,,,Musser JM JID 1996,Hazbon MH AAC 2006,,982,TGG/GGG,328,328,Trp/Gly,,1996,USA Brazil  Rwanda  Belgium  Yemen  Japan  Philippines  Netherlands  Hongkong  Mexico,,Sequencing,Whole gene,HR,>=1ug/ml for I,Proportion method,34/46,1/0,,0,8537659,309,0,,,,,,
294,Rv1908c,175,INH,katG,,,Haas WA AAC 1997,Ramaswamy S Musser JM Tubercle lung Dis 1998,,983,TGG/TTG,328,328,Trp/Leu,,1997,NationalTuberculosis Research program South Africa  Sierra Leone  Uganda,Free state  Lesotho  Eastern Cape  Natal  Swaziland  Gauteng,PCR-RFLP,894 bp central fragment of katG,H,,,124/212,1/0,,0,9210694,310,0,,,,,,
295,Rv1908c,176,INH,katG,,,Boonaiam S CMI 2009,,,984,TGG/TCG,328,328,Trp/Ser,,2005-2006,Molecular Mycology and Mycobacteriology Laboratory,Thailand,Sequencing,Whole gene,MDR,>=1ug/ml for I,Disk elution method,160/170,1/0,,0,19486070,311,0,,,,,,
296,Rv1908c,177,INH,katG,,,Haas WA AAC 1997,Ramaswamy S Musser JM Tubercle lung Dis 1998,,984,TGG/TGC,328,328,Trp/Cys,,1997,NationalTuberculosis Research program South Africa  Sierra Leone  Uganda,Free state  Lesotho  Eastern Cape  Natal  Swaziland  Gauteng,PCR-RFLP,894 bp central fragment of katG,H,,,124/212,1/0,,0,9210694,312,0,,,,,,
297,Rv1908c,178,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,984,TGG/TGT,328,328,Trp/Cys,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,4/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,313,0,,,,,,
298,Rv1908c,179,INH,katG,,,Zenteno-Cuevas R MemInstOswaldCruz 2009,,,991,AGT/TGT,331,331,Ser/Cys,,2007,,Mexico,Sequencing,codon 240-390 of katG,HRS,N.S.,BACTEC 460,17/25,1/0,katG S315T,0,19547874,314,0,,,,,,
299,Rv1908c,180,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,See Note,,334,334,Ile/Thr Error,Error? Residue 334 is Glu (GAG) not Ile.,,,,,,,,,,,,0,10645439,315,0,,,,,,
300,Rv1908c,181,INH,katG,,,Rouse DA AAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1004,ATC/ACC,335,335,Ile/Thr,,,,,,,,,,,,,0,8585728,316,0,,,,,,
301,Rv1908c,182,INH,katG,,,Lipin MY CMI 2007,,,1003,ATC/GTC,335,335,Ile/Val,,1998-2001,Tula & Serpokov district  Moscow,Russia,Sequencing,nt 872-1568,HRS,1 ug/ml I  5 ug/ml S  20ug/ml R,Absolute concentration method,217/217,1/0,315 AGC/AGA katG,0,17403134,317,0,,,,,,
302,Rv1908c,183,INH,katG,,,Lee ASG AAC 1999,Hazbon MH AAC 2006,,1007,CTG/CGG,336,336,Leu/Arg,,,,,,,,,,,,,0,10428945,318,0,,,,,,
303,Rv1908c,184,INH,katG,,,Cockerill FR JID 1995,,,1010,TAC/TTC,337,337,Tyr/Phe,,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,0.25ug/ml,Proportion method,,,Pro2Ser  Ala65Thr  Ala66Pro  Met126Ile  Ala243Ser  Asn258Ser  Ala264Thr,0,7798673,319,0,,,,,,
304,Rv1908c,185,INH,katG,,,Cockerill FR JID 1995,,,1010,TAC/TGC,337,337,Tyr/Cys,,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,1ug/ml,Proportion method,,1/0,Arg429Leu  Trp505Arg  Met609Ile,0,7798673,320,0,,,,,,
305,Rv1908c,186,INH,katG,,,Morlock GP AAC 2003,,,1022,TGG/TCG,341,341,Trp/Ser,,2003,USA  Brazil  Russia,Brazil,Sequencing,fragment encompassing codons 249 to 342,HEth,5o Eth  >32 I,Microplate alamar blue assay,17/41,1/0,4463S ethA  C(-15)T inhA regulator,0,14638486,321,0,,,,,,
306,Rv1908c,187,INH,katG,,,Gagneux S PLOS Path 2006,,,1034,AAG/ACG,345,345,Lys/Thr,,,,,,,,,,,,,0,16789833,322,0,,,,,,
307,Rv1908c,188,INH,katG,,,Chan RCY JAC 2007,,,,del G,346,346,Frameshift,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,2,0,17360809,323,0,,,,,,
308,Rv1908c,189,INH,katG,,,Rouse et al MM 1996,Hazbon MH AAC 2006,,1048,GCT/ACT,350,350,Ala/Thr,site directed mutagenesis to create mutants.,1996,INH-resistant clinical isolates and in vitro mutants of katG in mtb,,,,,,N.S.,n/a,,,0,8939440,324,0,,,,,,
309,Rv1908c,190,INH,katG,,,Rouse DA AAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1048,GCT/TCT,350,350,Ala/Ser,site directed mutagenesis ,1995,Washington D.C Bethesda South Korea,,PCR SSCP,Whole gene,H,1 ug/ml,Absolute concentration method,26/26,1/0,,0,8585728,325,0,,,,,,
310,Rv1908c,191,INH,katG,,,Boonaiam S CMI 2009,,,1054,CAA/TAA,352,352,Gln/STOP,,2005-2006,Molecular Mycology and Mycobacteriology Laboratory,Thailand,Sequencing,Whole gene,MDR,>=1ug/ml for I,Disk elution method,160/170,1/0,,0,19486070,326,0,,,,,,
311,Rv1908c,192,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,1069,GAC/CAC,357,357,Asp/His,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,1/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,327,0,,,,,,
312,Rv1908c,193,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,1069,GAC/AAC,357,357,Asp/Asn,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,1/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,328,0,,,,,,
313,Rv1908c,194,INH,katG,,,Huang WL JCM 2009,,,1082,GCC/GAC,361,361,Ala/Asp,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,329,0,,,,,,
314,Rv1908c,195,INH,katG,,,Huang WL JCM 2009,,,1091,del T,364,364,Frameshift,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,330,0,,,,,,
315,Rv1908c,196,INH,katG,,,Huang WL JCM 2009,,,1133,CTG/CCG,378,378,Leu/Pro,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,331,0,,,,,,
316,Rv1908c,197,INH,katG,,,Huang WL JCM 2009,,,1136,GCC/GTC,379,379,Ala/Val,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,332,0,,,,,,
317,Rv1908c,198,INH,katG,,,Chan RCY JAC 2007,,,1139,ACT/ATT,380,380,Thr/Ile,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,2,0,17360809,333,0,,,,,,
318,Rv1908c,199,INH,katG,,,Rouse et al MM 1996,Hazbon MH AAC 2006,,1142,GAC/GGC,381,381,Asp/Gly,site directed mutagenesis to create mutants.,1996,INH-resistant clinical isolates and in vitro mutants of katG in mtb,,,,,,N.S.,n/a,,,0,8939440,334,0,,,,,,
319,Rv1908c,200,INH,katG,,,Gagneux S PLOS Path 2006,,,1151,CTG/CGG,384,384,Leu/Arg,,,,,,,,,,,,,0,16789833,335,0,,,,,,
320,Rv1908c,201,INH,katG,,,Chan RCY JAC 2007,,,1169,ACT/ATT,390,390,Thr/Ile,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,2,0,17360809,336,0,,,,,,
321,Rv1908c,202,INH,katG,,,Sekigushi J JCM 2007,,,1170,ins CTA,390,390,ins Leu,,2007,Japam & Poland,Japan,Sequencing,Whole gene,,,Proportion method  BACTEC,38/138,2/0,,0,17596354,337,0,,,,,,
322,Rv1908c,203,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1178,ATC/AAC,393,393,Ile/Asn,,,,,,,,,,,,,0,10645439,338,0,,,,,,
323,Rv1908c,204,INH,katG,,,Gagneux S PLOS Path 2006,,,1180,ACG/GCG,394,394,Thr/Ala,,,,,,,,,,,,,0,16789833,339,0,,,,,,
324,Rv1908c,205,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,1191,TGG/TAG,397,397,Trp/STOP,,,,,,,,,,,,,0,16870753,340,0,,,,,,
325,Rv1908c,206,INH,katG,,,Huang WL JCM 2009,,,,del C,401,401,Frameshift,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,341,0,,,,,,
326,Rv1908c,207,INH,katG,,,Pretorius GS AAC 1995,,,1225-1226,GCC/CGC,409,409,Ala/Arg,,1995,USA  Switzerland  South Africa,South Africa,PCR-SSCP  Sequencing,,HRSEryB,2.5 ug/ml,Agar dilution method,39/69,1/0,,0,8619582,342,0,,,,,,
327,Rv1908c,208,INH,katG,,,Chan RCY JAC 2007,,,1226,GCC/GAC,409,409,Ala/Asp,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,2,0,17360809,343,0,,,,,,
328,Rv1908c,209,INH,katG,,,Huang WL JCM 2009,,,1237,TAC/CAC,413,413,Tyr/His,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,344,0,,,,,,
329,Rv1908c,210,INH,katG,,,Bolotin S JAC 2009,,,1242,AAG/AAC,414,414,Lys/Asn,,1999-2001,Ontario Agency for Health Protection and Promotion,Canada,Sequencing,codon 250-500,H  HR,,MGIT 960,154/504,1/0,,0,19520719,345,0,,,,,,
330,Rv1908c,211,INH,katG,,,Ghiladi RA J Am Chem Soc 2005,,,1253,CGA/CTA,418,418,Arg/Leu,,,,,,,,,,,,,0,16173777,346,0,,,,,,
331,Rv1908c,212,INH,katG,,,Mo L Microb Drug Res 2004,,,1253,CGA/CAA,418,418,Arg/Gln,,,,,,,,,,,,,0,15650370,347,0,,,,,,
332,Rv1908c,213,INH,katG,,,Huang WL JCM 2009,,,1255,GAC/CAC,419,419,Asp/His,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,348,0,,,,,,
333,Rv1908c,214,INH,katG,,,Cockerill FR JID 1995,,,1271,GCG/GAG,424,424,Ala/Glu,,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,<0.12ug/ml,Proportion method,,0/1,Gln224Glu and Pro429Ser in katG.,0,7798673,349,0,,,,,,
334,Rv1908c,215,INH,katG,,,Cockerill FR JID 1995,,,1271,GCG/GTG,424,424,Ala/Val,,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,>32ug/ml,Proportion method,,1/0,8-bp deletion in codon 10 + Ala550Asp in katG.,0,7798673,350,0,,,,,,
335,Rv1908c,216,INH,katG,,,Cockerill FR JID 1995,,,1285,CCG/TCG,429,429,Pro/Ser,,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,<0.12ug/ml,Proportion method,,0/1,Gln224Glu and Ala 424Glu in katG.,0,7798673,351,0,,,,,,
336,Rv1908c,217,INH,katG,,,Ramaswamy SV AAC 2003,,,1300,CAG/TAG,434,434,Gln/STOP,,,38 epidemiologically unrelated INH-monoresistant and 86 INH-susceptible isolates,USA  Mexico,Sequencing,,,>256,BACTEC radiometric method (0.1ug/ml); E-test,38/121,1/0,V163I (Rv0340),0,12654653,352,0,,,,,,
337,Rv1908c,218,INH,katG,,,Zhang M J Clin Microb 2005,Hazbon MH AAC 2006,,1329,ins A,438,438,Frameshift,,2005,Clinical isolates,China,IS6110-based RFLP; Sequencing.,Whole gene,H,,BACTEC MGIT 960,1/87,1/0,Arg463Leu in katG; also 1 mutation in oxy-ahpC  and 1 in efpA.,0,16272473,353,0,,,,,,
338,Rv1908c,219,INH,katG,,,Hai Hua Lin TubercRespirDis 2007,,,1330,GCG/ACG,444,444,Ala/Thr,,2004,,South Korea,Sequencing,Whole gene,MDR,N.S.,N.S,29/29,1/0,None,0,2007582629,354,0,,,,,,
339,Rv1908c,220,INH,katG,,,Doustdar F MDR 2008,,,1345,CTC/TTC,449,449,Leu/Phe,,2005-2006,,Iran,Sequencing,250bp around 315 and 212 bp around 463  238bp of inhA and 293bp of ahpC,H,N.S.,Proportion method,48/93,1/0,None,0,19090721,355,0,,,,,,
340,Rv1908c,221,INH,katG,,,Bostanabad SZ Tuberk Torak 2007,,,1360,GAG/CGA,454,454,Glu/Arg,,2004-2005,Clinical INH-R MTB isolates.,Belarus,PCR  Sequencing.,209-bp segment.,H,>1ug/ml,Proportion method  BACTEC,42/42,2/0,Most had 1-4 other katG mutations (most often in codon 315).,0,18445950,356,0,,,,,,
341,Rv1908c,222,INH,katG,,,Bolotin S JAC 2009,,,1370,AGC/ATC,457,457,Ser/Ile,,1999-2001,Ontario Agency for Health Protection and Promotion,Canada,Sequencing,codon 250-500,H  HR,,MGIT 960,154/504,1/0,,0,19520719,357,10,,,,,,
342,Rv1908c,223,INH,katG,,,Hai Hua Lin TubercRespirDis 2007,,,1385,ATC/ACC,462,462,Ile/Thr,,2004,,South Korea,Sequencing,Whole gene,MDR,N.S.,N.S,29/29,1/0,inhA -15 (C/T),0,2007582629,358,0,,,,,,
343,Rv1908c,224,INH,katG,,,Heym B MolMicro 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1389,CGG/CTG,463,463,Arg/Leu,,,,,,,,,,,,,0,7746145,359,0,,,,,,
344,Rv1908c,225,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1431,TGG/TGA,477,477,Trp/STOP,,,,,,,,,,,,,0,10645439,360,0,,,,,,
345,Rv1908c,226,INH,katG,,,Baker LV AAC 2005,,,1450,CGT/AGT,484,484,Arg/Ser,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,,0,15793126,361,0,,,,,,
346,Rv1908c,227,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1454,GGT/GTT,485,485,Gly/Val,,,,,,,,,,,,,0,10645439,362,0,,,,,,
347,Rv1908c,228,INH,katG,,,Marttila HJ AAC 1996,Hazbon MH AAC 2006,,1464,G/C,488,488,Lys/Asn,,1989-1995,Clinical isolates.,Finland,PCR  Sequencing.,Whole gene,H,>1ug/ml,Disk elution method.,17/19,1/0,katG Gln295STOP,0,8878604,363,0,,,,,,
348,Rv1908c,229,INH,katG,,,Baker LV AAC 2005,,,1469,CGC/TGC,490,490,Arg/Cys,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,,0,15793126,364,0,,,,,,
349,Rv1908c,230,INH,katG,,,Lavender C AAC 2005,,,1471,GGC/TGC,491,491,Gly/Cys,,2001-2003,Victorian Inf DiseaseReference Lab,Australia,Multiplex allele specific PCR assay,Whole gene,H,0.4 ug/ml,BACTEC MGIT960 method,52/104,1/0,,0,16189082,365,0,,,,,,
350,Rv1908c,231,INH,katG,,,Hai Hua Lin TubercRespirDis 2007,,,1506,CAA/CAT,502,502,Gln/His,,2004,,South Korea,Sequencing,Whole gene,MDR,N.S.,N.S,29/29,1/0,inhA -15 (C/T),0,2007582629,366,0,,,,,,
351,Rv1908c,232,INH,katG,,,Abe C JCM 2008,,,1513,TGG/TCG,505,505,Trp/Ser,,Published in 2008,,Japan,Sequencing,Whole gene,H,,MGIT 960,96/96,1/0,,0,18508939,367,0,,,,,,
352,Rv1908c,233,INH,katG,,,Cockerill FR JID 1995,,,1513,TGG/CGG,505,505,Trp/Arg,,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,>32ug/ml,Proportion method,,1/0,Tyr337Phe  Arg429Leu  Met609Ile,0,7798673,368,0,,,,,,
353,Rv1908c,234,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,ins ?,511,511,Frameshift,Primary paper not found.,,,,,,,,,,,,0,10645439,369,0,,,,,,
354,Rv1908c,235,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,ins ?,513,513,Frameshift,Primary paper not found.,,,,,,,,,,,,0,10645439,370,0,,,,,,
355,Rv1908c,236,INH,katG,,,Zhang M J Clin Microb 2005,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,1543,CGC/TGC,515,515,Arg/Cys,,2005,Clinical isolates,China,Sequencing.,Whole gene,H,8ug/ml,BACTEC MGIT 960,87/137,1/0,Arg463Leu in katG.,0,16272473,371,0,,,,,,
356,Rv1908c,237,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,ins ?,521,521,Frameshift,Primary paper not found.,,,,,,,,,,,,0,10645439,372,0,,,,,,
357,Rv1908c,238,INH,katG,,,Zhang M J Clin Microb 2005,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,1559,ins 64bp,521,521,Frameshift,,2005,Clinical isolates,China,Sequencing.,Whole gene,H,>256ug/ml,BACTEC MGIT 960,87/137,1/0,Arg463Leu in katG; also 1 mutation in oxy-ahpC  and 1 in efpA.,0,16272473,373,0,,,,,,
358,Rv1908c,239,INH,katG,,,Marttila HJ AAC 1996,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1574,CAG/CCG,525,525,Gln/Pro,,1989-1995,Finland,Finland,Sequencing,Whole gene,H,0.4 ug/ml for I,disk elution method,54/56,1/0,,0,8878604,374,0,,,,,,
359,Rv1908c,240,INH,katG,,,Ramaswamy SV AAC 2003,Hazbon MH AAC 2006,,1585,AAC/GAC,529,529,Asn/Asp,,2003,Clinical isolates.,USA  Mexico  Central America  Southeast Asia  and Africa.,Sequencing,Whole gene,H,N/A,E-Test,38/124,1/0,katG Trp397Tyr  no other mutations in the 19 genes sequenced.,0,12654653,375,0,,,,,,
360,Rv1908c,241,INH,katG,,,Cockerill FR JID 1995,,,1649,GCC/GAC,550,550,Ala/Asp,,1995,Isolates from the Mayo Clinic,USA,Sequencing.,Whole gene,H,0.12->32ug/ml,Proportion method,,,R strain also Ala424Val; S strain also Gln224Glu   Ala243Ser.,0,7798673,376,0,,,,,,
361,Rv1908c,242,INH,katG,,,Hai Hua Lin TubercRespirDis 2007,,,1652,GCC/GGC,551,551,Ala/Gly,,2004,,South Korea,Sequencing,Whole gene,MDR,N.S.,N.S,29/29,1/0,None,0,2007582629,377,0,,,,,,
362,Rv1908c,243,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,1667,del C,556,556,Frameshift,Primary paper not found.,,,,,,,,,,,,0,16870753,378,0,,,,,,
363,Rv1908c,244,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1700,TTC/TCC,567,567,Phe/Ser,,,,,,,,,,,,,0,10645439,379,0,,,,,,
364,Rv1908c,245,INH,katG,,,Gagneux S PLOS Path 2006,,,1717,GAT/AAT,573,573,Asp/Asn,,,,,,,,,,,,,0,16789833,380,0,,,,,,
365,Rv1908c,246,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,1721,GCG/GAG,574,574,Ala/Glu,,,,,,,,,,,,,0,16870753,381,0,,,,,,
366,Rv1908c,247,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1721,GCG/GTG,574,574,Ala/Val,,,,,,,,,,,,,0,10645439,382,0,,,,,,
367,Rv1908c,248,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,1759,CTG/ATG,587,587,Leu/Ile,,,,,,,,,,,,,0,16870753,383,0,,,,,,
368,Rv1908c,249,INH,katG,,,Heym B MolMicro 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1759,CTG/ATG,587,587,Leu/Met,,1995,Isolates from patients of Pitie Salpietre hospital in France during 1991-92,N.S.,PCR-SSCP  Sequencing,Whole gene,H,>5 ug/ml,Proportion method,39/39,1/0,,0,7746145,384,0,,,,,,
369,Rv1908c,250,INH,katG,,,Marttila HJ AAC 1996,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,1760,CTG/CCG,587,587,Leu/Pro,,1989-1995,Finland,Finland,Sequencing,Whole gene,H,0.4ug/ml,disk elution method,54/56,1/0,,0,8878604,385,0,,,,,,
370,Rv1908c,251,INH,katG,,,Cockerill FR JID 1995,,,1765,CCC/ACC,589,589,Pro/Thr,Correct residue at codon.,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,32ug/ml,Proportion method,40071,1/0,Arg429Leu  Ala264Thr in katG.,0,7798673,386,0,,,,,,
371,Rv1908c,252,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1778,GGC/GAC,593,593,Gly/Asp,,,,,,,,,,,,,0,10645439,387,10,,,,,,
372,Rv1908c,253,INH,katG,,,Gagneux S PLOS Path 2006,,,1819,GAG/AAG,607,607,Glu/Lys,,,,,,,,,,,,,0,16789833,388,0,,,,,,
373,Rv1908c,254,INH,katG,,,Cockerill FR JID 1995,,,1827,ATG/ATT  ATG/ATC or ATG/ATA,609,609,Met/Ile,Multiple mutations are possible  could not verify the actual mutation of these isolates after contact with the authors.All 3 mutations possible.,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,<0.12-32ug/ml,Proportion method,,,The 2 R isolates also had Arg463Leu + one other mutation each; the S isolate had no other mutations.,0,7798673,389,0,,,,,,
374,Rv1908c,255,INH,katG,,,Marttila HJ AAC 1996,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1849,ins AC,617,617,Frameshift,,1989-1995,Finland,Finland,Sequencing,Whole gene,H,1 ug/ml,disk elution method,54/56,1/0,,0,8878604,390,0,,,,,,
375,Rv1908c,256,INH,katG,,,Wei CJ AAC 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1856,CTC/CCC,619,619,Leu/Pro,Site directed mutagenesis,2003,,,,,,,,,,,0,12543676,391,0,,,,,,
376,Rv1908c,257,INH,katG,,,Rouse DA AAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,1888,GGC/AGC,629,629,Gly/Ser,site directed mutagenesis,1995,WashingtonD.C  Bethesda  South Korea,,PCR SSCP analysis,Whole gene,H,1ug/ml,Absolute concentration method,26/26,1/0,,0,8585728,392,0,,,,,,
377,Rv1908c,258,INH,katG,,,Wei CJ AAC 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1900,CTC/TTC,634,634,Leu/Phe,site directed mutagenesis,2003,,,,,,,,,,,0,12543676,393,0,,,,,,
378,Rv1908c,259,INH,katG,,,Gagneux S PLOS Path 2006,,,1907,GCA/GAA,636,636,Ala/Glu,,,,,,,,,,,,,0,16789833,394,0,,,,,,
379,Rv1908c,260,INH,katG,,,Gagneux S PLOS Path 2006,,,1958,CTG/CCG,653,653,Leu/Pro,,,,,,,,,,,,,0,16789833,395,0,,,,,,
380,Rv1908c,261,INH,katG,,,Zhang M J Clin Microb 2005,Hazbon MH AAC 2006,,2053,GGC/CGC,685,685,Gly/Arg,,2005,Clinical isolates,China,Sequencing.,Whole gene,H,2ug/ml,BACTEC MGIT 960,1/87,1/0,Ser315Thr in katG.,0,16272473,396,0,,,,,,
381,Rv1908c,262,INH,katG,,,Pretorius GS AAC 1995,,,2084,GAC/GCC,695,695,Asp/Ala,,1995,USA South Africa  Switzerland,South Africa,PCR-SSCP  Sequencing,,HRS,40,Agar dilution method,39/69,1/0,,0,8619582,397,0,,,,,,
382,Rv1908c,263,INH,katG,,,Baker LV AAC 2005,,,2096,GGG/GAG,699,699,Gly/Gln,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,,0,15793126,398,0,,,,,,
383,Rv1908c,264,INH,katG,,,Marttila HJ AAC 1996,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,2098,TCC/CCC,700,700,Ser/Pro,,1989-1995,Finland,Finland,Sequencing,Whole gene,H,1 ug/ml,disk elution method,54/56,1/0,,0,8878604,399,0,,,,,,
384,Rv1908c,265,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,2129,GTC/GCC,710,710,Val/Ala,,,,,,,,,,,,,0,10645439,400,0,,,,,,
385,Rv1908c,266,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,2137,GCC/CCC,713,713,Ala/Pro,,,,,,,,,,,,,0,16870753,401,0,,,,,,
386,Rv1908c,267,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,2150,CAG/CCG,717,717,Gln/Pro,,,,,,,,,,,,,0,16870753,402,0,,,,,,
387,Rv1908c,268,INH,katG,,,Rouse DA AAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,2146,GCG/CCG,716,716,Ala/Pro,site directed mutagenesis,1995,WashingtonD.C  Bethesda  South Korea,USA  South Korea,PCR-SSCP,Whole gene,HRP,50ug/ml,Absolute concentration method,26/26,1/0,,0,8585728,403,0,,,,,,
388,Rv1908c,269,INH,katG,,,Ramaswamy SV J Med Micro 2004,,,2180,GCC/GAC,727,727,Ala/Asp,,1996-1998,Jose Gonzalez Hospital Mexica,Mexico,Directed Oligonucleotide array   Sequencing,codon 228-357,HRS,>=1% growth 0.2ug/ml I  40ug/ml R  4ug/ml S  2ug/ml E,Proportion method,37/50,1/0,Ser450Leu rpoB  nt491C/T rrs  Met306Ile embB,0,14729930,404,0,,,,,,
389,Rv1908c,270,INH,katG,,,Gagneux S PLOS Path 2006,,,2184,TGG/TGT or TGG/TGC,728,728,Trp/Cys,,,,,,,,,,,,,0,16789833,405,0,,,,,,
390,Rv1908c,271,INH,katG,,,Gagneux S PLOS Path 2006,,,2203-2205,del GAC,735,735,del Asp,,,,,,,,,,,,,0,16789833,406,0,,,,,,
391,Rv1908c,272,INH,katG,,,Gagneux S PLOS Path 2006,,,2203,GAC/AAC,735,735,Asp/Asn,,,,,,,,,,,,,0,16789833,407,0,,,,,,
392,Rv1908c,273,INH,katG,,,Wei CJ AAC 2003,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,2204,GAC/GCC,735,735,Asp/Ala,Site directed mutagenesis,2003,,,,,,,,,,,0,12543676,408,0,,,,,,
393,Rv2245,1,INH,kasA,,,Mdluli K Science 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon et al 2006,196,GAT/AAT,66,66,Asp/Asn,,1998,,,Sequencing,Whole gene,H,,,28/71,1/0,not mentioned,0,9616124,409,0,,,,,,
394,Rv2245,2,INH,kasA,,,Ramaswamy SV AAC 2003,,,231,ATG/ATA,77,77,Met/Ile,,2004,Jose Gonzalez tuberculosis clinic in Mexico,Mexico,,,,,,,,,0,12654653,410,0,,,,,,
395,Rv2245,3,INH,kasA,,,Lee ASG AAC 1999,,,362,AGG/AAG,121,121,Arg/Lys,,1994-1996,Central Tuberculosis Lab  Singapore,Singapore,Sequencing,Whole gene,H,0.1ug/ml,BACTEC 460,160/192,1/0,present but not mentioned,0,10428945,411,0,,,,,,
396,Rv2245,4,INH,kasA,,,Mdluli K Science 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,805,GGT/AGT,269,269,Gly/Ser,,1998,,,Sequencing,Whole gene,H,,,28/71,1/0,not mentioned,1,9616124,412,10,,,,,,
397,Rv2245,5,INH,kasA,,,Mdluli K Science 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,934,GGC/AGC,312,312,Gly/Ser,,,,,Sequencing,Whole gene,H,,,28/71,1/0,not mentioned,0,9616124,413,0,,,,,,
398,Rv2245,6,INH,kasA,,,Lee ASG AAC 1999,,,1160,GGC/GAC,387,387,Gly/Asp,,1994-1996,Central Tuberculosis Lab  Singapore,Singapore,Sequencing,Whole gene,H,0.1ug/ml,BACTEC 460,160/192,1/0,present but not mentioned,0,10428945,414,0,,,,,,
399,Rv2245,7,INH,kasA,,,Mdluli K Science 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,1239,TTC/TTA,413,413,Phe/Leu,,1998,,,Sequencing,Whole gene,H,0.1ug/ml,,28/71,1/0,not mentioned,0,9616124,415,0,,,,,,
400,Rv1854c,1,INH,ndh,,,Cardoso RF Mem Inst Oswaldo Cruz 2007,,,37,CGT/TGT,13,13,Arg/Cys,,2006,Institute Adofe Lutz of Ribeirao Preto  Sorocaba  Institute Clemente Ferreira  Sao Paulo and Clinical Bacteriology Lab Parana,Brazil,Sequencing,Whole gene,H,>32ug/ml,Microplate alamar blue assay,24/36,1/0,S315T katG,0,17294000,416,0,,,,,,
401,Rv1854c,2,INH,ndh,,,Cardoso RF Mem Inst Oswaldo Cruz 2007,,,53,GTG/GCG,18,18,Val/Ala,,2006,Institute Adofe Lutz of Ribeirao Preto  Sorocaba  Institute Clemente Ferreira  Sao Paulo and Clinical Bacteriology Lab Parana,Brazil,Sequencing,Whole gene,H,32ug/ml,Microplate alamar blue assay,24/36,1/0,insA at nt17 katG,0,17294000,417,0,,,,,,
402,Rv1854c,3,INH,ndh,,,Lee ASG AAC 2001,Hazbon MH AAC 2006,,328,ACC/GCC,110,110,Thr/Ala,,1994-1996,Central Tuberculosis Laboratory  Singapore General Hospital,Singapore,Sequencing,Whole gene,H,,BACTEC 460,84/106,1/0,none,0,11408244,418,0,,,,,,
403,Rv1854c,4,INH,ndh,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,716,CTG/CCG,239,239,Leu/Pro,Primary paper not found.,,,,,,,,,,,,0,16870753,419,0,,,,,,
404,Rv1854c,5,INH,ndh,,,Lee ASG AAC 2001,Hazbon MH AAC 2006,,804,CGC/CAC,268,268,Arg/His,,1994-1996,Central Tuberculosis Laboratory  Singapore General Hospital,Singapore,Sequencing,Whole gene,H,,BACTEC 460,84/106,7/0,,0,11408244,420,0,,,,,,
405,Rv2427A,1,INH,oxyR,,,Sreevatsan S AAC 1997  (*),Hazbon MH AAC 2006,,331,A/C,110,110,,M Microti  M Bovis  M Africanum MTB studied here,1997,,Brazil  Chile  Mexico  Venezuela  Kenya  Yemen  Philippines  Japan  Netherlands  Romania  USA,Sequencing,Whole gene,H,,Proportion method  BACTEC 460,70/181,only in susceptible,not mentioned,0,9056000,421,0,,,,,,
406,Rv2427A,2,INH,oxyR,,,Sreevatsan S AAC 1997  (*),Hazbon MH AAC 2006,,325,G/T,108,108,,M Microti  M Bovis  M Africanum MTB studied here,1997,,Brazil  Chile  Mexico  Venezuela  Kenya  Yemen  Philippines  Japan  Netherlands  Romania  USA,Sequencing,Whole gene,H,,Proportion method  BACTEC 460,70/181,1/0,not mentioned,0,9056000,422,0,,,,,,
407,Rv2427A,3,INH,oxyR,,,Sreevatsan S Escalante P JCM 1996  (*),Hazbon MH AAC 2006,,285,G/A,95,95,,M Microti  M Bovis  M Africanum MTB studied here. Author found that this polymorphism uniformly differentiated Mbovis(adenine) from non Mbovis(guanine)    using DNA sequencing all 29 Mbovis had adenine at this position and 76 non Mbovis did not. Using RFLP for 255 isolates again same association confirmed,1996,,Brazil  Chile  Ecuador  India  Trinidad-Tobago  Mongolia  Romania  Yugoslavia  Spain  Israel  Turkey  Guinea  Algeria  Kenya  Zaire  Somalia   Mexico  Venezuela  Kenya  Yemen  Philippines  Japan  Netherlands  Romania  USA,Sequencing,410 bp of oxyR,,,,,,,0,8818900,423,0,,,,,,
408,Rv2427A,4,INH,oxyR,,,Sreevatsan S AAC 1997  (*),Hazbon MH AAC 2006,,67,ins GGCG,22,22,Frameshift,M Microti  M Bovis  M Africanum MTB studied here,1997,,Brazil  Chile  Mexico  Venezuela  Kenya  Yemen  Philippines  Japan  Netherlands  Romania  USA,Sequencing,Whole gene,,,Proportion method  BACTEC 460,70/181,N.S.,not mentioned,0,9056000,424,0,,,,,,
409,Rv2427A,5,INH,oxyR,,,Sreevatsan S AAC 1997  (*),Hazbon MH AAC 2006,,37,C/T,12,12,,M Microti  M Bovis  M Africanum MTB studied here,1997,,Brazil  Chile  Mexico  Venezuela  Kenya  Yemen  Philippines  Japan  Netherlands  Romania  USA,Sequencing,Whole gene,,,Proportion method  BACTEC 460,70/181,N.S.,not mentioned,0,9056000,425,0,,,,,,
410,Rv2427A,6,INH,oxyR,,,Lee ASG AAC 1999,,,28,C/A,9,9,,,1994-1996,Singapore Gnereal Hospital Pathology Lab,Singapore,Sequencing,promoter region of ahpC,H,0.1ug/ml,BACTEC 460,160/192,1/0,mostly S315T katG or inhA promoter mutation,0,10428945,426,0,,,,,,
411,Rv2427A,7,INH,oxyR,,,Lee ASG AAC 1999,,,27,G/T,9,9,,,1994-1996,Singapore Gnereal Hospital Pathology Lab,Singapore,Sequencing,promoter region of ahpC,H,0.1ug/ml,BACTEC 460,160/192,1/0,mostly S315T katG or inhA promoter mutation,0,10428945,427,0,,,,,,
412,Rv2427A,8,INH,oxyR,,,Lee ASG AAC 1999,Hazbon MH AAC 2006,,18,G/A,6,6,,,1994-1996,Singapore Gnereal Hospital Pathology Lab,Singapore,Sequencing,promoter region of ahpC,H,0.1ug/ml,BACTEC 460,160/192,39814,mostly S315T katG or inhA promoter mutation,0,10428945,428,0,,,,,,
413,Rv2428,1,INH,ahpC,,,Rindi L Int J Tuberc Lung Dis 2005,,,-74,G/A,-74,-74,,,1994-2002,Clinical Mycobacterial Lab  Pisa and Regional reference centre  Careggi Hospital,Italy,Sequencing,nt 583-819,36H 9MDR,0.1ug/ml,BACTEC 460,45/45,1/0,not mentiond,0,15675557,429,10,,,,,,
414,Rv2428,2,INH,ahpC,,,Huang WL JCM 2009,,,-66,G/A,-66,-66,,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,2/0,not mentiond,0,19494067,430,10,,,,,,
415,Rv2428,3,INH,ahpC,,,Rindi L Int J Tuberc Lung Dis 2005,,,-54,C/T,-54,-54,,,1994-2002,Clinical Mycobacterial Lab  Pisa and Regional reference centre  Careggi Hospital,Italy,Sequencing,nt 583-819,36H 9MDR,0.1ug/ml,BACTEC 460,45/45,1/0,not mentiond,0,15675557,431,10,,,,,,
416,Rv2428,4,INH,ahpC,,,Gagneux S PLOS Path 2006,,,-54,ins ATGT,-54,-54,,,,,,,,,,,,,,0,16789833,432,0,,,,,,
417,Rv2428,5,INH,ahpC,,,No Publication Listed,,,-52,C/T,-52,-52,,Primary paper not found.,,,,,,,,,,,,0,,433,10,,,,,,
418,Rv2428,6,INH,ahpC,,,Doustdar F MDR 2008,,,-49,T/G,-49,-49,,,2005-2006,,Iran,Sequencing,250bp around 315 and 212 bp around 463  238bp of inhA and 293bp of ahpC,H,N.S.,Proportion method,48/93,1/0,None,0,19090721,434,0,,,,,,
419,Rv2428,7,INH,ahpC,,,Ramaswamy SV AAC 2003,,,-48,G/A,-48,-48,,,,,,,,,,,,,,0,12654653,435,10,,,,,,
420,Rv2428,8,INH,ahpC,,,Lee ASG AAC 1999,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-46,G/A,-46,-46,,,1994-1996,Singapore Gnereal Hospital Pathology Lab,Singapore,Sequencing,oxyRahpC intergenic region,H,0.1ug/ml,BACTEC 460,160/192,1/0,katG del/mut or inhA  mutation,1,10428945,436,10,,,,,,
421,Rv2428,9,INH,ahpC,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,-46,del G,-46,-46,,Primary paper not found.,,,,,,,,,,,,0,16870753,437,0,,,,,,
422,Rv2428,10,INH,ahpC,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,-45,C/T,-45,-45,,Primary paper not found.,,,,,,,,,,,,0,10645439,438,10,,,,,,
423,Rv2428,11,INH,ahpC,,,Sreevatsan S AAC 1997  (*),Ramaswamy S Musser JM Tubercle lung Dis 1998,,-44,T/A,-44,-44,,,1997,,Brazil  Chile  Mexico  Venezuela  Kenya  Yemen  Philippines  Japan  Netherlands  Romania  USA,Sequencing,oxyRahpC intergenic region,,,Proportion method  BACTEC 460,70/169,1/0,katG deletion,0,9056000,439,0,,,,,,
424,Rv2428,12,INH,ahpC,,,Silva MS JCM 2003,,,-40,T/C,-40,-40,,,1996-1999,Lab Central Rio Grande  De Sul  Rio de Janeiro  Instituto Adolfo Lutz  Sao Paulo,Brazil,PCR-SSCP  Sequencing,oxyRahpC intergenic region,H HR HRS HRP HS HRE HRES HRESP,,Proportion method,69/69,1/0,S315T kat G,0,12958298,440,0,,,,,,
425,Rv2428,13,INH,ahpC,,,Silva MS JCM 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-39,C/T,-39,-39,,,1996-1999,Lab Central Rio Grande  De Sul  Rio de Janeiro  Instituto Adolfo Lutz  Sao Paulo,Brazil,PCR-SSCP  Sequencing,oxyRahpC intergenic region,H HR HRS HRP HS HRE HRES HRESP,,Proportion method,69/69,2/0,none,1,12958298,441,10,,,,,,
426,Rv2428,14,INH,ahpC,,,Baker LV AAC 2005,Ramaswamy S Musser JM Tubercle lung Dis 1998,,-34,T/A,-34,-34,,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,oxyRahpC intergenic region,H HS HE HSE MDR,ratio>=1,Resistance ratio method,202/378,1/0,Arg463Leu katG,0,15793126,442,0,,,,,,
427,Rv2428,15,INH,ahpC,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,-34,T/C,-34,-34,,Primary paper not found.,,,,,,,,,,,,0,10645439,443,0,,,,,,
428,Rv2428,16,INH,ahpC,,,Baker LV AAC 2005,,,-34,del T,-34,-34,,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array  Sequencing,oxyR'-ahpC intergenic region,H HS HE HSE MDR,ratio>=1,Resistance ratio method,202/378,1/0,S315T  Arg463Leu katG,0,15793126,444,0,,,,,,
429,Rv2428,17,INH,ahpC,,,Sreevatsan S AAC 1997  (*),Ramaswamy S Musser JM Tubercle lung Dis 1998,,-32,G/A,-32,-32,,,1997,,Brazil  Chile  Mexico  Venezuela  Kenya  Yemen  Philippines  Japan  Netherlands  Romania  USA,Sequencing,oxyRahpC intergenic region,H,,BACTEC 460 radiometric method or Proportion method for MTB and Mafricanum isolates only,70/169,1/0,none,0,9056000,445,10,,,,,,
430,Rv2428,18,INH,ahpC,,,Huang WL JCM 2009,,,-32,C/T,-32,-32,,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,446,10,,,,,,
431,Rv2428,19,INH,ahpC,,,Lee ASG AAC 1999,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-30,C/T,-30,-30,,,1994-1996,Singapore Gnereal Hospital Pathology Lab,Singapore,Sequencing,oxyRahpC intergenic region,H,0.1ug/ml,BACTEC 460,160/192,2/0,katG del/mut or inhA mut,0,10428945,447,10,,,,,,
432,Rv2428,20,INH,ahpC,,,Baker LV AAC 2005,,,-20,C/T,-20,-20,,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,oxyRahpC intergenic region,H HS HE HSE MDR,ratio>=1,resistance ratio method,202/378,1/0,none,0,15793126,448,10,,,,,,
433,Rv2428,21,INH,ahpC,,,Gagneux S PLOS Path 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-15,C/T,-15,-15,,Primary paper not found.,,,,,,,,,,,,0,16789833,449,10,,,,,,
434,Rv2428,22,INH,ahpC,,,Lee ASG AAC 1999,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-12,C/T,-12,-12,,,1994-1996,Singapore Gnereal Hospital Pathology Lab,,,,,,,,,,0,10428945,450,10,,,,,,
435,Rv2428,23,INH,ahpC,,,Gagneux S PLOS Path 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-10,C/A,-10,-10,,Primary paper not found.,,,,,,,,,,,,0,16789833,451,0,,,,,,
436,Rv2428,24,INH,ahpC,,,Gagneux S PLOS Path 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-10,C/T,-10,-10,,,,,,,,,,,,,,0,16789833,452,10,,,,,,
437,Rv2428,25,INH,ahpC,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,-10,C/G,-10,-10,,Primary paper not found.,,,,,,,,,,,,0,16870753,453,0,,,,,,
438,Rv2428,26,INH,ahpC,,,Silva MS JCM 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-9,G/A,-9,-9,,,1996-1999,Lab Central Rio Grande  De Sul  Rio de Janeiro  Instituto Adolfo Lutz  Sao Paulo,Brazil,PCR-SSCP  Sequencing,Promoter region of ahpC,H HR HRS HRP HS HRE HRES HRESP,,Proportionmethod on Ogawa medium,69/69,1/0,none,0,12958298,454,10,,,,,,
439,Rv2428,27,INH,ahpC,,,Lee ASG AAC 1999,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon et al 2006,-6,G/A,-6,-6,,,1994-1996,Singapore general hospital Pathology Lab,Singapore,Sequencing,Promoter region of ahpC,H,0.1ug/ml,BACTEC 460,160/192,1/0,katG del/mut or inhA mut,0,10428945,455,10,,,,,,
440,Rv2428,28,INH,ahpC,,,Huang WL JCM 2009,,,-5,G/A,-5,-5,,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,456,10,,,,,,
441,Rv2428,29,INH,ahpC,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,-4,A/G,-4,-4,,Primary paper not found.,,,,,,,,,,,,0,10645439,457,0,,,,,,
442,Rv2428,30,INH,ahpC,,,Huang WL JCM 2009,,,-4,ins A,-4,-4,,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,458,0,,,,,,
443,Rv2428,31,INH,ahpC,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,-4,ins T,-4,-4,,Primary paper not found.,,,,,,,,,,,,0,16870753,459,0,,,,,,
444,Rv2428,32,INH,ahpC,,,Gagneux S PLOS Path 2006,,,0,T/C,0,0,,,,,,,,,,,,,,0,16789833,460,0,,,,,,
445,Rv2428,33,INH,ahpC,,,Lee ASG AAC 1999,Hazbon MH AAC 2006,,4,CCA/TCA,2,2,Pro/Ser,,1994-1996,Singapore general hospital Pathology Lab,Singapore,Sequencing,Promoter region of ahpC,H,0.1ug/ml,BACTEC 460,160/192,1/0,katG del/mut or inhA mut,0,10428945,461,0,,,,,,
446,Rv2428,34,INH,ahpC,,,Kiepiela P Tuber Lung Dis 2000,,,7,CTG/AAG,3,3,Leu/Lys,,1995,King George V Hospital Mycobacterial Lab Durban,South Africa,PCR-SSCP  Sequencing,N.S,H,>8ug/ml,BACTEC 460,79/96,1/0,Pro2Pro ahpC  katG mut present but not specified,0,10897383,462,0,,,,,,
447,Rv2428,35,INH,ahpC,,,Lee ASG AAC 1999,Hazbon MH AAC 2006,,14,ACC/ATC,5,5,Thr/Ile,,1994-1996,Singapore general hospital Pathology Lab,Singapore,Sequencing,Promoter region of ahpC,H,0.1ug/ml,BACTEC 460,160/192,1/0,katG del/mut or inhA mut,0,10428945,463,0,,,,,,
448,Rv2428,36,INH,ahpC,,,Silva MS JCM 2003,,,28,TTC/ATC,10,10,Phe/Ile,,1996-1999,Lab Central Rio Grande  De Sul  Rio de Janeiro  Instituto Adolfo Lutz  Sao Paulo,Brazil,PCR-SSCP  Sequencing,Promoter region of ahpC,H HR HRS HRP HS HRE HRES HRESP,,Proportionmethod on Ogawa medium,69/69,1/0,S315T katG,0,12958298,464,0,,,,,,
449,Rv2428,37,INH,ahpC,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,97,GAC/AAC,33,33,Asp/Asn,Primary paper not found.,,,,,,,,,,,,0,10645439,465,0,,,,,,
450,Rv2428,38,INH,ahpC,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,217,GAC/CAC,73,73,Asp/His,,,,,,,,,,,,,0,16870753,466,0,,,,,,
451,Rv2428,39,INH,ahpC,,,Chan RCY JAC 2007,,,226,GAG/AAG,76,76,Glu/Lys,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,2,0,17360809,467,0,,,,,,
452,Rv2428,40,INH,ahpC,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,572,CTC/CGC,191,191,Leu/Arg,,,,,,,,,,,,,0,16870753,468,0,,,,,,
453,Rv1483,1,INH,fabG1,,,Ramaswamy SV AAC 2003,Hazbon MH AAC 2006,,-147,G/T,-147,-147,,Primary paper not found. Mutation is in Rv1482c/ TBFG 11511 Hypothetical protein Rv1482c Asp3Tyr (GAT/TAT),,,,,,,,,,,,0,12654653,469,0,,,,,,
454,Rv1483,2,INH,fabG1,,,Lee ASG AAC 1999,,,-92,A/T,-92,-92,,,1994-1996,Singapore general hospital Pathology Lab,Singapore,Sequencing,Promoter region of inhA,H,0.1ug/ml,BACTEC 460,160/192,1/0,katG or ahpC-oxyR mut,0,10428945,470,0,,,,,,
455,Rv1483,3,INH,fabG1,,,Doustdar F MDR 2008,,,-67,G/C,-67,-67,,,2005-2006,,Iran,Sequencing,250bp around 315 and 212 bp around 463  238bp of inhA and 293bp of ahpC,H,N.S.,Proportion method,48/93,1/0,inhA 40 G/C and ahpC -6 G/A,0,19090721,471,0,,,,,,
456,Rv1483,4,INH,fabG1,,,Rindi L Int J Tuberc Lung Dis 2005,Ramaswamy S Musser JM Tubercle lung Dis 1998,,-24,G/T,-24,-24,,,1994-2002,Clinical Mycobacterial Lab  Pisa and Regional reference centre  Careggi Hospital,Italy,Sequencing,nt 56-303,,,,45/45,1/0,not mentioned,0,15675557,472,0,,,,,,
457,Rv1483,5,INH,fabG1,,,Rouse DA AAC 1995,,,-24,G/T,-24,-24,,site directed mutagenesis ,1995,WashingtonD.C  Bethesda  South Korea,,PCR SSCP analysis ,N.S.,HS,0.2ug/ml I  4ug/mlS,Absolute concentration method,26/26,1/0,R463l katG,0,8585728,473,0,,,,,,
458,Rv1483,6,INH,fabG1,,,Baker LV AAC 2005,,,-24,G/T,-24,-24,,Error in paper? Nt at -24 is G  not T (see Rouse 1995  Rindi 2005),1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,inhA promoter region,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,S315T Arg463Leu in katG  -46G/A in oxyRahpc intergenic region,0,15793126,474,0,,,,,,
459,Rv1483,7,INH,fabG1,,,Morlock GP AAC 2003,Hazbon MH AAC 2006,,-17,G/T,-17,-17,,,2003,USA CDC  Brazil  Russia,USA,Sequencing,284 bp of inhA promoter and nt 13-379 of inhA,HEth,100ug/ml E  8 ug/ml I,Proportion method,41/42,1/0,I21T inhA ORF,0,14638486,475,0,,,,,,
460,Rv1483,8,INH,fabG1,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,-16,A/G,-16,-16,,Primary paper not found.,,,,,,,,,,,,0,10645439,476,0,,,,,,
461,Rv1483,9,INH,fabG1,,,Lee ASG AAC 1999,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-15,C/T,-15,-15,,,1994-1996,Singapore general hospital Pathology Lab,Singapore,Sequencing,Promoter region of inhA,H,0.1UG/ML,BACTEC 460 radimetric method,160/192,43/0,katG or ahpC-oxyR mut,0,10428945,477,0,,,,,,
462,Rv1483,10,INH,fabG1,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,-11,A/T,-11,-11,,Primary paper not found.,,,,,,,,,,,,0,16870753,478,0,,,,,,
463,Rv1483,11,INH,fabG1,,,Lee ASG AAC 1999,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,-8,T/A,-8,-8,,,1994-1996,Singapore general hospital Pathology Lab,Singapore,Sequencing,Promoter region of inhA,H,0.1UG/ML,BACTEC 460 radimetric method,160/192,1/0,katG or ahpC-oxyR mut,0,10428945,479,0,,,,,,
464,Rv1483,12,INH,fabG1,,,Baker LV AAC 2005,Hazbon MH AAC 2006,,-8,T/C,-8,-8,,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Promoter region of inhA,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,none,0,15793126,480,0,,,,,,
465,Rv1483,13,INH,fabG1,,,Rouse DA AAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,-8,T/G,-8,-8,,site directed mutagenesis ,1995,WashingtonD.C  Bethesda  South Korea,,PCR SSCP analysis,not specified,H,0.2ug/ml,Absolute concentration method,39990,1/0,none,0,8585728,481,0,,,,,,
466,Rv1483,14,INH,fabG1,,,Sekigushi J JCM 2007,,,-5,T/A,-5,-5,,,2007,Japan & Poland,,Sequencing,nt-217 to -198  1145-1126,,,Proportion method  BACTEC,38/138,1/0,M257T R463L katG,0,17596354,482,0,,,,,,
467,Rv1483,15,INH,fabG1,,,Doustdar F MDR 2008,,,13,GCC/CCC,5,5,Ala/Pro,,2005-2006,,Iran,Sequencing,250bp around 315 and 212 bp around 463  238bp of inhA and 293bp of ahpC,H,N.S.,Proportion method,48/93,1/0,mabA -15 C/T and ahpC -6 G/A,0,19090721,483,0,,,,,,
468,Rv1483,16,INH,fabG1,,,Doustdar F MDR 2008,,,40,GTA/CTA,14,14,Val/Leu,,2005-2006,,Iran,Sequencing,250bp around 315 and 212 bp around 463  238bp of inhA and 293bp of ahpC,H,N.S.,Proportion method,48/93,1/0,mabA -67 G/C and ahpC -6 G/A,0,19090721,484,0,,,,,,
469,Rv1483,17,INH,fabG1,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,61,ACC/GCC,21,21,Thr/Ala,,,,,,,,,,,,,0,16870753,485,0,,,,,,
470,Rv1484,1,INH,inhA,,,Hai Hua Lin TubercRespirDis 2007,,,24,AAA/AAC,8,8,Lys/Asn,,2004,,South Korea,Sequencing,Whole gene,MDR,N.S.,N.S,29/29,1/0,inhA -15 (C/T),0,2007582629,486,0,,,,,,
471,Rv1484,2,INH,inhA,,,Basso L JID 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,47,ATC/ACC,16,16,Ile/Thr,,1998,,USA,Sequencing,Whole gene,H,1.0ug/ml,BACTEC,N.S.,1/0,none,0,9728546,487,0,,,,,,
472,Rv1484,3,INH,inhA,,,Morlock GP AAC 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,61,ATC/GTC,21,21,Ile/Val,,2003,USA CDC  Brazil  Russia,USA,Sequencing,284 bp inhA promoter and nt 13-379 of inhA,HEth,8ug/mlI  >200ug/ml Eth,Proportion metho,41/42,2/0,C(-15)T inhA regulator,0,14638486,488,0,,,,,,
473,Rv1484,4,INH,inhA,,,Morlock GP AAC 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,62,ATC/ACC,21,21,Ile/Thr,,2003,USA CDC  Brazil  Russia,USA,Sequencing,284 bp inhA promoter and nt 13-379 of inhA,HEth,>32ug/ml  8ug/ml I  >200 ug/ml or 100ug/ml Eth,Proportion method,41/42,3/0,C(-15)T  G(-17)T inhA regulator ,0,14638486,489,0,,,,,,
474,Rv1484,5,INH,inhA,,,Basso L JID 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,140,ATT/ACT,47,47,Ile/Thr,,1998,,USA,Sequencing,Whole gene,H,1.0 ug/ml,BACTEC,N.S.,1/0,none,0,9728546,490,0,,,,,,
475,Rv1484,6,INH,inhA,,,Basso L JID 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,233,GTG/GCG,78,78,Val/Ala,,1998,,USA,Sequencing,Whole gene,H,1.0 ug/ml,BACTEC,N.S.,1/0,none,0,9728546,491,0,,,,,,
476,Rv1484,7,INH,inhA,,,Lee H Int J Tuberc Lung Dis 2000,Hazbon MH AAC 2006,,280,TCG/GCG,94,94,Ser/Ala,,2000,Korean Institute of TB Seoul,South Korea,Sequencing,nt174-382,HR,0.2ug/ml I  20ug/ml R,,24/24,1/0,,0,10815738,492,0,,,,,,
477,Rv1484,8,INH,inhA,,,Vilcheze C Nat Med 2006,Hazbon MH AAC 2006,,281,TCG/TTG,94,94,Ser/Leu,Using linkage transduction showed that S94A confers resistance to INH by decreased binding to INH-NAD inhibitor,,,,,,,,,,,,0,16906155,493,0,,,,,,
478,Rv1484,9,INH,inhA,,,Ristow M Lancet 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,283-284,ATT/CCT,95,95,Ile/Pro,,1995,,Germany  Nepal,Sequencing,inhA codon 94,HEth,All 7 were resistant to I or Eth or both.,Proportion method,38/47,7/0,not mentioned,0,7637495,494,0,,,,,,
479,Rv1484,10,INH,inhA,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,284,ATT/ACT,95,95,Ile/Thr,Primary paper not found. Couldnt locate mutant. The figure in the reference paper only shows I95P not I95T,,,,,,,,,,,,0,10645439,495,0,,,,,,
480,Rv1484,11,INH,inhA,,,Leung ET AAC 2006,Hazbon MH AAC 2006,,581,ATC/ACC,194,194,Ile/Thr,,1999-2002,HongKong  South China,Hong Kong  China,Sequencing,-38 to-13  250-268 381-399 510-492 860-840 ,H,>1ug/ml,Proportion method,102/375,1/0,not mentioned,0,16495272,496,0,,,,,,
481,Rv1484,12,INH,inhA,,,Huang WL JCM 2009,,,,,202,202,Arg/Gly,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,497,0,,,,,,
482,Rv1484,13,INH,inhA,,,Huang WL JCM 2009,,,,,217,217,Glu/Asp,,2007-2008,,Taiwan,Sequencing,N.S.,242MDR,N.S.,MGIT 960,242/272,1/0,not mentiond,0,19494067,498,0,,,,,,
483,Rv3795,1,INH,embB,,,Shi R AAC 2007,,,997,TAT/CAT,333,333,Tyr/His,These mutations did not confer EMB resistance but were found in RIF and INH resistant isolates,2000,,China,Sequencing,Whole gene,HRS,,,141/181,1/0,not mentioned,0,17846128,499,0,,,,,,
484,Rv1909c,1,INH,furA,,,Ramaswamy SV AAC 2003,Colangeli R Mol Micro 2005,,13,TCC/CCC,5,5,Ser/Pro,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,500,0,,,,,,
485,Rv0340,1,INH,Rv0340,,,Ramaswamy SV AAC 2003,,,487,GTT/ATT,163,163,Val/Ile,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,501,0,,,,,,
486,Rv0341,1,INH,iniB,,,Ramaswamy SV AAC 2003,,,665,del 12 bp,222,222,,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,502,0,,,,,,
487,Rv0342,1,INH,iniA,,,Ramaswamy SV AAC 2003,,,7,CCC/GCC,3,3,Pro/Ala,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,503,0,,,,,,
488,Rv0342,2,INH,iniA,,,Ramaswamy SV AAC 2003,,,282,del 5 bp,94,94,Frameshift,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,504,0,,,,,,
489,Rv0342,3,INH,iniA,,,Ramaswamy SV AAC 2003,,,1610,CGC/CAC,537,537,Arg/His,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,505,0,,,,,,
490,Rv0343,1,INH,iniC,,,Ramaswamy SV AAC 2003,,,247,TGG/GGG,83,83,Trp/Gly,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,506,0,,,,,,
491,Rv1592c,1,INH,Rv1592c,,,Ramaswamy SV AAC 2003,,,-29,G/A,-29,-29,,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,507,0,,,,,,
492,Rv1592c,2,INH,Rv1592c,,,Ramaswamy SV AAC 2003,,,125,CCT/CTT,42,42,Pro/Leu,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,508,0,,,,,,
493,Rv1592c,3,INH,Rv1592c,,,Ramaswamy SV AAC 2003,,,1289,GTG/GCG,430,430,Val/Ala,,,,,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,509,0,,,,,,
494,Rv1772,1,INH,Rv1772,,,Ramaswamy SV AAC 2003,,,10,ACA/GCA,4,4,Thr/Ala,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,510,0,,,,,,
495,Rv2242,1,INH,srmR homolog,,,Ramaswamy SV AAC 2003,,,8,GAC/GGC,3,3,Asp/Gly,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,511,0,,,,,,
496,Rv2242,2,INH,srmR homolog,,,Ramaswamy SV AAC 2003,,,968,ATG/ACG,323,323,Met/Thr,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,512,0,,,,,,
497,Rv2243,1,INH,fabD,,,Ramaswamy SV AAC 2003,,,824,AGC/AAC,275,275,Ser/Asn,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,513,0,,,,,,
498,Rv2247,1,INH,accD6,,,Ramaswamy SV AAC 2003,,,686,GAC/GGC,229,229,Asp/Gly,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,514,0,,,,,,
499,Rv0129c,1,INH,fbpC,,,Ramaswamy SV AAC 2003,,,-63,C/T,-63,-63,,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,515,0,,,,,,
500,Rv0129c,2,INH,fbpC,,,Ramaswamy SV AAC 2003,,,472,GGC/AGC,158,158,Gly/Ser,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,516,0,,,,,,
501,Rv3139,1,INH,fadE24,,,Ramaswamy SV AAC 2003,,,-64,ins 2 bp,-64,-64,Frameshift,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,517,0,,,,,,
502,Rv0129c,2,INH,fbpC,,,Ramaswamy SV AAC 2003,,,-23,A/C,-23,-23,,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,518,0,,,,,,
503,Rv2846c,1,INH,efpA,,,Ramaswamy SV AAC 2003,,,218,ATC/ACC,73,73,Ile/Thr,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,519,0,,,,,,
504,Rv3566c,1,INH,nat,,,Ramaswamy SV AAC 2003,,,201,GGC/GGT,67,67,Gly/Arg,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,520,0,,,,,,
505,Rv3566c,2,INH,nat,,,Ramaswamy SV AAC 2003,,,620,GGG/GAG,207,207,Gly/Glu,,2003,,USA  Mexico,Sequencing,Whole gene,H,,Resistance ratio method  E-test,,,,0,12654653,521,0,,,,,,
506,Rv3919c,1,SM,gid,,,Okamoto S MolMicro 2007,,,47,CCT/CGT,16,16,Leu/Arg,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,HRSE,20 ug/ml,Absolute concentration method,57/132,1/0,G257C(rpsL),0,17238915,522,0,,,,,,
507,Rv3919c,2,SM,gid,,,Okamoto S MolMicro 2007,,,102,del G,34,34,Frameshift,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R H S E K PAS,20 ug/ml,Absolute concentration method,57/132,1/0,A276C (gidB); A908G (rrs),0,17238915,523,0,,,,,,
508,Rv3919c,3,SM,gid,,,Okamoto S MolMicro 2007,,,115,del C,39,39,Frameshift,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S,20 ug/ml,Absolute concentration method,57/132,1/0,none,0,17238915,524,0,,,,,,
509,Rv3919c,4,SM,gid,,,Okamoto S MolMicro 2007,,,118,G/T,40,40,Glu/STOP,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,H  SM  K  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,A262C(rpsL),0,17238915,525,0,,,,,,
510,Rv3919c,5,SM,gid,,,Okamoto S MolMicro 2007,,,140,G/A,47,47,Arg/Gln,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,A908G(rrs),0,17238915,526,0,,,,,,
511,Rv3919c,6,SM,gid,,,Okamoto S MolMicro 2007,,,164,T/G,55,55,Ile/Ser,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E  K  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,A276C (gidB)  A513C (rrs),0,17238915,527,0,,,,,,
512,Rv3919c,7,SM,gid,,,Okamoto S MolMicro 2007,,,199,G/C,67,67,Asp/His,,After 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,S,8 ug/ml,Absolute concentration method,57/132,1/0,none,0,17238915,528,0,,,,,,
513,Rv3919c,8,SM,gid,,,Okamoto S MolMicro 2007,,,208,A/C,70,70,Ser/Arg,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E  K  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,A276C (gidB); A513C (rrs),0,17238915,529,0,,,,,,
514,Rv3919c,9,SM,gid,,,Okamoto S MolMicro 2007,,,210,C/A,70,70,Ser/Arg,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,none,0,17238915,530,0,,,,,,
515,Rv3919c,10,SM,gid,,,Okamoto S MolMicro 2007,,,212,G/T,71,71,Gly/Val,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E ,20 ug/ml,Absolute concentration method,57/132,1/0,A276C (gidB),0,17238915,531,0,,,,,,
516,Rv3919c,11,SM,gid,,,Okamoto S MolMicro 2007,,,223,C/G,75,75,Pro/Ala,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,H  S  E  K,20 ug/ml,Absolute concentration method,57/132,1/0,none,0,17238915,532,0,,,,,,
517,Rv3919c,12,SM,gid,,,Spies FS AAC 2008,,,,TGG/TGC,45,45,Trp/Cys,,Published 2008,Rio Grande do Sul,Brazil,Sequencing,675bp fragment,H R S E,15 6 ug/ml,Resazurin microtiter assay,47/32,1/0,none,0,18541729,533,0,,,,,,
518,Rv3919c,12,SM,gid,,,Okamoto S MolMicro 2007,,,276,GAA/GAC,92,92,Glu/Asp,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,A128G(rpsL),0,17238915,534,0,,,,,,
519,Rv3919c,13,SM,gid,,,Okamoto S MolMicro 2007,,,307,G/T,103,103,Glu/STOP,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E,N.S,Absolute concentration method,57/132,1/0,A513C (rrs),0,17238915,535,0,,,,,,
520,Rv3919c,14,SM,gid,,,Okamoto S MolMicro 2007,,,351,del G,117,117,Frameshift,,After 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,S,8ug/ml,Absolute concentration method,57/132,2/0,,0,17238915,536,0,,,,,,
521,Rv3919c,15,SM,gid,,,Okamoto S MolMicro 2007,,,373,C/T,125,125,Gln/STOP,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,N.S,N.S,Absolute concentration method,57/132,1/0,,0,17238915,537,0,,,,,,
522,Rv3919c,16,SM,gid,,,Okamoto S MolMicro 2007,,,380,A/C,127,127,Gln/Pro,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,N.S,N.S,Absolute concentration method,57/132,1/0,,0,17238915,538,0,,,,,,
523,Rv3919c,17,SM,gid,,,Okamoto S MolMicro 2007,,,401,C/A,134,134,Ala/Glu,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,N.S,N.S,Absolute concentration method,57/132,1/0,,0,17238915,539,0,,,,,,
524,Rv3919c,18,SM,gid,,,Okamoto S MolMicro 2007,,,413,C/T,138,138,Ala/Glu,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  K  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,,0,17238915,540,0,,,,,,
525,Rv3919c,12,SM,gid,,,Spies FS AAC 2008,,,,TGG/CGG,148,148,Trp/Arg,,Published 2008,Rio Grande do Sul,Brazil,Sequencing,675bp fragment,H R S E,15 6 ug/ml,Resazurin microtiter assay,47/32,1/0,none,0,18541729,541,0,,,,,,
526,Rv3919c,19,SM,gid,,,Okamoto S MolMicro 2007,,,548,C/A,183,183,Ala/Glu,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,N.S,N.S,Absolute concentration method,57/132,1/0,,0,17238915,542,0,,,,,,
527,Rv3919c,20,SM,gid,,,Okamoto S MolMicro 2007,,,563,T/G,188,188,Val/Gly,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,R  H  S  E  K  PAS,20 ug/ml,Absolute concentration method,57/132,1/0,a276C (gidB)  G888A (rrs),0,17238915,543,0,,,,,,
528,Rv3919c,21,SM,gid,,,Okamoto S MolMicro 2007,,,599,C/A,200,200,Ala/Glu,,,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,Whole gene,N.S,N.S,Absolute concentration method,57/132,1/0,,0,17238915,544,0,,,,,,
529,Rv0682,1,SM,rpsL,,,Sreevatsan S AAC 1996,,,23,CGC/CAC,9,9,Arg/His,,,,,,,,,,,,,0,8849220,545,0,,,,,,
530,Rv0682,2,SM,rpsL,,,Brzostek A IntJ TubLungDis 2004,,,119,ACC/ATC,40,40,Thr/Ile,novel missense mutation,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,region of rpsL,S,N.S,Proportion method  BACTEC 460,4/88,4/0,,0,15305490,546,0,,,,,,
531,Rv0682,3,SM,rpsL,,,Brzostek A IntJ TubLungDis 2004,,,122,ACT/AGT,41,41,Thr/Ser,,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,region of rpsL,S,N.S,Proportion method  BACTEC 460,1/88,1/0,Thr41Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn  Val52Gly  Gly84Val  Arg86Trp  Val87Leu,0,15305490,547,0,,,,,,
532,Rv0682,4,SM,rpsL,,,Nair J Mol Micro 1993,Musser J CMRev 1995,,128,AAG/AGG,43,43,Lys/Arg,,1950,,USA,Sequencing,Whole gene,S  H  E,N.S,N.S,40033,1/0,,1,7968530,548,28,,,,,,
533,Rv0682,5,SM,rpsL,,,Finken M Mol Micro 1993,,,128,AAG/ACG,43,43,Lys/Thr,mutations in rpsL at codon 43 and 88 present in 20 of 38 STR-res.  none of STR-suscept. 9 of 18 STR-res strains had mutations at 513 or 516 of rrs,1993,m. luteus  m.tb,,Sequencing,Whole gene,MDR,N.S,Proportion method  BACTEC 460,38/73,5/0,not specified,0,7934937,549,0,,,,,,
534,Rv0682,6,SM,rpsL,,,Brzostek A IntJ TubLungDis 2004,,,153,AAG/AAC,51,51,Lys/Asn,,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,region of rpsL,S,N.S,Proportion method  BACTEC 460,1/88,1/0,Thr51Ser is one of 18 silent mutations and 6 a.a. sub: Lys41Asn  Val52Gly  Gly84Val  Arg86Trp  Val87Leu,0,15305490,550,0,,,,,,
535,Rv0682,7,SM,rpsL,,,Brzostek A IntJ TubLungDis 2004,,,155,GTT/GGT,52,52,Val/Gly,,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,region of rpsL,S,N.S,Proportion method  BACTEC 460,1/88,1/0,Thr52Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn  Val41Gly  Gly84Val  Arg86Trp  Val87Leu,0,15305490,551,0,,,,,,
536,Rv0682,8,SM,rpsL,,,Brzostek A IntJ TubLungDis 2004,,,251,GGC/GTC,84,84,Gly/Val,,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,region of rpsL,S,N.S,Proportion method  BACTEC 460,1/88,1/0,Thr84Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn  Val52Gly  Gly41Val  Arg86Trp  Val87Leu,0,15305490,552,0,,,,,,
537,Rv0682,9,SM,rpsL,,,Brzostek A IntJ TubLungDis 2004,,,256,CGG/TGG,86,86,Arg/Trp,,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,region of rpsL,S,N.S,Proportion method  BACTEC 460,1/88,1/0,Thr86Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn  Val52Gly  Gly84Val  Arg41Trp  Val87Leu,0,15305490,553,0,,,,,,
538,Rv0682,10,SM,rpsL,,,Okamoto S MolMicro 2007,,,257,CGG/CCG,86,86,Arg/Pro,,Before 2000,132  Japanese TB patients (57 STR-res  75 STR-suscept.),Japan,Sequencing,,RHSE,20 ug/ml,Absolute concentration method,57/132,1/0,T47G (gidB),0,17238915,554,0,,,,,,
539,Rv0682,11,SM,rpsL,,,Brzostek A IntJ TubLungDis 2004,,,259,GTG/TTG,87,87,Val/Leu,Multiple mutations possible GTG/TTG or GTG/CTG,2000,88 patients with positive cultures from Poland's 2000 national survey,Poland,Sequencing,region of rpsL,S,N.S,Proportion method  BACTEC 460,1/88,1/0,Thr87Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn  Val52Gly  Gly84Val  Arg86Trp  Val41Leu,0,15305490,555,0,,,,,,
540,Rv0682,12,SM,rpsL,,,Sreevatsan S AAC 1996,,,262,AAG/CAG,88,88,Lys/Gln,*data aggregated by geographic locale **unusual isolate; 2 distinct rpsL mutations,1995,139 strains of mtb,Vietnam,Sequencing,Whole gene,S,>200ug/ml,Proportion method  BACTEC 460,78/139,1/0,GTG/ATG  Val/Met,1,8849220,556,14,,,,,,
541,Rv0682,13,SM,rpsL,,,Finken M Mol Micro 1993,,,263,AAG/AGG,88,88,Lys/Arg,mutations in rpsL at codon 43 and 88 present in 20 of 38 STR-res.  none of STR-suscept. 9 of 18 STR-res strains had mutations at 513 or 516 of rrs,1993,m. luteus  m.tb,,Sequencing,Whole gene,S,N.S,Proportion method,38/73,2/0,n/a,1,7934937,557,28,,,,,,
542,Rv0682,14,SM,rpsL,,,Katsukawa C J Appl Micro 1997,,,263,AAG/ATG,88,88,Lys/Met,,,,,,,,,,,,,0,9418025,558,0,,,,,,
543,Rv0682,15,SM,rpsL,,,Katsukawa C J Appl Micro 1997,,,263,AAG/ACG,88,88,Lys/Thr,,,,,,,,,,,,,0,9418025,559,0,,,,,,
544,Rv0682,16,SM,rpsL,,,Sreevatsan S AAC 1996,,,277,GTG/ATG,93,93,Val/Met,,,,,,,,,,,,,0,8849220,560,0,,,,,,
545,Rv2043c,1,PZA,pncA,,,Marttila HJ AAC 1999,,,-12,T/G,-12,-12,,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,561,0,,,,,,
546,Rv2043c,2,PZA,pncA,,,Scorpio A AAC 1997,,,-11,A/C,-11,-11,,*PZA-res mutant made in vitro,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,562,0,,,,,,
547,Rv2043c,3,PZA,pncA,,,Sreevatsan S AAC 1997,,,-11,A/G,-11,-11,,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,2/0,,1,9056006,563,10,,,,,,
548,Rv2043c,4,PZA,pncA,,,Morlock GP AAC 2000,,,-7,T/C,-7,-7,,,1999,,,Sequencing,Whole gene,Z,100,Proportion method,37/60,1/0,,0,11083630,564,0,,,,,,
549,Rv2043c,5,PZA,pncA,,,Hou L Epi Infect 2000,,,1,del 8bp,1,1,Frameshift,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZRHSE,>2000,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,565,0,,,,,,
550,Rv2043c,6,PZA,pncA,,,Scorpio A AAC 1997,,,1,del 11bp,1,1,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,2/0,,0,9055989,566,0,,,,,,
551,Rv2043c,7,PZA,pncA,,,Portugal I AAC 2004,,,2,ATG/ACG,1,1,Met/Thr,,2000-2001,several hospitals in Lisbon,Portugal,Sequencing,Whole gene,Z,,BACTEC MGIT 960,55,55,,0,10449496,567,0,,,,,,
552,Rv2043c,8,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,3,ATG/ATT,1,1,Met/Ile,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,568,0,,,,,,
553,Rv2043c,9,PZA,pncA,,,Lemaitre N AAC 1999,,,7,GCG/CCG,3,3,Ala/Pro,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1986,,France,Sequencing,Whole gene,ZHR,1000,,,1/0,,1,10390238,569,10,,,,,,
554,Rv2043c,10,PZA,pncA,,,Sekiguchi JI JCM 2007,,,8,GCG/GAG,3,3,Ala/Glu,,2006,TB patients in Japan and Poland,Japan,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,1/0,,0,17596354,570,10,,,,,,
555,Rv2043c,11,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,11,TTG/TGG,4,4,Leu/Trp,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,571,0,,,,,,
556,Rv2043c,12,PZA,pncA,,,Morlock GP AAC 2000,,,11,TTG/TCG,4,4,Leu/Ser,,1999,,,Sequencing,Whole gene,Z,800,Proportion method,37/60,1/0,,0,11083630,572,0,,,,,,
557,Rv2043c,13,PZA,pncA,,,Scorpio A AAC 1997,,,14,ATC/AGC,5,5,Ile/Ser,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,573,0,,,,,,
558,Rv2043c,14,PZA,pncA,,,Escalante P TuberLung Dis 1998,,,19,GTC/ATC,7,7,Val/Ile,,1995  1996,patients w/ pulmonary TB,Peru,Sequencing,Whole gene,ZHRPES,,Proportion method,40146,1/0,katG  315  AGC/ACC; rpoB  531  TCG/TTG;,0,10645449,574,0,,,,,,
559,Rv2043c,15,PZA,pncA,,,Escalante P TuberLung Dis 1998,,,19,GTC/TTC,7,7,Val/Phe,,1995  1996,patients w/ pulmonary TB,Peru,Sequencing,Whole gene,ZHRPS,,Proportion method,40146,1/0,katG  315  AGC/ACC; rpoB  531  TCG/TTG; embB  328  GAT:A del,0,10645449,575,0,,,,,,
560,Rv2043c,16,PZA,pncA,,,Hirano  K TLD 1997,,,20,GTC/GGC,7,7,Val/Gly,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Yemen,Sequencing,Whole gene,ZHRSE,>800,Proportion method,33/168,2/0,,0,9692180,576,20,,,,,,
561,Rv2043c,17,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,20,GTC/GAC,7,7,Val/Asp,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,577,0,,,,,,
562,Rv2043c,18,PZA,pncA,,,Marttila HJ AAC 1999,,,22,GAC/TAC,8,8,Asp/Tyr,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,578,0,,,,,,
563,Rv2043c,19,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,23,GAC/GGC,8,8,Asp/Gly,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,579,10,,,,,,
564,Rv2043c,20,PZA,pncA,,,Scorpio A AAC 1997,,,24,GAC/GAG,8,8,Asp/Glu,*PZA-res mutant made in vitro,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,580,0,,,,,,
565,Rv2043c,21,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,26,GTG/GCG,9,9,Val/Ala,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,581,10,,,,,,
566,Rv2043c,22,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,26,GTG/GGG,9,9,Val/Gly,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,582,20,,,,,,
567,Rv2043c,23,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,26,GTG/TTG,9,9,Val/Leu,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,583,0,,,,,,
568,Rv2043c,24,PZA,pncA,,,Chan RCY JAC 2007,,,27,GTG/TCG,9,9,Val/Ser,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,584,0,,,,,,
569,Rv2043c,25,PZA,pncA,,,Scorpio A AAC 1997,,,28,del C,10,10,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,585,0,,,,,,
570,Rv2043c,26,PZA,pncA,,,Marttila HJ AAC 1999,,,28,CAA/AAA,10,10,Gln/Lys,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,586,0,,,,,,
571,Rv2043c,27,PZA,pncA,,,Marttila HJ AAC 1999,,,28,CAA/TAA,10,10,Gln/STOP,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,587,0,,,,,,
572,Rv2043c,28,PZA,pncA,,,Cheng SJ AAC 2000,,,29,CAG/CGA,10,10,Gln/Arg,,1990-1992,,USA,Sequencing,Whole gene,ZHREO,>900,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,588,0,,,,,,
573,Rv2043c,29,PZA,pncA,,,Hirano  K TLD 1997,,,29,CAG/CCG,10,10,Gln/Pro,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Myanmar,Sequencing,Whole gene,ZHRSE,>800,Proportion method,33/168,1/0,,1,9692180,589,20,,,,,,
574,Rv2043c,30,PZA,pncA,,,Morlock GP AAC 2000,,,29,CAG/CCA,10,10,Gln/Pro,,1999,,,Sequencing,Whole gene,Z,800,Proportion method,37/60,1/0,,0,11083630,590,0,,,,,,
575,Rv2043c,31,PZA,pncA,,,Scorpio A AAC 1997,,,34,GAC/AAC,12,12,Asp/Asn,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,591,0,,,,,,
576,Rv2043c,32,PZA,pncA,,,Scorpio A AAC 1997,,,35,GAC/GCC,12,12,Asp/Ala,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,1,9055989,592,10,,,,,,
577,Rv2043c,33,PZA,pncA,,,Lemaitre N AAC 1999,,,38,TTC/TCC,13,13,Phe/Ser,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1987,,France,Sequencing,Whole gene,ZHRES,>2000,,19/35,1/0,,0,10390238,593,0,,,,,,
578,Rv2043c,34,PZA,pncA,,,Scorpio A AAC 1997,,,40,TGC/CGC,14,14,Cys/Arg,*PZA-res mutant made in vitro,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,1,9055989,594,20,,,,,,
579,Rv2043c,35,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,40,TGC/CGC,14,14,Cys/His,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,1,16848344,595,20,,,,,,
580,Rv2043c,36,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,41,TGC/TAC,14,14,Cys/Tyr,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,596,0,,,,,,
581,Rv2043c,37,PZA,pncA,,,Chan RCY JAC 2007,,,47,del G,16,16,Frameshift,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,597,0,,,,,,
582,Rv2043c,38,PZA,pncA,,,Hirano  K TLD 1997,,,50,GGC/GAC,17,17,Gly/Asp,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Thailand,Sequencing,Whole gene,ZHRS,>800,Proportion method,33/168,2/0,,1,9692180,598,10,,,,,,
583,Rv2043c,39,PZA,pncA,,,Chan RCY JAC 2007,,,50,GGC/GTC,17,17,Gly/Val,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,599,0,,,,,,
584,Rv2043c,40,PZA,pncA,,,Cheng SJ AAC 2000,,,52,ins GG,17,17,Frameshift,,,,USA,Sequencing,Whole gene,ZHR,>900,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,600,0,,,,,,
585,Rv2043c,41,PZA,pncA,,,Chan RCY JAC 2007,,,56,CTG/CGG,19,19,Leu/Arg,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,601,20,,,,,,
586,Rv2043c,42,PZA,pncA,,,Sreevatsan S AAC 1997,,,56,CTG/CCG,19,19,Leu/Pro,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,1,9056006,602,30,,,,,,
587,Rv2043c,43,PZA,pncA,,,Chan RCY JAC 2007,,,62,GTA/GGA,21,21,Val/Gly,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,1,17360809,603,10,,,,,,
588,Rv2043c,44,PZA,pncA,,,Chan RCY JAC 2007,,,64,del A,22,22,Frameshift,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,604,0,,,,,,
589,Rv2043c,45,PZA,pncA,,,Hou L Epi Infect 2000,,,59,del C,20,20,Frameshift,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZRSE,1800,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,605,0,,,,,,
590,Rv2043c,46,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,68-69,GGT/GTC,23,23,Gly/Val,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,606,0,,,,,,
591,Rv2043c,47,PZA,pncA,,,Sreevatsan S AAC 1997,,,70,del G,24,24,Frameshift,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,7/0,,1,9056006,607,0,,,,,,
592,Rv2043c,48,PZA,pncA,,,Hou L Epi Infect 2000,,,71,del G,24,24,Frameshift,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZRH,600,Proportion method  BACTEC 460,35/65,1/0,,1,10813147,608,0,,,,,,
593,Rv2043c,49,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,74-75,GCC/GAA,25,25,Ala/Glu,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,609,0,,,,,,
594,Rv2043c,50,PZA,pncA,,,Scorpio A AAC 1997,,,77,GCG/GGG,26,26,Ala/Gly,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,610,0,,,,,,
595,Rv2043c,51,PZA,pncA,,,Marttila HJ AAC 1999,,,84,del C,28,28,Frameshift,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,611,0,,,,,,
596,Rv2043c,52,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,83,GCC/GAC,28,28,Ala/Asp,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,612,0,,,,,,
597,Rv2043c,53,PZA,pncA,,,Hannan MM JCM 2001,,,88-112,del 24bp,29,,Frameshift,,1996-1999,isolates from 5 counties in California,California  USA,Sequencing,Whole gene,Z,,BACTEC radiometric testing,39883,1/0,,0,11158123,613,0,,,,,,
598,Rv2043c,54,PZA,pncA,,,Scorpio A AAC 1997,,,98-216,del 118bp,33,,Frameshift,*PZA-res mutant made in vitro,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,614,0,,,,,,
599,Rv2043c,55,PZA,pncA,,,Scorpio A AAC 1997,,,100,ins T,34,34,Frameshift,*PZA-res mutant made in vitro,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,615,0,,,,,,
600,Rv2043c,56,PZA,pncA,,,Hirano  K TLD 1997,,,101,TAC/TCC,34,34,Tyr/Ser,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Thailand,Sequencing,Whole gene,ZHRSE,>800,Proportion method,33/168,2/0,,1,9692180,616,10,,,,,,
601,Rv2043c,57,PZA,pncA,,,Stavrum R PlosOne 2009,,,104,CTG/CCG,35,35,Leu/Pro,,Published 2009,,India,Sequencing,Whole gene,,,N.S.,,1/0,,0,19234602,617,30,,,,,,
602,Rv2043c,58,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,104,CTG/CGG,35,35,Leu/Arg,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,1,16848344,618,20,,,,,,
603,Rv2043c,59,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,109-110,GGA/TAA,37,37,Glu/STOP,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,619,0,,,,,,
604,Rv2043c,60,PZA,pncA,,,Morlock GP AAC 2000,,,106,del 5.3kb,35,,Frameshift/Truncation,,1999,,,Sequencing,Whole gene,Z,800,Proportion method,37/60,1/0,,0,11083630,620,0,,,,,,
605,Rv2043c,61,PZA,pncA,,,Hou L Epi Infect 2000,,,121,TAC/CAC,41,41,Tyr/His,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZHRE,600,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,621,0,,,,,,
606,Rv2043c,62,PZA,pncA,,,Hirano  K TLD 1997,,,123,TAC/TAA,41,41,Tyr/STOP,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Thailand,Sequencing,Whole gene,ZHRSE,>800,Middlebrook 7H11 agar w/ pH of 6.0,33/168,1/0,,0,9692180,622,0,,,,,,
607,Rv2043c,63,PZA,pncA,,,Sreevatsan S AAC 1997,,,123,TAC/TAG,41,41,Tyr/STOP,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,1,9056006,623,30,,,,,,
608,Rv2043c,64,PZA,pncA,,,Hirano  K TLD 1997,,,128,CAC/CCC,43,43,His/Pro,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Thailand,Sequencing,Whole gene,ZHR,>800,Proportion method,33/168,1/0,,0,9692180,624,10,,,,,,
609,Rv2043c,65,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,134,GTG/GGG,45,45,Val/Gly,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,625,20,,,,,,
610,Rv2043c,66,PZA,pncA,,,Hirano  K TLD 1997,,,136,ins G,46,46,Frameshift,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Yemen,Sequencing,Whole gene,ZHE,>800,Proportion method,33/168,1/0,,0,9692180,626,0,,,,,,
611,Rv2043c,67,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,136,GCA/CCA,46,46,Ala/Pro,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,627,0,,,,,,
612,Rv2043c,68,PZA,pncA,,,Cheng SJ AAC 2000,,,137,GCA/GAA,46,46,Ala/Glu,,,,South korea,Sequencing,Whole gene,Z,>500,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,628,0,,,,,,
613,Rv2043c,69,PZA,pncA,,,Cheng SJ AAC 2000,,,137,GCA/GTA,46,46,Ala/Val,,,,South korea,Sequencing,Whole gene,Z,>500,Proportion method  BACTEC 460,59/59,1/0,,1,10681313,629,10,,,,,,
614,Rv2043c,70,PZA,pncA,,,Hou L Epi Infect 2000,,,139,ACC/CCC,47,47,Thr/Pro,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZRSE,1500,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,630,0,,,,,,
615,Rv2043c,71,PZA,pncA,,,Marttila HJ AAC 1999,,,139,ACC/TCC,47,47,Thr/Ser,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,631,0,,,,,,
616,Rv2043c,72,PZA,pncA,,,Sreevatsan S AAC 1997,,,139,ACC/GCC,47,47,Thr/Ala,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,11/0,,1,9056006,632,10,,,,,,
617,Rv2043c,73,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,145,GAC/CAC,49,49,Asp/His,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,633,0,,,,,,
618,Rv2043c,74,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,146,GAC/GCC,49,49,Asp/Ala,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,634,10,,,,,,
619,Rv2043c,75,PZA,pncA,,,Marttila HJ AAC 1999,,,146,GAC/GTC,49,49,Asp/Val,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,635,0,,,,,,
620,Rv2043c,76,PZA,pncA,,,Marttila HJ AAC 1999,,,146,GAC/GGC,49,49,Asp/Gly,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,636,10,,,,,,
621,Rv2043c,77,PZA,pncA,,,Rodrigues V de F AAC 2005,,,151,CAC/AAC,51,51,His/Asn,,1998-2003,Selected according to culture availability in health centers in Brazl,Brazil,Sequencing,Whole gene,Z,,Proportion method,59,40,,0,15616332,637,0,,,,,,
622,Rv2043c,78,PZA,pncA,,,Mestdagh M AAC 1999,,,151,CAC/TAC,51,51,His/Tyr,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Scotland,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,638,10,,,,,,
623,Rv2043c,79,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,151-230,del 80bp,50,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,639,0,,,,,,
624,Rv2043c,80,PZA,pncA,,,Hirano  K TLD 1997,,,152,CAC/CCC,51,51,His/Pro,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Thailand,Sequencing,Whole gene,ZHR,>800,Proportion method,33/168,1/0,,1,9692180,640,10,,,,,,
625,Rv2043c,81,PZA,pncA,,,Hirano  K TLD 1997,,,152,CAC/CGC,51,51,His/Arg,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Thailand,Sequencing,Whole gene,ZHR,>800,Proportion method,33/168,1/0,,1,9692180,641,10,,,,,,
626,Rv2043c,82,PZA,pncA,,,Sekiguchi JI JCM 2007,,,153,CAC/CAG,51,51,His/Gln,,2006,TB patients in Japan and Poland,Poland,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,1/0,,0,17596354,642,0,,,,,,
627,Rv2043c,83,PZA,pncA,,,Sekiguchi JI JCM 2007,,,153,CAC/CAA,51,51,His/Gln,,2006,TB patients in Japan and Poland,Japan,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,2/0,,0,17596354,643,0,,,,,,
628,Rv2043c,84,PZA,pncA,,,Sekiguchi JI JCM 2007,,,151,GAC/AAC,53,53,Asp/Asn,,2006,TB patients in Japan and Poland,Japan,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,1/0,,0,17596354,644,0,,,,,,
629,Rv2043c,85,PZA,pncA,,,Cheng SJ AAC 2000,,,158,GAC/GCC,53,53,Asp/Ala,,,,South korea,Sequencing,Whole gene,Z,>100,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,645,10,,,,,,
630,Rv2043c,86,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,158,del A,53,53,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,646,0,,,,,,
631,Rv2043c,87,PZA,pncA,,,Sreevatsan S AAC 1997,,,160,CCG/ACG,54,54,Pro/Thr,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,1,9056006,647,10,,,,,,
632,Rv2043c,88,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,161,CCG/CTG,54,54,Pro/Leu,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,648,0,,,,,,
633,Rv2043c,89,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,161,del C,54,54,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,649,0,,,,,,
634,Rv2043c,90,PZA,pncA,,,Scorpio A AAC 1997,,,162,ins T,54,54,Frameshift,*PZA-res mutant made in vitro,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,650,0,,,,,,
635,Rv2043c,91,PZA,pncA,,,Scorpio A Nature Med 1996,,,162,del G,54,54,Frameshift,,,clinical isolates from L. Heifets  National Jewish Center for Immunology and Resp. Diseases,USA,Sequencing,Whole gene,MDR,>500ug/ml,7H9 liquid medium  pH5.6; PZase activity assayed according to Wayne's method,39910,1/0,,0,8640557,651,0,,,,,,
636,Rv2043c,92,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,169,CAC/TAC,57,57,His/Tyr,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,1,16848344,652,10,,,,,,
637,Rv2043c,93,PZA,pncA,,,Sreevatsan S AAC 1997,,,169,CAC/GAC,57,57,His/Asp,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,2/0,,0,9056006,653,0,,,,,,
638,Rv2043c,94,PZA,pncA,,,Brown TJ JMedMicro 2000,,,170,CAC/CCC,57,57,His/Pro,all sensitive isolates were WT and mutants and resistant ones had mutant genotypes,2000,4 sensitive  6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK,Turkey,Sequencing,Whole gene,ZHRP,,BACTEC radiometric-based culture method  standard protocol; and PZase activity,13/18,1/0,A2416T (rpoB),0,10882091,654,10,,,,,,
639,Rv2043c,95,PZA,pncA,,,Chan RCY JAC 2007,,,170,CAC/CTC,57,57,His/Leu,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,655,0,,,,,,
640,Rv2043c,96,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,172,del T,58,58,Frameshift,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,1,16848344,656,0,,,,,,
641,Rv2043c,97,PZA,pncA,,,Escalante P TuberLung Dis 1998,,,172,TTC/CTC,58,58,Phe/Leu,,1995-1996,patients w/ pulmonary TB,Peru,Sequencing,Whole gene,ZHR,,Proportion method,40146,1/0,katG  315  AGC/ACC; rpoB  526 cac/ctc; embB  306  ATG/ATA,0,10645449,657,0,,,,,,
642,Rv2043c,98,PZA,pncA,,,Hirano  K TLD 1997,,,174,TTC/TTG,58,58,Phe/Leu,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Canada,Sequencing,Whole gene,ZHRS,400,Proportion method,33/168,1/0,,0,9692180,658,0,,,,,,
643,Rv2043c,99,PZA,pncA,,,Brown TJ JMedMicro 2000,,,175,TCC/CCC,59,59,Ser/Pro,all sensitive isolates were WT and mutants and resistant ones had mutant genotypes,2000,4 sensitive  6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK,Turkey,Sequencing,Whole gene,ZHRP,,BACTEC 460,13/18,1/0,C2431T (rpoB),0,10882091,659,0,,,,,,
644,Rv2043c,100,PZA,pncA,,,Lemaitre N AAC 1999,,,181,ACA/CCA,61,61,Thr/Pro,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1992,,France,Sequencing,Whole gene,ZHRES,500ug/ml,,19/35,1/0,,0,10390238,660,10,,,,,,
645,Rv2043c,101,PZA,pncA,,,Mestdagh M AAC 1999,,,185,CCG/CAG??,62,62,Pro/His,Error? CCG/CAG Is Pro/Gln,1999,54 MDR mtb clinical strains,Azerbaijan,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,661,0,,,,,,
646,Rv2043c,102,PZA,pncA,,,Morlock GP AAC 2000,,,185,CCG/CGG,62,62,Pro/Arg,,1999,,,Sequencing,Whole gene,Z,>800,Proportion method,37/60,1/0,,0,11083630,662,0,,,,,,
647,Rv2043c,103,PZA,pncA,,,Chan RCY JAC 2007,,,186,CCG/CTG,62,62,Pro/Leu,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,663,0,,,,,,
648,Rv2043c,104,PZA,pncA,,,Hirano  K TLD 1997,,,188,GAC/GGC,63,63,Asp/Gly,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Yemen,Sequencing,Whole gene,ZHRS,>800,Proportion method,33/168,1/0,,1,9692180,664,10,,,,,,
649,Rv2043c,105,PZA,pncA,,,Scorpio A Nature Med 1996,,,187,GAC/CAC,63,63,Asp/His,,,clinical isolates from L. Heifets  National Jewish Center for Immunology and Resp. Diseases,USA (Colorado),Sequencing,Whole gene,MDR,>500ug/ml,PZase test with Wayne's method,39910,1/0,,0,8640557,665,0,,,,,,
650,Rv2043c,106,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,190,TAT/GAT,64,64,Tyr/Asp,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,666,0,,,,,,
651,Rv2043c,107,PZA,pncA,,,Lemaitre N AAC 1999,,,192,ins A,64,64,Frameshift,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1996,,France,Sequencing,Whole gene,ZSHE,1000ug/ml,,,1/0,,0,10390238,667,0,,,,,,
652,Rv2043c,108,PZA,pncA,,,Mestdagh M AAC 1999,,,195-263,del 68bp,65,,Frameshift,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Azerbaijan,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,668,0,,,,,,
653,Rv2043c,109,PZA,pncA,,,Marttila HJ AAC 1999,,,196,TCG/CCG,66,66,Ser/Pro,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,1,10390239,669,20,,,,,,
654,Rv2043c,110,PZA,pncA,,,Hirano  K TLD 1997,,,199,TCG/CCG,67,67,Ser/Pro,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Canada,Sequencing,Whole gene,ZHRSE,>800,Proportion method,33/168,1/0,,1,9692180,670,20,,,,,,
655,Rv2043c,111,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,202,TGG/CGG,68,68,Trp/Arg,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,1,11641519,671,10,,,,,,
656,Rv2043c,112,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,202,TGG/GGG,68,68,Trp/Gly,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,1,11641519,672,10,,,,,,
657,Rv2043c,113,PZA,pncA,,,Cheng SJ AAC 2000,,,203,TGG/TCA,68,68,Trp/STOP,,,,USA,Sequencing,Whole gene,Z,>900,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,673,0,,,,,,
658,Rv2043c,114,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,203,TGG/TCG,68,68,Trp/Ser,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,674,0,,,,,,
659,Rv2043c,115,PZA,pncA,,,Sreevatsan S AAC 1997,,,203,TGG/TTG,68,68,Trp/Leu,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,1,9056006,675,10,,,,,,
660,Rv2043c,116,PZA,pncA,,,Scorpio A AAC 1997,,,206,CCA/CGA,69,69,Pro/Arg,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>300ug/ml,Pzase testing by Wayne's method,46/46,2/0,,0,9055989,676,0,,,,,,
661,Rv2043c,117,PZA,pncA,,,Hou L Epi Infect 2000,,,206,CCA/CGA,69,69,Pro/Arg,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZRHSE,1200,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,677,0,,,,,,
662,Rv2043c,118,PZA,pncA,,,Lemaitre N AAC 1999,,,206,CCA/CTA,69,69,Pro/Leu,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1994,,France,Sequencing,Whole gene,ZHR,(pH 5.6  5.8) >2000/>2000,,19/35,1/0,,0,10390238,678,0,,,,,,
663,Rv2043c,119,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,211,CAT/TAT,71,71,His/Tyr,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,679,0,,,,,,
664,Rv2043c,120,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,212,CAT/GAT,71,71,His/Asp,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,680,0,,,,,,
665,Rv2043c,121,PZA,pncA,,,Morlock GP AAC 2000,,,212,CAT/CGT,71,71,His/Arg,,1999,,,Sequencing,Whole gene,Z,>800,Proportion method,37/60,1/0,,1,11083630,681,30,,,,,,
666,Rv2043c,122,PZA,pncA,,,Cheng SJ AAC 2000,,,213,CAT/CAG,71,71,His/Glu,,,,USA,Sequencing,Whole gene,ZHRS,>900,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,682,0,,,,,,
667,Rv2043c,123,PZA,pncA,,,Scorpio A AAC 1997,,,214,TGC/CGC,72,72,Cys/Arg,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,1,9055989,683,20,,,,,,
668,Rv2043c,124,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,215,TGC/TAC,72,72,Cys/Tyr,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,684,0,,,,,,
669,Rv2043c,125,PZA,pncA,,,Sekiguchi JI JCM 2007,,,216,TGC/TGG,72,72,Cys/Trp,,2006,TB patients in Japan and Poland,Japan,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,1/0,,0,17596354,685,0,,,,,,
670,Rv2043c,126,PZA,pncA,,,Lemaitre N AAC 1999,,,215,ins 29bp,72,,Frameshift,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1986,,France,Sequencing,Whole gene,ZHRS,>2000,,19/35,1/0,,0,10390238,686,0,,,,,,
671,Rv2043c,127,PZA,pncA,,,Sekiguchi JI JCM 2007,,,218,ins CGCATTGCCG,73,,Frameshift,,2006,TB patients in Japan and Poland,,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,1/0,,0,17596354,687,0,,,,,,
672,Rv2043c,128,PZA,pncA,,,Mestdagh M AAC 1999,,,221,ins G,74,74,Frameshift,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,United Kingdom,Sequencing,Whole gene,Z,,BACTEC 460,23/62,2/0,,0,10471589,688,0,,,,,,
673,Rv2043c,129,PZA,pncA,,,Chan RCY JAC 2007,,,224,ATG/ACG,75,75,Met/Thr,36% resistant to PZA  80% of PZA-r had mutations  80% mutants had resistance  11% drug susceptible had mutations,1994-2004,250 drug-res. Mtb from Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,ZORH,100ug/ml,BACTEC MGIT 960,89/250,1/0,Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB); Ser315Thr(katG),0,17360809,689,0,,,,,,
674,Rv2043c,130,PZA,pncA,,,Sreevatsan S AAC 1997,,,226,ACT/CCT,76,76,Thr/Pro,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,1,9056006,690,10,,,,,,
675,Rv2043c,131,PZA,pncA,,,Brown TJ JMedMicro 2000,,,227,ACT/ATT,76,76,Thr/Ile,all sensitive isolates were WT and mutants and resistant ones had mutant genotypes,2000,4 sensitive  6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK,United Kindom  Turkey,Sequencing,Whole gene,ZHRP,,BACTEC 460,13/18,8/0,C2431T (rpoB),0,10882091,691,0,,,,,,
676,Rv2043c,132,PZA,pncA,,,Morlock GP AAC 2000,,,233,GGC/GAC,78,78,Gly/Asp,,1999,,,Sequencing,Whole gene,Z,>800,Proportion method,37/60,1/0,,0,11083630,692,10,,,,,,
677,Rv2043c,133,PZA,pncA,,,Chan RCY JAC 2007,,,236,GCG/GGG,79,79,Ala/Gly,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,693,0,,,,,,
678,Rv2043c,134,PZA,pncA,,,Brown TJ JMedMicro 2000,,,239,del A,80,,Frameshift,all sensitive isolates were WT and mutants and resistant ones had mutant genotypes,2000,4 sensitive  6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK,Turkey,Sequencing,Whole gene,Z,,BACTEC 460,13/18,1/0,C2431T (rpoB),0,10882091,694,0,,,,,,
679,Rv2043c,135,PZA,pncA,,,Sachais BS MolDiag 1998,,,241,TTC/GTC,80,80,Phe/Val,*novel mutation **10/10 susceptible isolates had WT phenotype  4/6 resistant also had WT,1993-1999,clinical isolates from Microbio. Lab of Hospital of Univ. of Penn. & Episcopal Hosp. in PA,USA,Sequencing,Whole gene,Z,,BACTEC at pH 6.4,39856,1/0,,0,10089282,695,0,,,,,,
680,Rv2043c,136,PZA,pncA,,,Brown TJ JMedMicro 2000,,,244,CAT/TAT Error? This makes Tyr not Asp.,82,82,His/Asp,all sensitive isolates were WT and mutants and resistant ones had mutant genotypes,2000,4 sensitive  6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK,Turkey,Sequencing,Whole gene,ZHRP,,BACTEC 460,13/18,1/0,A2386T (rpoB),0,10882091,696,0,,,,,,
681,Rv2043c,137,PZA,pncA,,,Cheng SJ AAC 2000,,,245,CAT/CGT,82,82,His/Arg,,,,USA,Sequencing,Whole gene,ZHRES,300,Proportion method  BACTEC 460,59/59,1/0,,1,10681313,697,30,,,,,,
682,Rv2043c,138,PZA,pncA,,,Rodrigues V de F AAC 2005,,,246,CAT/CTT,82,82,His/Leu,,1998-2003,Selected according to culture availability in health centers in Brazl,Brazil,Sequencing,Whole gene,Z,,Proportion method,59,40,,0,15616332,698,0,,,,,,
683,Rv2043c,139,PZA,pncA,,,Peridgao J MDR 2008,,,250,ins C,,,Frameshift,,2003,National Institute of Health  Lisbon,Portugal,Sequencing,Whole gene,ZHRS,,MGIT 960,48/58,3/0,,0,18573039,699,0,,,,,,
684,Rv2043c,140,PZA,pncA,,,Mestdagh M AAC 1999,,,254,CTG/CGG,85,85,Leu/Arg,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Azerbaijan,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,700,20,,,,,,
685,Rv2043c,141,PZA,pncA,,,Scorpio A AAC 1997,,,254,CTG/CCG,85,85,Leu/Pro,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,3/0,,1,9055989,701,30,,,,,,
686,Rv2043c,142,PZA,pncA,,,Lemaitre N AAC 1999,,,260,ACG/ATG,87,87,Thr/Met,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1987,,France,Sequencing,Whole gene,ZHRES,1000-1500,,19/35,1/0,,0,10390238,702,0,,,,,,
687,Rv2043c,143,PZA,pncA,,,Hou L Epi Infect 2000,,,263,TCG/TAG,88,88,Ser/STOP,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZHRES,>2000,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,703,0,,,,,,
688,Rv2043c,144,PZA,pncA,,,Hannan MM JCM 2001,,,269,ATC/AGC,90,90,Ile/Ser,,1996-1999,isolates from 5 counties in California,USA,Sequencing,Whole gene,Z,,BACTEC radiometric testing,39883,1/0,,0,11158123,704,0,,,,,,
689,Rv2043c,145,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,269,ATC/AGC,90,90,Ile/Ser,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,705,0,,,,,,
690,Rv2043c,146,PZA,pncA,,,Sreevatsan S AAC 1997,,,280,TTC/CCC,94,94,Phe/Pro,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,2/0,T281C,0,9056006,706,0,,,,,,
691,Rv2043c,147,PZA,pncA,,,Peridgao J MDR 2008,,,282,ins T,,,Frameshift,,2003,National Institute of Health  Lisbon,Portugal,Sequencing,Whole gene,ZHRS,,MGIT 960,48/58,1/0,,0,18573039,707,0,,,,,,
692,Rv2043c,148,PZA,pncA,,,Peridgao J MDR 2008,,,285,TAC/TAA,95,95,Tyr/STOP,,2003,National Institute of Health  Lisbon,Portugal,Sequencing,Whole gene,ZHRS,,MGIT 960,48/58,1/0,,0,18573039,708,0,,,,,,
693,Rv2043c,149,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,286,AAG/CAG,96,96,Lys/Gln,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,709,0,,,,,,
694,Rv2043c,150,PZA,pncA,,,Marttila HJ AAC 1999,,,286,AAG/GAG,96,96,Lys/Glu,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,710,0,,,,,,
695,Rv2043c,151,PZA,pncA,,,Scorpio A AAC 1997,,,287,AAG/ACG,96,96,Lys/Thr,*PZA-res mutant made in vitro,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,711,0,,,,,,
696,Rv2043c,152,PZA,pncA,,,Hirano  K TLD 1997,,,287,ins T,96,,Frameshift,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Canada,Sequencing,Whole gene,ZHRS,>800,Proportion method,33/168,1/0,,0,9692180,712,0,,,,,,
697,Rv2043c,153,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,287,ins T,96,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,713,0,,,,,,
698,Rv2043c,154,PZA,pncA,,,Scorpio A AAC 1997,,,288,AAG/AAT,96,96,Lys/Asn,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,1,9055989,714,10,,,,,,
699,Rv2043c,155,PZA,pncA,,,Scorpio A Nature Med 1996,,,288,del G,96,,Frameshift,,,clinical isolates from L. Heifets  National Jewish Center for Immunology and Resp. Diseases,USA,Sequencing,Whole gene,Z,>500ug/ml,PZase test with Wayne's method,39910,1/0,,0,8640557,715,0,,,,,,
700,Rv2043c,156,PZA,pncA,,,Cheng SJ AAC 2000,,,289,GGT/AGT,97,97,Gly/Ser,,,,USA,Sequencing,Whole gene,ZHRES,>900,Proportion method  BACTEC 460,59/59,2/0,,1,10681313,716,10,,,,,,
701,Rv2043c,157,PZA,pncA,,,Morlock GP AAC 2000,,,290,GGT/GAT,97,97,Gly/Asp,,1999,,,Sequencing,Whole gene,Z,400,Proportion method,37/60,1/0,,0,11083630,717,10,,,,,,
702,Rv2043c,158,PZA,pncA,,,Hirano  K TLD 1997,,,297,TAC/TAA,99,99,Tyr/STOP,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Thailand,Sequencing,Whole gene,ZHRSE,>800,Proportion method,33/168,1/0,,0,9692180,718,0,,,,,,
703,Rv2043c,159,PZA,pncA,,,Morlock GP AAC 2000,,,297,TAC/TAG,99,99,Tyr/STOP,,1999,,,Sequencing,Whole gene,Z,>800,Proportion method,37/60,2/0,,1,11083630,719,30,,,,,,
704,Rv2043c,160,PZA,pncA,,,Cheng SJ AAC 2000,,,301,ins G,100,,Frameshift,,,,South korea,Sequencing,Whole gene,Z,>500,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,720,0,,,,,,
705,Rv2043c,161,PZA,pncA,,,Hou L Epi Infect 2000,,,301,ins A,100,,Frameshift,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZHRS,900,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,721,0,,,,,,
706,Rv2043c,162,PZA,pncA,,,Marttila HJ AAC 1999,,,304,GCG/ACG,102,102,Ala/Thr,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,722,0,,,,,,
707,Rv2043c,163,PZA,pncA,,,Marttila HJ AAC 1999,,,305,GCG/GTG,102,102,Ala/Val,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,2/0,not tested,1,10390239,723,10,,,,,,
708,Rv2043c,164,PZA,pncA,,,Lemaitre N AAC 1999,,,306,ins C,102,,Frameshift,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1989,,France,Sequencing,Whole gene,ZHRES,500-1500,,19/35,1/0,,0,10390238,724,0,,,,,,
709,Rv2043c,165,PZA,pncA,,,Mestdagh M AAC 1999,,,307,TAC/CAC,103,103,Tyr/His,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Canada,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,725,0,,,,,,
710,Rv2043c,166,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,307,del TACAG,102,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,726,0,,,,,,
711,Rv2043c,167,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,308,TAC/TCC,103,103,Tyr/Ser,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,2/0,,0,11641519,727,10,,,,,,
712,Rv2043c,168,PZA,pncA,,,Lemaitre N AAC 1999,,,308,TAC/TGC,103,103,Tyr/Cys,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1994,,France,Sequencing,Whole gene,ZHRE,1500,,,1/0,,0,10390238,728,0,,,,,,
713,Rv2043c,169,PZA,pncA,,,Marttila HJ AAC 1999,,,309,TAC/TAG,103,103,Tyr/STOP,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,1,10390239,729,30,,,,,,
714,Rv2043c,170,PZA,pncA,,,Morlock GP AAC 2000,,,309,TAC/TAA,103,103,Tyr/STOP,,1999,,,Sequencing,Whole gene,Z,100,Proportion method,37/60,1/0,,0,11083630,730,0,,,,,,
715,Rv2043c,171,PZA,pncA,,,Scorpio A AAC 1997,,,312,del C,104,104,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,731,0,,,,,,
716,Rv2043c,172,PZA,pncA,,,Hirano  K TLD 1997,,,312,AGC/AGG,104,104,Ser/Arg,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Yemen,Sequencing,Whole gene,ZHRSE,>800,Middlebrook 7H11 agar w/ pH of 6.0,33/168,1/0,,1,9692180,732,10,,,,,,
717,Rv2043c,173,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,319,GAA/AAA,107,107,Gly/Lys,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,733,0,,,,,,
718,Rv2043c,174,PZA,pncA,,,Hirano  K TLD 1997,,,340,ACG/CCG,114,114,Thr/Pro,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Yemen,Sequencing,Whole gene,ZHR,>800,Middlebrook 7H11 agar w/ pH of 6.0,33/168,1/0,,1,9692180,734,10,,,,,,
719,Rv2043c,175,PZA,pncA,,,Cheng SJ AAC 2000,,,341,del C,114,,Frameshift,,,,South Korea,Sequencing,Whole gene,Z,>500,Proportion method  BACTEC 460,59/59,1/0?,,0,10681313,735,0,,,,,,
720,Rv2043c,176,PZA,pncA,,,Lemaitre N AAC 1999,,,341,ins 1355bp,114,,Frameshift,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1989,,France,Sequencing,Whole gene,ZHRE,1000,,19/35,1/0,,0,10390238,736,0,,,,,,
721,Rv2043c,177,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,346,CTG/GTG,116,116,Leu/Val,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,737,0,,,,,,
722,Rv2043c,178,PZA,pncA,,,Marttila HJ AAC 1999,,,347,CTG/CGG,116,116,Leu/Arg,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,1,10390239,738,20,,,,,,
723,Rv2043c,179,PZA,pncA,,,Hou L Epi Infect 2000,,,353,AAT/ACT,118,118,Asn/Thr,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZHRS,1000,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,739,0,,,,,,
724,Rv2043c,180,PZA,pncA,,,Sreevatsan S AAC 1997,,,355,TGG/CGG,119,119,Trp/Arg,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,0,9056006,740,10,,,,,,
725,Rv2043c,181,PZA,pncA,,,Stavrum R PlosOne 2009,,,357,TGG/TGC,119,119,Trp/Cys,,Published 2009,,India,Sequencing,Whole gene,RSHE,> 100 mg/L,Proportion method,13/39,(2/0),1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present,0,19234602,741,0,,,,,,
726,Rv2043c,182,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,357,TGG/TGA,119,119,Trp/STOP,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,742,0,,,,,,
727,Rv2043c,183,PZA,pncA,,,Portugal I AAC 2004,,,359,CTG/CCG,120,120,Leu/Pro,,2000-2001,several hospitals in Lisbon,Portugal,Sequencing,Whole gene,Z,,BACTEC MGIT 960,55,55,,0,10449496,743,30,,,,,,
728,Rv2043c,184,PZA,pncA,,,Sreevatsan S AAC 1997,,,362,CGG/CCG,121,121,Arg/Pro,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,1,9056006,744,10,,,,,,
729,Rv2043c,185,PZA,pncA,,,Hou L Epi Infect 2000,,,368,ins AG,123,,Frameshift,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZRHSE,1000,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,745,0,,,,,,
730,Rv2043c,186,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,368,ins 18bp,123,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,746,0,,,,,,
731,Rv2043c,187,PZA,pncA,,,Marttila HJ AAC 1999,,,374,GTC/GAC,125,125,Val/Asp,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,747,0,,,,,,
732,Rv2043c,188,PZA,pncA,,,Peridgao J MDR 2008,,,374,GTC/GGC,125,125,Val/Gly,,2003,National Institute of Health  Lisbon,Portugal,Sequencing,Whole gene,ZHRS,,MGIT 960,48/58,19/0,,0,18573039,748,20,,,,,,
733,Rv2043c,189,PZA,pncA,,,Marttila HJ AAC 1999,,,379-389,del 11bp,126,,Frameshift,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,749,0,,,,,,
734,Rv2043c,190,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,381,del GG,127,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,750,0,,,,,,
735,Rv2043c,191,PZA,pncA,,,Peridgao J MDR 2008,,,381,del 9bp,127,,Frameshift,,2003,National Institute of Health  Lisbon,Portugal,Sequencing,Whole gene,ZHRS,,MGIT 960,48/58,1/0,,0,18573039,751,0,,,,,,
736,Rv2043c,192,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,382,ins AG,127,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,752,0,,,,,,
737,Rv2043c,193,PZA,pncA,,,Rodrigues V de F AAC 2005,,,384,GTC/GGC,128,128,Val/Gly,,1998-2003,Selected according to culture availability in health centers in Brazl,Brazil,Sequencing,Whole gene,Z,,Proportion method and Pzase test,59,40,,1,15616332,753,20,,,,,,
738,Rv2043c,194,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,386-389,del ATGT,129,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,754,0,,,,,,
739,Rv2043c,195,PZA,pncA,,,Morlock GP AAC 2000,,,388,ins GAGGTCGAT,129,,ins Glu Val Asp,,1999,,,Sequencing,Whole gene,Z,>800,Proportion method,37/60,1/0,,0,11083630,755,0,,,,,,
740,Rv2043c,196,PZA,pncA,,,Sreevatsan S AAC 1997,,,388,ins AGGTCGATG,129,,Ins Arg Ser Met,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,4/0,,1,9056006,756,10,,,,,,
741,Rv2043c,197,PZA,pncA,,,Hirano  K TLD 1997,,,389,GTG/GGG,130,130,Val/Gly,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Canada,Sequencing,Whole gene,ZHRSE,>800,Middlebrook 7H11 agar w/ pH of 6.0,33/168,1/0,,1,9692180,757,20,,,,,,
742,Rv2043c,198,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,391,ins GG,130,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,1,11641519,758,0,,,,,,
743,Rv2043c,199,PZA,pncA,,,Lemaitre N AAC 1999,,,391,ins GG,130,,Frameshift,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1988,,France,Sequencing,Whole gene,ZHRES,500-1000,,19/35,1/0,,1,10390238,759,0,,,,,,
744,Rv2043c,200,PZA,pncA,,,Scorpio A AAC 1997,,,391,del G,130,,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,760,0,,,,,,
745,Rv2043c,201,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,392,ins G,131,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,761,0,,,,,,
746,Rv2043c,202,PZA,pncA,,,Hirano  K TLD 1997,,,395,GGT/GAT,132,132,Gly/Asp,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Myanmar,Sequencing,Whole gene,Z,>800,Proportion method,33/168,1/0,,0,9692180,762,10,,,,,,
747,Rv2043c,203,PZA,pncA,,,Scorpio A AAC 1997,,,394,GGT/AGT,132,132,Gly/Ser,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,2/0,,0,9055989,763,10,,,,,,
748,Rv2043c,204,PZA,pncA,,,Hirano  K TLD 1997,,,395-411 del,del 16bp,132,,Frameshift,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,India,Sequencing,Whole gene,ZR,>800,Proportion method,33/168,1/0,,0,9692180,764,0,,,,,,
749,Rv2043c,205,PZA,pncA,,,Sreevatsan S AAC 1997,,,397,ins T,132,,Frameshift,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,0,9056006,765,0,,,,,,
750,Rv2043c,206,PZA,pncA,,,Marttila HJ AAC 1999,,,398,ATT/ACT,133,133,Ile/Thr,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,766,0,,,,,,
751,Rv2043c,207,PZA,pncA,,,Morlock GP AAC 2000,,,398,ATT/AAT,133,133,Ile/Asn,,1999,,,Sequencing,Whole gene,Z,800,Proportion method,37/60,1/0,,0,11083630,767,0,,,,,,
752,Rv2043c,208,PZA,pncA,,,Escalante P TuberLung Dis 1998,,,401,GCC/GTC,134,134,Ala/Val,,1995-1996,patients w/ pulmonary TB,Peru,Sequencing,Whole gene,ZHRP,,Proportion method,40146,1/0,katG  315  AGC/ACC; rpoB  531  TCG/TTG;,1,10645449,768,10,,,,,,
753,Rv2043c,209,PZA,pncA,,,Morlock GP AAC 2000,,,403,ACC/CCC,135,135,Thr/Pro,,1999,,,Sequencing,Whole gene,Z,>800,Proportion method,37/60,1/0,,0,11083630,769,0,,,,,,
754,Rv2043c,210,PZA,pncA,,,Hou L Epi Infect 2000,,,403,ins CC,134,,Frameshift,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZRE,1000,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,770,0,,,,,,
755,Rv2043c,211,PZA,pncA,,,Sreevatsan S AAC 1997,,,403,ins C,134,,Frameshift,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,0,9056006,771,0,,,,,,
756,Rv2043c,212,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,406,GAT/TAT,136,136,Asp/Tyr,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,2/0,,0,11641519,772,0,,,,,,
757,Rv2043c,213,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,406,GAT/AAT,136,136,Asp/Asn,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,773,0,,,,,,
758,Rv2043c,214,PZA,pncA,,,Mestdagh M AAC 1999,,,406,GAT/CAT,136,136,Asp/His,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Scotland,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,774,0,,,,,,
759,Rv2043c,215,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,406,del G,135,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,775,0,,,,,,
760,Rv2043c,216,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,407,GAT/GGT,136,136,Asp/Gly,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,776,0,,,,,,
761,Rv2043c,217,PZA,pncA,,,Mestdagh M AAC 1999,,,407-408,ins C,136,,Frameshift,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Azerbaijan,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,777,0,,,,,,
762,Rv2043c,218,PZA,pncA,,,Scorpio A AAC 1997,,,410,CAT/CCT,137,137,His/Pro,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,778,0,,,,,,
763,Rv2043c,219,PZA,pncA,,,Sreevatsan S AAC 1997,,,410,CAT/CGT,137,137,His/Arg,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,2/0,,1,9056006,779,30,,,,,,
764,Rv2043c,220,PZA,pncA,,,Cheng SJ AAC 2000,,,413,TGT/TCT,138,138,Cys/Ser,,,,South korea,Sequencing,Whole gene,Z,>500,Proportion method  BACTEC 460,59/59,1/0?,,0,10681313,780,0,,,,,,
765,Rv2043c,221,PZA,pncA,,,Scorpio A Nature Med 1996,,,413,TGT/TAT,138,138,Cys/Tyr,,,clinical isolates from L. Heifets  National Jewish Center for Immunology and Resp. Diseases,USA (Colorado),Sequencing,Whole gene,MDR,>500ug/ml,Pzase testing by Wayne's method,39910,1/0,,1,8640557,781,10,,,,,,
766,Rv2043c,222,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,414,ins G,138,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,782,0,,,,,,
767,Rv2043c,223,PZA,pncA,,,Cheng SJ AAC 2000,,,415,GTG/ATG,139,139,Val/Met,,,,South korea,Sequencing,Whole gene,Z,>500,Proportion method  BACTEC 460,59/59,1/0?,,1,10681313,783,10,,,,,,
768,Rv2043c,224,PZA,pncA,,,Morlock GP AAC 2000,,,415,GTG/CTG,139,139,Val/Leu,,1999,,,Sequencing,Whole gene,Z,100,Proportion method,37/60,1/0,,1,11083630,784,10,,,,,,
769,Rv2043c,225,PZA,pncA,,,Morlock GP AAC 2000,,,416,GTG/GGG,139,139,Val/Gly,,1999,,,Sequencing,Whole gene,Z,>800,Proportion method,37/60,1/0,,0,11083630,785,20,,,,,,
770,Rv2043c,226,PZA,pncA,,,Sreevatsan S AAC 1997,,,416,GTG/GCG,139,139,Val/Ala,,1996,,Diverse geographical locations,Sequencing,Whole gene,Z,,BACTEC 460,67/118,1/0,,1,9056006,786,10,,,,,,
771,Rv2043c,227,PZA,pncA,,,Scorpio A AAC 1997,,,416,del TG,139,,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,787,0,,,,,,
772,Rv2043c,228,PZA,pncA,,,Cheng SJ AAC 2000,,,418,CGC/AGC,140,140,Arg/Ser,see mutations for nt. 446,,,,Sequencing,Whole gene,Z,,Proportion method  BACTEC 460,59/59,20/0,,1,10681313,788,10,,,,,,
773,Rv2043c,229,PZA,pncA,,,Lemaitre N AAC 1999,,,419,del 68bp,140,,Frameshift,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1992,,France,Sequencing,Whole gene,ZHRE,1000,,19/35,1/0,,0,10390238,789,0,,,,,,
774,Rv2043c,230,PZA,pncA,,,Cheng SJ AAC 2000,,,420,ins G,140,,Frameshift,,,,USA,Sequencing,Whole gene,ZR,>900,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,790,0,,,,,,
775,Rv2043c,231,PZA,pncA,,,Cheng SJ AAC 2000,,,420,ins GG,140,,Frameshift,,,,USA,Sequencing,Whole gene,ZHRSO,>900,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,791,0,,,,,,
776,Rv2043c,232,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,421,CAG/TAG,141,141,Gln/STOP,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,792,0,,,,,,
777,Rv2043c,233,PZA,pncA,,,Scorpio A Nature Med 1996,,,422,CAG/CCG,141,141,Gln/Pro,,,clinical isolates from L. Heifets  National Jewish Center for Immunology and Resp. Diseases,USA,Sequencing,Whole gene,MDR,>500ug/ml,Pzase testing by Wayne's method,invitro,1/0,,1,8640557,793,20,,,,,,
778,Rv2043c,234,PZA,pncA,,,Escalante P TuberLung Dis 1998,,,424,ACG/CCG,142,142,Thr/Pro,,1995  1996,patients w/ pulmonary TB,Peru,Sequencing,Whole gene,MDR,,Proportion method,40146,1/0,rpoB  516  GAC/TAC,0,10645449,794,10,,,,,,
779,Rv2043c,235,PZA,pncA,,,Hirano  K TLD 1997,,,424,ACG/GCG,142,142,Thr/Ala,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Myanmar,Sequencing,Whole gene,ZHRSE,>800,Middlebrook 7H11 agar w/ pH of 6.0,33/168,1/0,,0,9692180,795,0,,,,,,
780,Rv2043c,236,PZA,pncA,,,Scorpio A AAC 1997,,,425,ACG/AAG,142,142,Thr/Lys,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,1,9055989,796,10,,,,,,
781,Rv2043c,237,PZA,pncA,,,Scorpio A AAC 1997,,,425,ACG/ATG,142,142,Thr/Met,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,797,0,,,,,,
782,Rv2043c,238,PZA,pncA,,,Cheng SJ AAC 2000,,,428,ins GG,143,,Frameshift,,,,South korea,Sequencing,Whole gene,Z,>100,Proportion method  BACTEC 460,59/59,1/0?,,0,10681313,798,0,,,,,,
783,Rv2043c,239,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,436,GCG/ACG,146,146,Ala/Thr,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,799,0,,,,,,
784,Rv2043c,240,PZA,pncA,,,Lemaitre N AAC 1999,,,436,del G,145,,Frameshift,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1987,,France,Sequencing,Whole gene,ZHRE,1000-1500,,19/35,1/0,,0,10390238,800,0,,,,,,
785,Rv2043c,241,PZA,pncA,,,Hirano  K TLD 1997,,,437,GCG/GTG,146,146,Ala/Val,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,India,Sequencing,Whole gene,ZRS,>800,Proportion method,33/168,1/0,,0,9692180,801,10,,,,,,
786,Rv2043c,242,PZA,pncA,,,Peridgao J MDR 2008,,,439,ins CG,147,,Frameshift,,2003,National Institute of Health  Lisbon,Portugal,Sequencing,Whole gene,ZHRS,,MGIT 960,48/58,1/0,,0,18573039,802,0,,,,,,
787,Rv2043c,243,PZA,pncA,,,Sekiguchi JI JCM 2007,,,442,CGC/AGC,148,148,Arg/Ser,,2006,TB patients in Japan and Poland,Poland,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,1/0,,0,17596354,803,10,,,,,,
788,Rv2043c,244,PZA,pncA,,,Brown TJ JMedMicro 2000,,,442,C/A,148,148,Arg/Ser,all sensitive isolates were WT and mutants and resistant ones had mutant genotypes,2000,4 sensitive  6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK,Turkey,Sequencing,Whole gene,ZHRP,,BACTEC 460,13/18,1/0,C2431G(rpoB),0,10882091,804,0,,,,,,
789,Rv2043c,245,PZA,pncA,,,Scorpio A AAC 1997,,,443,del G,148,,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,805,0,,,,,,
790,Rv2043c,246,PZA,pncA,,,Cheng SJ AAC 2000,,,446,del 8bp,149,,Frameshift,20 PZA-monores. And 1 MDR isolate from Quebec had this mutation profile (8 bp del + Arg140Ser). Strains are highly related,1990-1992,Canadians,Canada,Sequencing,Whole gene,ZHRE,>300,Proportion method  BACTEC 460,59/59,1/0,,1,10681313,806,0,,,,,,
791,Rv2043c,247,PZA,pncA,,,Scorpio A AAC 1997,,,446,ins 8bp,149,,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,807,0,,,,,,
792,Rv2043c,248,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,452,del T,151,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South Korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,808,0,,,,,,
793,Rv2043c,249,PZA,pncA,,,Morlock GP AAC 2000,,,458,ACC/AAC,153,153,Thr/Asn,,1999,,,Sequencing,Whole gene,Z,800,Proportion method,37/60,1/0,,0,11083630,809,0,,,,,,
794,Rv2043c,250,PZA,pncA,,,Marttila HJ AAC 1999,,,460,AGG/GGG,154,154,Arg/Gly,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,1/0,not tested,0,10390239,810,0,,,,,,
795,Rv2043c,251,PZA,pncA,,,Lemaitre N AAC 1999,,,464,GTG/GGG,155,155,Val/Gly,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1987,,France,Sequencing,Whole gene,ZHRE,1500,,19/35,1/0,,1,10390238,811,20,,,,,,
796,Rv2043c,252,PZA,pncA,,,Escalante P TuberLung Dis 1998,,,464,GTG/GCG,155,155,Val/Ala,,1995  1996,patients w/ pulmonary TB,Peru,Sequencing,Whole gene,ZHRES,,Proportion method,40146,1/0,katG  315  AGC/ACC; rpoB  531  TCG/TTG;,0,10645449,812,10,,,,,,
797,Rv2043c,253,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,465,ins T,155,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,2/0,,0,11641519,813,0,,,,,,
798,Rv2043c,254,PZA,pncA,,,Scorpio A AAC 1997,,,475,del C,158,,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,814,0,,,,,,
799,Rv2043c,255,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,476,CTG/CCG,159,159,Leu/Pro,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,1,16848344,815,30,,,,,,
800,Rv2043c,256,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,476,CTG/CGG,159,159,Leu/Arg,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,816,20,,,,,,
801,Rv2043c,257,PZA,pncA,,,Marttila HJ AAC 1999,,,478,ACA/CCA,160,160,Thr/Pro,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,2/0,not tested,1,10390239,817,10,,,,,,
802,Rv2043c,258,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,480,ins TGAC,160,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,818,0,,,,,,
803,Rv2043c,259,PZA,pncA,,,Marttila HJ AAC 1999,,,481,GCG/CCG,161,161,Ala/Pro,*86.1% of PZA-res isolates mutated in region studied. Most frequent mutation A-11G **novel mutation,1994-1997,St. Petersburg Institute of Phthisiopulmonology,Russia,Sequencing,Whole gene,Z,,BACTEC 460,36/44,2/0,not tested,1,10390239,819,10,,,,,,
804,Rv2043c,260,PZA,pncA,,,Chan RCY JAC 2007,,,485,GGT/GAT,162,162,Gly/Asp,36% resistant to PZA  80% of PZA-r had mutations  80% mutants had resistance  11% drug susceptible had mutations,1994-2004,250 drug-res. Mtb from Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,ZOREth,100mg/L,BACTEC MGIT 960,89/250,1/0,Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB),1,17360809,820,10,,,,,,
805,Rv2043c,261,PZA,pncA,,,Hou L Epi Infect 2000,,,501,ins CG,167,,Frameshift,,1996-1998,patients from China,China,PCR-SSCP,Whole gene,ZSHE,900,Proportion method  BACTEC 460,35/65,1/0,,0,10813147,821,0,,,,,,
806,Rv2043c,262,PZA,pncA,,,Cheng SJ AAC 2000,,,503,ACC/AAC,168,168,Thr/Asn,,,,Canada,Sequencing,Whole gene,ZRO,300,Proportion method  BACTEC 460,59/59,1/0,,0,10681313,822,0,,,,,,
807,Rv2043c,263,PZA,pncA,,,Mestdagh M AAC 1999,,,511,GCG/ACG,171,171,Ala/Thr,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Bangladesh,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,823,0,,,,,,
808,Rv2043c,264,PZA,pncA,,,Sachais BS MolDiag 1998,,,511,GCG/CCG,171,171,Ala/Pro,*novel mutation; close to 3' end of coding region of pncA gene **10/10 susceptible isolates had WT phenotype  4/6 resistant also had WT,1993-1999,clinical isolates from Microbio. Lab of Hospital of Univ. of Penn. & Episcopal Hosp. in PA,USA,Sequencing,Whole gene,Z,,BACTEC at pH 6.4,39856,1/0,,0,10089282,824,10,,,,,,
809,Rv2043c,265,PZA,pncA,,,Mestdagh M AAC 1999,,,512,GCG/GTG,171,171,Ala/Val,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Scotland,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,825,10,,,,,,
810,Rv2043c,266,PZA,pncA,,,Rodrigues V de F AAC 2005,,,512,GCG/GAG,171,171,Ala/Glu,,1998-2003,Selected according to culture availability in health centers in Brazl,Brazil,Sequencing,Whole gene,Z,,Proportion method,59,40,,1,15616332,826,10,,,,,,
811,Rv2043c,267,PZA,pncA,,,Mestdagh M AAC 1999,,,512,del C,171,,Frameshift,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Rwanda,Sequencing,Whole gene,Z,,BACTEC 460,23/62,1/0,,0,10471589,827,0,,,,,,
812,Rv2043c,268,PZA,pncA,,,Hirano  K TLD 1997,,,515,CTG/CCG,172,172,Leu/Pro,32/33 PZase negative mtb strains had mutations in pncA gene.,1997,168 mtb strain isolated in 9 Asian countries and Canada,Canada,Sequencing,Whole gene,ZHRSE,>800,Proportion method,33/168,1/0,,1,9692180,828,30,,,,,,
813,Rv2043c,269,PZA,pncA,,,Mestdagh M AAC 1999,,,514-515,CTG/GCG,172,172,Leu/Ala,PZase negativity correlated to PZA-R  only 39 of 42 PZase positive test correl. to susceptibility,1999,54 MDR mtb clinical strains,Belgium,Sequencing,Whole gene,Z,,BACTEC 460,23/62,2/0,,0,10471589,829,0,,,,,,
814,Rv2043c,270,PZA,pncA,,,Scorpio A AAC 1997,,,518,ins 5bp,173,,Frameshift,some degree of mutational clustering in regions: 5-12  69-85  132-142,1992-1995,38 clinical isolates; 8 mutants made in vivo,,PCR-SSCP,Whole gene,Z,>900ug/ml,Pzase testing by Wayne's method,46/46,1/0,,0,9055989,830,0,,,,,,
815,Rv2043c,271,PZA,pncA,,,Sekiguchi JI JCM 2007,,,523,ATG/GTG,175,175,Met/Val,,2006,TB patients in Japan and Poland,Japan,Multi-plex PCR,Whole gene,Z,,Proportion method  rapid broth method,17/138,1/0,,0,17596354,831,0,,,,,,
816,Rv2043c,272,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,532,ins C,177,,Frameshift,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,832,0,,,,,,
817,Rv2043c,273,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,535,AGC/CGC,179,179,Ser/Arg,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,833,0,,,,,,
818,Rv2043c,274,PZA,pncA,,,Lee KW J Korean Med Sci 2001,,,538,GTC/TTC,180,180,Val/Phe,all PZA res strain concomitantly res. to ISN  RIF  ETH,2001,mtb sputum cultures from Korean Institute of TB,South korea,Sequencing,Whole gene,Z,,PZase test with Wayne's method,92/95,1/0,,0,11641519,834,0,,,,,,
819,Rv2043c,275,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,543,GAG/GAT,181,181,Glu/Asp,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,0,16848344,835,0,,,,,,
820,Rv2043c,276,PZA,pncA,,,Lemaitre N AAC 1999,,,545,TTG/TCG,182,182,Leu/Ser,16 susceptible (MIC?50ug/ml) and 19 highly res (?500ug/ml),1997,,France,Sequencing,Whole gene,ZHRS,500-2000ug/ml,,19/35,1/0,,0,10390238,836,0,,,,,,
821,Rv2043c,277,PZA,pncA,,,Louw GE Int J Tuberc Lung Dis 2006,,,554,AGC/ACC,185,185,Ser/Thr,,2001-2002,Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province.,South Africa,Sequencing,Whole gene,ZHRSEthK,,BACTEC MGIT 960,115,68,,1,16848344,837,10,,,,,,
822,Rv2043c,278,PZA,pncA,,,Chan RCY JAC 2007,,,554,AGC/ATC,185,185,Ser/Ile,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP   Sequencing,Whole gene,Z,,BACTEC MGIT 960,250,89,,0,17360809,838,0,,,,,,
823,Rv3793,1,EMB,embC,,,Sreevatsan S AAC 1997,,,13,GGT/AGT,5,5,Gly/Ser,,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,N.S.,BACTEC 460,16/19,1/0,,0,9257740,839,0,,,,,,
824,Rv3793,2,EMB,embC,,,Srivastava S JMM 2009,,,730-732,GCG/ACC,244,244,Ala/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,E,6ug/ml,Proportion method  E-Test,44/44,1/0,embB E368A  S380R  P397Q  R460C; embC G288W  V303G; embR L172R,0,19010731,840,0,,,,,,
825,Rv3793,3,EMB,embC,,,Srivastava S JMM 2009,,,739-741,GCC/CCG,247,247,Ala/Pro,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,8ug/ml,Proportion method  E-Test,44/44,1/0,embB A356F  A357V  L359I  E378A  A379D  Y384N  A388G  N399D; embC T270I  I297T,0,19010731,841,0,,,,,,
826,Rv3793,4,EMB,embC,,,Srivastava S CurrMicro 2006,,,752,CTG/CGT,251,251,Leu/Arg,Study aimed at detecting embB and embC mutations in EMB-R M.tb.  Out of 23 EMB-R isolates tested  16 (70%) carried mutations in the embB gene  with codon 306 being mutated most often (7 isolates = 20%). Ten isolates were also mutated in embC  with 8 (35%,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,12ug/ml,Proportion method  E-Test,23/23,1/0,Ala254Gly and Thr270Ile in embC. R/Tot and R/S calculated from Table 1.,0,16972132,842,0,,,,,,
827,Rv3793,5,EMB,embC,,,Srivastava S CurrMicro 2006,,,761,GCC/GGC,254,254,Ala/Gly,Has associated mutations in embC and embB.,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,12ug/ml,Proportion method  E-Test,23/23,1/0,Leu251Arg and Thr270Ile in embC. R/Tot and R/S calculated from Table 1.,0,16972132,843,0,,,,,,
828,Rv3793,6,EMB,embC,,,Sreevatsan S AAC 1997,,,809,ACC/ATC,270,270,Thr/Ile,Role unclear; also had a mutation at embB codon 306.,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,N.S.,BACTEC 460  agar diffusion method,16/19,1/0,Met306Val in embB.,0,9257740,844,0,,,,,,
829,Rv3793,7,EMB,embC,,,Srivastava S JMM 2009,,,809-810,ACC/ATT,270,270,Thr/Ile,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,4ug/ml,Proportion method  E-Test,44/44,1/0,embB G406A,0,19010731,845,0,,,,,,
830,Rv3793,8,EMB,embC,,,Srivastava S JMM 2009,,,814-815,GGC/GAC,272,272,Gly/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,6ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M  A431T; embC H285Y  M300R  A307T; embR A176V  I369T,0,19010731,846,0,,,,,,
831,Rv3793,9,EMB,embC,,,Srivastava S JMM 2009,,,853,CAT/TAT,285,285,His/Tyr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,6ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M  A431T; embC G272S  M300R  A307T; embR A176V  I369T,0,19010731,847,0,,,,,,
832,Rv3793,10,EMB,embC,,,Srivastava S JMM 2009,,,859-861,GTG/TTT,287,287,Val/Phe,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S  A379T; embC Y309N; embR L320V  S326N  V350G  H351Q  R356G  I369T,0,19010731,848,0,,,,,,
833,Rv3793,11,EMB,embC,,,Srivastava S JMM 2009,,,862-864,GGC/TGG,288,288,Gly/Trp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,E,6ug/ml,Proportion method  E-Test,44/44,1/0,embB E368A  S380R  P397Q  R460C; embC A244T  V303G; embR L172R,0,19010731,849,0,,,,,,
834,Rv3793,12,EMB,embC,,,Srivastava S JMM 2009,,,863-864,GGC/GTG,288,288,Gly/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB H312R  S317T  A356F  L359I  R367P; embC M310K  Y327N,0,19010731,850,0,,,,,,
835,Rv3793,13,EMB,embC,,,Srivastava S JMM 2009,,,886-888,TAT/CAT,296,296,Tyr/His,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306I; embC T270I  G308D  G325S,0,19010731,851,0,,,,,,
836,Rv3793,14,EMB,embC,,,Srivastava S JMM 2009,,,886-888,TAT/AGC,296,296,Tyr/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embC R302G,0,19010731,852,0,,,,,,
837,Rv3793,15,EMB,embC,,,Srivastava S JMM 2009,,,889-891,ATT/TTG,297,297,Ile/Leu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,E,3ug/ml,Proportion method  E-Test,44/44,1/0,embB G358V  E368Q  S380D  P397T  G406D  G448V; embC W326R,0,19010731,853,0,,,,,,
838,Rv3793,16,EMB,embC,,,Srivastava S JMM 2009,,,889-891,ATT/CTG,297,297,Ile/Leu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,48ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M; embC A247P  W326R; embR V7G,0,19010731,854,0,,,,,,
839,Rv3793,17,EMB,embC,,,Srivastava S JMM 2009,,,890-891,ATT/ACC,297,297,Ile/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB S347I  E368D  R460L; embR R230W  I396T,0,19010731,855,0,,,,,,
840,Rv3793,18,EMB,embC,,,Srivastava S JMM 2009,,,898-900,ATG/CGT,300,300,Met/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,6ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M  A431T; embC G272S  H285Y  A307T; embR A176V  I369T,0,19010731,856,0,,,,,,
841,Rv3793,19,EMB,embC,,,Srivastava S JMM 2009,,,904-906,CGT/GGC,302,302,Arg/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embC Y296S,0,19010731,857,0,,,,,,
842,Rv3793,20,EMB,embC,,,Srivastava S JMM 2009,,,908-909,GTG/GGC,303,303,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,E,6ug/ml,Proportion method  E-Test,44/44,1/0,embB E368A  S380R  P397Q  R460C; embC A244T  G288W; embR L172R,0,19010731,858,0,,,,,,
843,Rv3793,21,EMB,embC,,,Srivastava S JMM 2009,,,919-921,GCG/ACC,307,307,Ala/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,6ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M  A431T; embC G272S  H285Y  M300R; embR A176V  I369T,0,19010731,859,0,,,,,,
844,Rv3793,22,EMB,embC,,,Srivastava S JMM 2009,,,923-924,GGC/GAT,308,308,Gly/Asp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306I; embC T270I  Y296H'  G325S,0,19010731,860,0,,,,,,
845,Rv3793,23,EMB,embC,,,Srivastava S JMM 2009,,,925-927,TAT/AAC,309,309,Tyr/Asn,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EH,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A357S  A379T; embC V287F; embR L320V  S326N  V350G  H351Q  R356G  I369T,0,19010731,861,0,,,,,,
846,Rv3793,24,EMB,embC,,,Srivastava S JMM 2009,,,929-930,ATG/AAA,310,310,Met/Lys,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB H312R  S317T  A356F  L359I  R367P; embC G288V  Y327N,0,19010731,862,0,,,,,,
847,Rv3793,25,EMB,embC,,,Srivastava S JMM 2009,,,973,GGC/AGC,325,325,Gly/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306I; embC T270I  Y296H  G308D,0,19010731,863,0,,,,,,
848,Rv3793,26,EMB,embC,,,Srivastava S JMM 2009,,,976-978,TGG/CGT,326,326,Trp/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,E,3ug/ml,Proportion method  E-Test,44/44,1/0,embB G358V  E368Q  S380D  P397T  G406D  G448V; embC I297L,0,19010731,864,0,,,,,,
849,Rv3793,27,EMB,embC,,,Srivastava S JMM 2009,,,979-981,TAT/AAC,327,327,Tyr/Asn,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB H312R  S317T  A356F  L359I  R367P; embC G288V  M310K,0,19010731,865,0,,,,,,
850,Rv3793,28,EMB,embC,,,Ramaswamy SV AAC 2000,,,1180,AAC/GAC,394,394,Asn/Asp,Role unclear; see multiple other mutations.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Gly350Asp and Pro913Ser in embA; Leu276Arg in Rv3124; -12 G deletion in Rv0340.,0,10639358,866,0,,,,,,
851,Rv3793,29,EMB,embC,,,Ramaswamy SV AAC 2000,,,2213,CGG/CAG,738,738,Arg/Gln,Role unclear; see multiple other mutations.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,N.S.,BACTEC 460  agar diffusion method,75/108,1/0,-16 C/T in embA;  Met306Ile in embB  Pro54Ser in RV3124.,0,10639358,867,0,,,,,,
852,Rv3793,30,EMB,embC,,,Sreevatsan S AAC 1997,,,2941,GTG/CTG or GTG/TTG,981,981,Val/Leu,M.tb H-strains (by IS6110 profile) with this mutation were found to be resistant in this study  but were ID'd variously as R or S in other studies. Authors hypothesize this depends on method of susceptibility testing.,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,15ug/ml,BACTEC 460  agar diffusion method,16/19,,All three isolates also had a synonymous G/A substitution at nt 2898 of embA.,0,9257740,868,0,,,,,,
853,Rv3794,1,EMB,embA,,,Ramaswamy SV AAC 2000,,,-43,del CG,-43,-43,Frameshift,Role unclear; see other mutations.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,20-30ug/ml,BACTEC 460,75/108,2/0,Met306Ile in embB at MIC=20ug/ml; Gly406Ser in embB at MIC=30ug/ml.,0,10639358,869,0,,,,,,
854,Rv3794,2,EMB,embA,,,Ramaswamy SV AAC 2000,,,-16,C/T,-16,-16,,Multiple mutations possible. Located in the embC-embA intergenic region  immediately upstream of putative TATA box. Considered a compensatory mutation in the regulatory region  following a residue-replacing mutation in embB.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-40ug/ml,BACTEC 460,75/108,2/0,Arg738Gln in embC  Met306Ile in embB  and Pro54Ser in Rv3124 at MIC=40ug/ml; Ser501Trp at MIC>10ug/mL.,0,10639358,870,0,,,,,,
855,Rv3794,3,EMB,embA,,,Ramaswamy SV AAC 2000,,,-12,C/T,-12,-12,,Located in the embC-embA intergenic region  immediately upstream of putative TATA box. Considered a compensatory mutation in the regulatory region  following a residue-replacing mutation in embB.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30ug/ml,BACTEC 460,75/108,2/0,Gln497Lys in embB in one isolate; Gln497Lys in embB and Ser501Trp in iniA in another isolate.,0,10639358,871,0,,,,,,
856,Rv3794,4,EMB,embA,,,Ramaswamy SV AAC 2000,,,-11,C/A,-11,-11,,Located in the embC-embA intergenic region  immediately upstream of putative TATA box. Considered a compensatory mutation in the regulatory region  following a residue-replacing mutation in embB.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,20ug/ml,BACTEC 460,75/108,1/0,Met306Ile in embB.,0,10639358,872,0,,,,,,
857,Rv3794,5,EMB,embA,,,Ramaswamy SV AAC 2000,,,10,GAC/AAC,4,4,Asp/Asn,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,40ug/ml,BACTEC 460,75/108,1/0,Gly406Asp in embB,0,10639358,873,0,,,,,,
858,Rv3794,6,EMB,embA,,,Ramaswamy SV AAC 2000,,,601,GCG/ACG,201,201,Ala/Thr,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30ug/ml,BACTEC 460,75/108,1/0,Asp328Tyr and Tyr334His in embB.,0,10639358,874,0,,,,,,
859,Rv3794,7,EMB,embA,,,Ramaswamy SV AAC 2000,,,961,GGC/AGC,321,321,Gly/Ser,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-30ug/ml,BACTEC 460,75/108,1/0,,0,10639358,875,0,,,,,,
860,Rv3794,8,EMB,embA,,,Ramaswamy SV AAC 2000,,,1049,GGC/GAC,350,350,Gly/Asp,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-30ug/ml,BACTEC 460,75/108,2/0,,0,10639358,876,0,,,,,,
861,Rv3794,9,EMB,embA,,,Ramaswamy SV AAC 2000,,,1385,GCG/GTG,462,462,Ala/Val,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-30ug/ml,BACTEC 460,75/108,1/0,,0,10639358,877,0,,,,,,
862,Rv3794,10,EMB,embA,,,Ramaswamy SV AAC 2000,,,2498,GAC/GGC,833,833,Asp/Ala,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-30ug/ml,BACTEC 460,75/108,1/0,,0,10639358,878,0,,,,,,
863,Rv3794,11,EMB,embA,,,Ramaswamy SV AAC 2000,,,2737,CCG/TCG,913,913,Pro/Ser,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,40-50ug/ml,BACTEC 460,75/108,2/0,Gln351STOP in iniC at MIC=40ug/ml; Asn394Asp in embC  Gly350Asp in embA  Leu276Arg in Rv3124  and -24 G deletion in Rv0340  at MIC=50ug/ml.,0,10639358,879,0,,,,,,
864,Rv3795,1,EMB,embB,,,Srivastava S CurrMicro 2006,,,383,GTC/GGG,128,128,Val/Gly,Study aimed at detecting embB and embC mutations in EMB-R M.tb.  Out of 23 EMB-R isolates tested  16 (70%) carried mutations in the embB gene  with codon 306 being mutated most often (7 isolates = 20%). Ten isolates were also mutated in embC  with 8 (35%,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,5ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,880,0,,,,,,
865,Rv3795,2,EMB,embB,,,Jain A IndJMedRes 2008,,,662-663,GCG/GGC,221,221,Ala/Gly,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,881,0,,,,,,
866,Rv3795,3,EMB,embB,,,Jain A IndJMedRes 2008,,,673-674,GCG/AGC,225,225,Ala/Ser,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,882,0,,,,,,
867,Rv3795,4,EMB,embB,,,Jain A IndJMedRes 2008,,,680-681,GTG/GGC,227,227,Val/Gly,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,883,0,,,,,,
868,Rv3795,5,EMB,embB,,,Srivastava S CurrMicro 2006,,,716,CTC/CCC,239,239,Leu/Pro,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,256ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,884,0,,,,,,
869,Rv3795,6,EMB,embB,,,Srivastava S CurrMicro 2006,,,718,GAC/CAC,240,240,Asp/His,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,4ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,885,0,,,,,,
870,Rv3795,7,EMB,embB,,,Srivastava S JMM 2009,,,769-771,CGT/TGG,257,257,Arg/Trp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embC V287F  Y309N; embR A176V  R230W  I369T,0,19010731,886,0,,,,,,
871,Rv3795,8,EMB,embB,,,Jain A IndJMedRes 2008,,,812,GCG/GTG,271,271,Ala/Val,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,887,0,,,,,,
872,Rv3795,9,EMB,embB,,,Jain A IndJMedRes 2008,,,814,AGC/TGC,272,272,Ser/Cys,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,888,0,,,,,,
873,Rv3795,10,EMB,embB,,,Jain A IndJMedRes 2008,,,815-816,AGC/ATT,272,272,Ser/Ile,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,889,0,,,,,,
874,Rv3795,11,EMB,embB,,,Wu  X  Chinese J of Antibiotics 2002,,,821,CGC/CCC,274,274,Arg/Pro,,,,,,,,,,,,,0,12622890,890,0,,,,,,
875,Rv3795,12,EMB,embB,,,Jain A IndJMedRes 2008,,,841,GCG/CCG,281,281,Ala/Pro,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,891,0,,,,,,
876,Rv3795,13,EMB,embB,,,Jain A IndJMedRes 2008,,,841-843,TTT/CTG,281,281,Phe/Leu,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,892,0,,,,,,
877,Rv3795,14,EMB,embB,,,Srivastava S JMM 2009,,,845,GTG/GGG,282,282,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,12ug/ml,Proportion method  E-Test,44/44,1/0,None in region embB  embC or embR',0,19010731,893,0,,,,,,
878,Rv3795,15,EMB,embB,,,Jain A IndJMedRes 2008,,,844,GTG/CTG,282,282,Val/Leu,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,894,0,,,,,,
879,Rv3795,16,EMB,embB,,,Sreevatsan S AAC 1997,,,855,TTC/TTA,285,285,Phe/Leu,,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,N.S.,BACTEC 460  agar diffusion method,69/99,1/0,,0,9257740,895,0,,,,,,
880,Rv3795,17,EMB,embB,,,Jain A IndJMedRes 2008,,,860-861,TTT/TGC,287,287,Phe/Cys,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,896,0,,,,,,
881,Rv3795,18,EMB,embB,,,Jain A IndJMedRes 2008,,,859-861,TTT/GTG,287,287,Phe/Val,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,897,0,,,,,,
882,Rv3795,19,EMB,embB,,,Jain A IndJMedRes 2008,,,878-879,ATT/AAC,293,293,Ile/Asn,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,898,0,,,,,,
883,Rv3795,20,EMB,embB,,,Jain A IndJMedRes 2008,,,880,GGC/AGC,294,294,Gly/Ser,,2002-2004,,India,Sequencing,ERDR,EHRS,>20ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,899,13,,,,,,
884,Rv3795,21,EMB,embB,,,Srivastava S JMM 2009,,,888,AAT/AAA,296,296,Asn/Lys,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,16ug/ml,Proportion method  E-Test,44/44,1/0,embB E368D  G406S; embC I297T,0,19010731,900,0,,,,,,
885,Rv3795,22,EMB,embB,,,Ramaswamy SV AAC 2000,,,889,TCG/GCG,297,297,Ser/Ala,embB mutations at codon 306 occur abundantly in EMB-esistant M.tb  but rarely in susceptible strains.,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,901,0,,,,,,
886,Rv3795,23,EMB,embB,,,Plinke C AAC 2006,,,890,TCG/TTG,297,297,Ser/Leu,,2001,EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159.,Germany,Sequencing,ERDR,E + INH + RIF,N.S.,Proportion method  BACTEC 460,101/159,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16641474,902,0,,,,,,
887,Rv3795,24,EMB,embB,,,Srivastava S CurrMicro 2006,,,897,GAC/GAA,299,299,Asp/Glu,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,2-6ug/ml,Proportion method  E-Test,23/23,4/0,Out of 4 isolates  2 were WT in all other loci analyzed except for a synonymous mutation (GCA/GCC) at embB259. These isolates had MIC=4-6ug/ml. Both other isolates contained the embB mutation Glu378Ala (GAA/GCG); one of them was also mutated at embB Pro44,0,16972132,903,0,,,,,,
888,Rv3795,25,EMB,embB,,,Sreevatsan S AAC 1997,,,916,ATG/CTG,306,306,Met/Leu,In this paper  the authors started by sequencing a 7.5kb portion of embCAB in 19 resistant isolates. Upon finding mutations at the 306 codon of embB to be mutated in 8/19 samples  they sequenced a 1 892nt segment of embB containing this codon specifically,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=76,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,40ug/ml,BACTEC 460  agar diffusion method,69/99,1/0,,1,9257740,904,13,,,,,,
889,Rv3795,26,EMB,embB,,,Lee HY YonseiMedJ 2002,,,916,ATG/TTG,306,306,Met/Leu,Distinguish between high-level (MIC>20ug/ml) and low-level EMB resistance. Out of 21 EMB-R isolates  12 (57%) had embB mutations (10 at embB306  2 at other sites within a 312-bp region)  while the 5 EMB-S isolates contained no mutations in any region of E,Published 2002,Clinical isolates obtained from the Korean Institute of TB  Seoul. N=26.,South Korea,Sequencing,Whole gene,E ,2ug/ml,Proportion method,21/26,1/0,None in region amplified (see Gene coverage).,0,11854934,905,0,,,,,,
890,Rv3795,27,EMB,embB,,,Sreevatsan S AAC 1997,,,916,ATG/GTG,306,306,Met/Val,,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,40ug/ml,BACTEC 460  agar diffusion method,69/99,12/0,,1,9257740,906,13,,,,,,
891,Rv3795,28,EMB,embB,,,Sreevatsan S AAC 1997,,,918,ATG/ATA,306,306,Met/Ile,,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,20ug/ml,BACTEC 460  agar diffusion method,69/99,11/0,,1,9257740,907,13,,,,,,
892,Rv3795,29,EMB,embB,,,Sreevatsan S AAC 1997,,,918,ATG/ATT,306,306,Met/Ile,,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,20ug/ml,BACTEC 460  agar diffusion method,69/99,2/0,,1,9257740,908,13,,,,,,
893,Rv3795,30,EMB,embB,,,Sreevatsan S AAC 1997,,,918,ATG/ATC,306,306,Met/Ile,,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,20ug/ml,BACTEC 460  agar diffusion method,69/99,3/0,,1,9257740,909,13,,,,,,
894,Rv3795,31,EMB,embB,,,Lee HY YonseiMedJ 2002,,,917-918,ATG/ACG,306,306,Met/Thr,,Published 2002,Clinical isolates obtained from the Korean Institute of TB  Seoul. N=26.,South Korea,Sequencing,ERDR,E,2ug/ml,Proportion method,21/26,1/0,None in region amplified (see Gene coverage).,0,11854934,910,0,,,,,,
895,Rv3795,32,EMB,embB,,,Srivastava S JMM 2009,,,926-927,GTG/GGC,309,309,Val/Gly,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  A310R  D311R  V369A  P375A  F398Y  P461S; embC T270I; embR G240R,0,19010731,911,0,,,,,,
896,Rv3795,33,EMB,embB,,,Srivastava S JMM 2009,,,928-930,GCG/CGT,310,310,Ala/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  V309G  D311R  V369A  P375A  F398Y  P461S; embC T270I; embR G240R,0,19010731,912,0,,,,,,
897,Rv3795,34,EMB,embB,,,Srivastava S JMM 2009,,,931-932,GAC/CGT,311,311,Asp/Arg,Reported as GAT/CGT but it should be GAC/CGT,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  V309G  A310R  V369A  P375A  F398Y  P461S; embC T270I; embR G240R,0,19010731,913,0,,,,,,
898,Rv3795,35,EMB,embB,,,Srivastava S CurrMicro 2006,,,931,GAC/CAC,311,311,Asp/His,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,12ug/ml,Proportion method  E-Test,23/23,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16972132,914,0,,,,,,
899,Rv3795,36,EMB,embB,,,Srivastava S JMM 2009,,,935,CAT/CGT,312,312,His/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB S317T  A356F  L359I  R367P; embC G288V  M310K  Y327N,0,19010731,915,0,,,,,,
900,Rv3795,37,EMB,embB,,,Lee HY YonseiMedJ 2002,,,941,GGC/GCG,314,314,Gly/Ala,A double substitution mutation with codon 322.,Published 2002,Clinical isolates obtained from the Korean Institute of TB  Seoul. N=26.,South Korea,Sequencing,ERDR,E,4ug/ml,Proportion method,21/26,1/0,Tyr322Cys on embB.,0,11854934,916,0,,,,,,
901,Rv3795,38,EMB,embB,,,Tracevska T ResMicro 2004,,,941-942,GGC/GAG,314,314,Gly/Glu,,Published 2004; isolates collected in 2001-2002,Patients with primary and relapsed pulmonary MDR-TB: 33 EMB-R and 33 EMB-S (N=66).,Latvia,Sequencing,ERDR,EHRS,N.S.,BACTEC radiorespiratory method (7.5ug/ml EMB)  and absolute concentration method on L-J medium (cutoff 2.0ug/ml EMB),33/66,1/0,None in region amplified (see Gene coverage).,0,15567277,917,0,,,,,,
902,Rv3795,39,EMB,embB,,,Srivastava S JMM 2009,,,943-945,TAT/CTG,315,315,Tyr/Leu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,256ug/ml,Proportion method  E-Test,44/44,1/0,embB L239P  N318S  V377G  E378A  Y384N  N400K  V452L,0,19010731,918,0,,,,,,
903,Rv3795,40,EMB,embB,,,Srivastava S JMM 2009,,,950,AGC/ACC,317,317,Ser/Thr,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB H312R  A356F  L359I  R367P; embC G288V  M310K  Y327N,0,19010731,919,0,,,,,,
904,Rv3795,41,EMB,embB,,,Srivastava S JMM 2009,,,352,AAC/CAT,318,318,Asn/His,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,16ug/ml,Proportion method  E-Test,44/44,1/0,embC T270I,0,19010731,920,0,,,,,,
905,Rv3795,42,EMB,embB,,,Srivastava S JMM 2009,,,953,AAC/AGC,318,318,Asn/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,256ug/ml,Proportion method  E-Test,44/44,1/0,embB L239P  Y315L  V377G  E378A  Y384N  N400K  V452L,0,19010731,921,0,,,,,,
906,Rv3795,43,EMB,embB,,,Srivastava S JMM 2009,,,954,AAC/AAA,318,318,Asn/Lys,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,32ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  N368A  S380R  P397Q  G459A  R460C; embR T32P  D53H,0,19010731,922,0,,,,,,
907,Rv3795,44,EMB,embB,,,Sugawara I Jpn J Infect Dis 2005,,,955,TAT/GAT,319,319,Tyr/Cys,,,,,,,,,,,,,0,16377878,923,0,,,,,,
908,Rv3795,45,EMB,embB,,,Chan RCY JAC 2007,,,955,TAT/AAT,319,319,Tyr/Asn,,,,,,,,,,,,,0,17360809,924,0,,,,,,
909,Rv3795,46,EMB,embB,,,Sugawara I Jpn J Infect Dis 2005,,,956,TAT/TGT,319,319,Tyr/Cys,,,,,,,,,,,,,0,16377878,925,0,,,,,,
910,Rv3795,47,EMB,embB,,,Plinke C AAC 2006,,,956,TAT/TCT,319,319,Tyr/Ser,,2001,EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159.,Germany,Sequencing,ERDR,EHR,N.S.,Proportion method  BACTEC 460,101/159,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16641474,926,0,,,,,,
911,Rv3795,48,EMB,embB,,,Lee HY YonseiMedJ 2002,,,965,TAT/TGT,322,322,Tyr/Cys,A double substitution mutation with codon 314.,Published 2002,Clinical isolates obtained from the Korean Institute of TB  Seoul. N=26.,South Korea,Sequencing,ERDR,E,4ug/ml,Proportion method,21/26,1/0,Ala314Gly on embB.,0,11854934,927,0,,,,,,
912,Rv3795,49,EMB,embB,,,Ramaswamy SV AAC 2000,,,982,GAT/TAT,328,328,Asp/Tyr,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Ala201Thr in embA  Tyr334His in embB.,0,10639358,928,0,,,,,,
913,Rv3795,50,EMB,embB,,,Ramaswamy SV AAC 2000,,,983,GAT/GGT,328,328,Asp/Gly,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,10-50ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,,0,10639358,929,0,,,,,,
914,Rv3795,51,EMB,embB,,,Plinke C AAC 2006,,,983-984,GAT/GTG,328,328,Asp/Val,,2001,EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159.,Germany,Sequencing,ERDR,EHR,N.S.,Proportion method  BACTEC 460,101/159,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16641474,930,0,,,,,,
915,Rv3795,52,EMB,embB,,,Escalante P TuberLung Dis 1998,,,983,del A,328,,Frameshift,Out of 29 strains tested  19 were resistant to INH + RIF  and most of these were also resistant to one or two other first-line drugs; 3 resistant only to STR; 1 resistant only to INH; and 2 were pan-susceptible. One strain had a frame-shift mutation at co,Published 1998; isolates collected 1995-1996,Isolates from patients with pulmonary  suspected drug-resistant TB on the basis of failure of treatment with first-line drugs. N=29,Peru,Sequencing,ERDR,E,N.S.,Proportion method,40146,1/0,None in region amplified (see Gene coverage).,0,10645449,931,0,,,,,,
916,Rv3795,53,EMB,embB,,,Sreevatsan S AAC 1997,,,988,TTC/GTC,330,330,Phe/Val,,Published 1997,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118,USA  Mexico  Europe  Yemen  the Philippines  Japan  India,PCR-SSCP  Sequencing,Whole gene,E,40ug/ml,BACTEC 460  agar diffusion method,69/99,1/0,,0,9257740,932,0,,,,,,
917,Rv3795,54,EMB,embB,,,Srivastava S JMM 2009,,,991-993,GGC/CGT,331,331,Gly/Arg,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,ER,16ug/ml,Proportion method  E-Test,44/44,1/0,embB V360M  G374V  G401S; embC I297T; embR D223E,0,19010731,933,0,,,,,,
918,Rv3795,55,EMB,embB,,,Lee HY YonseiMedJ 2002,,,991,GAT/TAT,331,331,Asp/Tyr,,Published 2002,Clinical isolates obtained from the Korean Institute of TB  Seoul. N=26.,Korea,Sequencing,ERDR,E,4ug/ml,Proportion method,21/26,1/0,None in region amplified (see Gene coverage).,0,11854934,934,0,,,,,,
919,Rv3795,56,EMB,embB,,,Plinke C AAC 2006,,,994-995,TGG/CTG,332,332,Trp/Leu,,2001,EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159.,Germany,Sequencing,ERDR,EHR,N.S.,Proportion method  BACTEC 460,101/159,1/0,None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.,0,16641474,935,0,,,,,,
920,Rv3795,57,EMB,embB,,,Sugawara I Jpn J Infect Dis 2005,,,997,TAT/CAT,333,333,Tyr/His,,,,,,,,,,,,,0,16377878,936,0,,,,,,
921,Rv3795,58,EMB,embB,,,Ramaswamy SV AAC 2000,,,1000,TAC/CAC,334,334,Tyr/His,,Published 2000,Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108,USA  Russia,Sequencing,Whole gene,E,30ug/ml,BACTEC 460  agar diffusion method,75/108,1/0,Ala201Thr in embA  Asp328Tyr in embB.,0,10639358,937,0,,,,,,
922,Rv3795,59,EMB,embB,,,Escalante P TuberLung Dis 1998,,,1040,AGT/ACT,347,347,Ser/Thr,Out of 29 strains tested  19 were resistant to INH + RIF  and most of these were also resistant to one or two other first-line drugs; 3 resistant only to STR; 1 resistant only to INH; and 2 were pan-susceptible.,Published 1998; isolates collected 1995-1996,Isolates from patients with pulmonary  suspected drug-resistant TB on the basis of failure of treatment with first-line drugs. N=29,Peru,Sequencing,ERDR,E,N.S.,Proportion method,40146,1/0,None in region amplified (see Gene coverage).,0,10645449,938,0,,,,,,
923,Rv3795,60,EMB,embB,,,Srivastava S JMM 2009,,,1040,AGT/ATT,347,347,Ser/Ile,Reported as AGC/ATT but it should be AGT/ATT,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB E368D  R460L; embC I297T; embR R230W  I396T,0,19010731,939,0,,,,,,
924,Rv3795,61,EMB,embB,,,Srivastava S JMM 2009,,,1066-1068,GCG/TTT,356,356,Ala/Phe,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB H312R  S317T  L359I  R367P; embC G288V  M310K  Y327N,0,19010731,940,0,,,,,,
925,Rv3795,62,EMB,embB,,,Srivastava S JMM 2009,,,1066-1068,GCG/AGC,356,356,Ala/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB D299E  P371R  E378K; embR R230W  L292M  L303E,0,19010731,941,0,,,,,,
926,Rv3795,63,EMB,embB,,,Srivastava S JMM 2009,,,1067,GCG/GTG,356,356,Ala/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  S366P  W395R  A434G  V435G  V436G  T437A; embC T270I,0,19010731,942,0,,,,,,
927,Rv3795,64,EMB,embB,,,Srivastava S JMM 2009,,,1069-1071,GCG/AGC,357,357,Ala/Ser,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,2ug/ml,Proportion method  E-Test,44/44,1/0,embB A379T; embC V287F  Y309N; embR L320V S326N  V350G  H351Q  R356G  I369T,0,19010731,943,0,,,,,,
928,Rv3795,65,EMB,embB,,,Srivastava S JMM 2009,,,1070,GCG/GTG,357,357,Ala/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,8ug/ml,Proportion method  E-Test,44/44,1/0,embB A356F  L359I  E378A  A379D  Y384N  A388G  N399D  G406P; embC A247P  T270I  I297T,0,19010731,944,0,,,,,,
929,Rv3795,66,EMB,embB,,,Srivastava S JMM 2009,,,1073-1074,GGC/GTG,358,358,Gly/Val,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,3ug/ml,Proportion method  E-Test,44/44,1/0,embB E368Q  S380D  P397T  G406D  G448V; embC I287L  W326R,0,19010731,945,0,,,,,,
930,Rv3795,67,EMB,embB,,,Srivastava S JMM 2009,,,1075-1077,CTG/ATT,359,359,Leu/Ile,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB H312R  S317T  A356F  R367P; embC G288V  M310K  Y327N,0,19010731,946,0,,,,,,
931,Rv3795,68,EMB,embB,,,Srivastava S JMM 2009,,,1078,GTG/ATG,360,360,Val/Met,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,ER,16ug/ml,Proportion method  E-Test,44/44,1/0,embB G331R  G374V  G401S; embC I297T; embR D223E,0,19010731,947,0,,,,,,
932,Rv3795,69,EMB,embB,,,Srivastava S JMM 2009,,,1096,AGC/CCG,366,366,Ser/Pro,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,6ug/ml,Proportion method  E-Test,44/44,1/0,embB M306L  A356V  W395R  A434G  V435G  V436G  T437A; embC T270I,0,19010731,948,0,,,,,,
933,Rv3795,70,EMB,embB,,,Srivastava S JMM 2009,,,1100-1101,CGT/CCG,367,367,Arg/Pro,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,96ug/ml,Proportion method  E-Test,44/44,1/0,embB H312R  S317T  A356F  L359I; embC G288V  M310K  Y327N,0,19010731,949,0,,,,,,
934,Rv3795,71,EMB,embB,,,Srivastava S JMM 2009,,,1102-1104,GAA/CAG,368,368,Glu/Gln,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,3ug/ml,Proportion method  E-Test,44/44,1/0,embB G358V  S380D  P397T  G406D  G448V; embC I287L  W326R,0,19010731,950,0,,,,,,
935,Rv3795,72,EMB,embB,,,Srivastava S JMM 2009,,,1104,GAA/GAT,368,368,Glu/Asp,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,4ug/ml,Proportion method  E-Test,44/44,1/0,embB S347I  R460L; embC I297T; embR R230W  I396T,0,19010731,951,0,,,,,,
936,Rv3795,73,EMB,embB,,,Srivastava S CurrMicro 2006,,,1103-1104,GAA/GCG,368,368,Glu/Ala,,Published 2006,Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23,India,Sequencing,ERDR,E  EHR  HR  EH,32ug/ml,Proportion method,23/23,1/0,Met306Val  Ser380Arg  and Pro397Gln on embB.,0,16972132,952,0,,,,,,
937,Rv3795,74,EMB,embB,,,Srivastava S JMM 2009,,,1105,GTG/CTG,369,369,Val/Leu,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,12ug/ml,Proportion method  E-Test,44/44,1/0,embB M306I; embC L251R  A354G  T270I,0,19010731,953,0,,,,,,
938,Rv3795,75,EMB,embB,,,Srivastava S JMM 2009,,,1106,GTG/GCG,369,369,Val/Ala,,Published 2009,44 isolates from unrelated adult patients with pulmonary TB.,India,Sequencing,Whole gene,EHR,128ug/ml,Proportion method  E-Test,44/44,1/0,embB M306V  V309G  A310R  D311R  P375A  F398Y  P461S; embC T270I; embR G240R,0,19010731,954,0,,,,,,
939,Rv0667,1,RIF,rpoB,,,Heep M AAC 2000,O'Sullivan DM JAntiChemo 2005,,,GTC/TTC,146,146,Val/Phe,Comparison of equivalent mutation conferring RIF-resistance in Mtb and H. pylori,Published 2003,6 isolates from Japan for which MICs of rifampin were elevated but with wild-type sequence in the rpoB cluster region. N=6,Japan,Sequencing,Whole gene,R,1-4  8-32 ug/ml,N.S.,(6/6 || 3 high level of resistance / 6 total),(3/0),,0,10722516,1,0,,,,,,
940,Rv0667,2,RIF,rpoB,,,Taniguchi H FEMS Micro 1996,,,,GCG/GTG,381,381,Ala/Val,,Published 1997,39 clinical isolates (including MDR-TB strains) from Koga Hospital  Nougata central hospital  and Fukuoka-Higashi hospital. N=39,Japan,Sequencing,Whole gene,R,200 ug/ml,Proportion method  absolute concentration method,21/39,(1/0),,0,8870258,2,0,,,,,,
941,Rv0667,3,RIF,rpoB,,,Cavusoglu C JCM 2002,O'Sullivan DM JAntiChemo 2005,,,CAG/CAT,490,490,Gln/His,Objective: determine drug resistance profiles of study population and detect and identify mutations present in the gene. Results: The most frequent mutation was 531 Ser/Leu. Comparisons were made of the frequencies of some mutations in Turkey compared to other countries: 3 mutations (526 TAC  526 GAC and 516 GTC) were much lower in freq in the Turkish isolates.Novel mutations: 1) 490 CAG/CAT was outside the 81 bp hot-spot region 2) 515 ATG/ATC 3) 533 CTG/CCG 4) insertion of CGG betw 514-515. No association was found between specific mutations and MDR patterns. Postulates: (i) mutants isolated more freq in clinical practice have higher mean relative fitness and the prevalence of each mutant type depends on its ability to survive. (ii) mutations w/in 526 and 516 have shown to lead to high level RIF resistance; therefore  mutations continue to arise in these codons  probably due to abaility of Mtb to adapt to drug exp.,Published 2002,41 RIF-resistant isolates from Reion Tuberculosis Laboratory and Ege University Mycobacteriology Laboratory. N=41,Turkey,Line probe assay  Sequencing,RRDR,R  RE  RHE  RH  RHES  RHS,N.S.,Proportion method,41/41,(1/0),,0,12454132,3,0,,,,,,
942,Rv0667,4,RIF,rpoB,,,Schilke K IntJTubLungDis 1999,,,,GAG/GCG,504,504,Glu/Ala,Of note:  Outside of hot-spot region; Both isolates carried a separate missense mutation at codon 531  independently conveying drug resistance; isolates were recovered 5 wks apart from 2 different patients attending the same hospital; DNA finterprint analysis suggested a clonal relationship for those strainscontrary to findings of Sreevatsan et al and cannot be resolved with these findings.,Published 1999,87 MDR strains from 12 hospitals in Southern African regions + 13 RIF-resistant strains of M. africanum + 3 RIF-resistant strains of M. tuberculosis from Sierra Leone and Uganda + 2 RIF-resistant strains of M. tuberculosis from Namibia. N=105,South Africa,Sequencing,RRDR,MDR,N.S.,Not specified,105/105,(2/0),Double mutation with 531,0,10423225,4,0,,,,,,
943,Rv0667,5,RIF,rpoB,,,Heym B Lancet 1994,,,,TTC/TTG,505,505,Phe /Leu,Objective: To use new methods in a retrospective study of drug-resistant isolates  and have correlated the molecular findings with available clinical and microbiological data. Results: 13 of 39 resistant to R; 11 of 13 MDR (H R) - 2 strains resistant to R but not H were from patients w/ poor compliance with chemotherapy,1991-1992,39 drug-resistant isolates analyzed: 16 strains resistant to H  1 control - fully susceptible  15 strains from other French hospitals but where susceptibility testing was done at the Pitie-Salpetriere lab. Taken from survey from 1991-1992 of drug resistance among isolates received for testing at Pietie-Salpetriere Hospital. N=39,La Reunion,PCR-SSCP,,RSHE,> 100 mg/L,Proportion method,13/39,(2/0),1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present,0,7914261,5,0,,,,,,
944,Rv0667,6,RIF,rpoB,,,Stavrum R PlosOne 2009,,,,TTC/TTA,505,505,Phe /Leu,,Published 2009,,India,Sequencing,Whole gene,RSHE,> 100 mg/L,Proportion method,13/39,(2/0),1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present,0,19234602,6,0,,,,,,
945,Rv0667,7,RIF,rpoB,,,Wang Q JProtRes 2007,,,,TTC/TCC,505,505,Phe/Ser,,Published 1997,,China,Sequencing,Whole gene,R,N.S.,Proportion method  absolute concentration method,112/30,1/0,,0,17970586,7,0,,,,,,
946,Rv0667,8,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,GGC/AGC,507,507,Gly/Ser,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,<50 ug/ml,Proportion method,41/286,1/0,rpoB T508P,0,19721079,8,0,,,,,,
947,Rv0667,9,RIF,rpoB,,,Kim BJ JCM 1997,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,GGC/GAC,507,507,Gly/Asp,DNA analysis of the 32 RIF-R strains showed 14 different kinds of mutations affecting 9 amino acids within a 75-bp region of the gene. The highest mutation frequencies were observed at His526 (37.8%) and Ser531 (24.4%). Another characteristic finding was,Published 1997,Clinical isolates  both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58,South Korea,PCR-SSCP  Sequencing,RRDR,R,N.S.,Absolute concentration method.,32/58,1/0,Location of double mutants not specified.,0,9003625,9,0,,,,,,
948,Rv0667,10,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,GGC/GAT,507,507,Gly/Asp,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,>100 ug/ml,Proportion method,41/286,2/0,rpoB Q513STOP  H526Y  S531F,0,19721079,10,0,,,,,,
949,Rv0667,11,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,del GGC ACC,507,507-508,del Gly Thr,,,,,,,,,,,,,0,10645439,11,0,,,,,,
950,Rv0667,12,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,ACC/CAC,508,508,Thr/His,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,>100 ug/ml,Proportion method,41/286,6/0,rpoB H526Q  S531F,0,19721079,12,0,,,,,,
951,Rv0667,13,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,ACC/CCC,508,508,Thr/Pro,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,<50 ug/ml,Proportion method,41/286,4/0,rpoB G507S,0,19721079,13,0,,,,,,
952,Rv0667,14,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,ACC/GCC,508,508,Thr/Ala,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,<75 ug/ml,Proportion method,41/286,2/0,rpoB G523A,0,19721079,14,0,,,,,,
953,Rv0667,15,RIF,rpoB,,,Mani C JCM 2001,,,,ACC/AGC,508,508,Thr/Ser,Three new mutations within RRDR found  and two new mutations outside the RRDR.,Published 2001,RIF-R (n=44) and RIF-S (n=6) isolates from 50 patients. Total N=50,India,Sequencing,RRDR,R,>128ug/ml,Proportion method,44/50,1/0,None described in the region sequenced.,0,11474030,15,0,,,,,,
954,Rv0667,16,RIF,rpoB,,,Matsiota-Bernard P JCM 1998,,,,ACC/GCT,508,508,Thr/Ser,,1995-1996,RIF-R clinical isolates. N=17,Greece,Line probe assay  Sequencing,RRDR,RHSEth,N.S.,Proportion method,17/17,1/0,None described in the region sequenced.,0,9431913,16,0,,,,,,
955,Rv0667,17,RIF,rpoB,,,Zenteno-Cuevas R MemInstOswaldCruz 2009,,,,AGC/CAG,509,509,Ser/Gln,,2007,,Mexico,Sequencing,RRDR,HRSEZ,N.S.,BACTEC 460,15/25,1/0,None,0,19547874,17,0,,,,,,
956,Rv0667,18,RIF,rpoB,,,Williams D AAC 1994,,,,AGC/ACC,509,509,Ser/Thr,Objective: To further characterize mutation assoicated with the RIF-resistent phenotype in TB  M. leprae and other pathogenic mycobacteria using a newly developed rapid PCr0based  DNA sequencing protocol targeted to a 305 bp region of the gene. Of note: It is not known if the Gln-527 or Thr-509 substituted amino acid could confer RIF-resistance. Further study is needed.,Published 1994,110 RIF-resistant and 10 RIF-susceptible strains from different geographic regions across the world. N=120,Canada,Sequencing,RRDR,RHES,N.S.,Proportion method,108/120,(1/0),Double mutation with 526 (Asp),0,7840574,18,0,,,,,,
957,Rv0667,19,RIF,rpoB,,,Sekiguchi J JCM 2007 Jan,,,,AGC/AGG,509,509,Ser/Arg,Objective: Describe a new PCR-based method for simultaneous detection of mutations in eight genes responsible for resistance to six drugs. Results: S450L and S509R were novel mutations. S450L was susceptible indicated that it is not associated with RIF resistance.,Published 2007,105 and 33 clinical isolates were obtained from patients with pulmonary tuberculosis in Japan and Poland  respectively. N=138,Japan,Sequencing,RRDR,R  MDR,N.S.,Proportion method  BACTEC,28/138,(0/1),,0,17108078,19,0,,,,,,
958,Rv0667,20,RIF,rpoB,,,Zenteno-Cuevas R MemInstOswaldCruz 2009,,,,CAG/AAG,510,510,Gln/Lys,,2007,,Mexico,Sequencing,RRDR,HREZ,N.S.,BACTEC 460,15/25,1/0,None,0,19547874,20,0,,,,,,
959,Rv0667,21,RIF,rpoB,,,Sajduda A JCM 2004,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAG/CAC,510,510,Gln/His,,2000,105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible  4 INH-sensitive  3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113,Poland,real-time sequencing FRET,RRDR,R  MDR,N.S.,BACTEC 460,64/113,(2/0),rpoB: double mutation with 516 GAC/TAC,0,15184414,21,0,,,,,,
960,Rv0667,22,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CTG/CCG,511,511,Leu/Pro,A total of 23 distinct mutations in rpoB were identified. Over 90% of RIF-R strains had sequence alterations within a 69-bp region of the gene rpoB; most of these were missense mutations. Of the 121 RIF-R strains  3 were WT in rpoB. The analysis also iden,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,4/0,One of the strains was also Asp441Glu; another was Asp441Tyr; the third was also Ser437Thr.,1,8027320,22,30,,,,,,
961,Rv0667,23,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CTG/CGG,511,511,Leu/Arg,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,2/0,None described in the region sequenced.,0,8027320,23,0,,,,,,
962,Rv0667,24,RIF,rpoB,,,Siddiqi N AAC 2002,O'Sullivan DM JAntiChemo 2005,,,CTG/GTG,511,511,Leu/Val,,1995-1998,126 clinical isolates that were drug resistant. N=126,India,Sequencing,RRDR,R O,Not listed in Table,Proportion method,94/126,(2/0),1) rpoB dual mutation with N518T; gyrA S95T; 2) gyrA S95T,0,11796356,24,0,,,,,,
963,Rv0667,25,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,AGC/ACC,512,512,Ser/Thr,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,1/0,Also mutated at Leu436Pro.,0,8027320,25,0,,,,,,
964,Rv0667,26,RIF,rpoB,,,Sajduda A JCM 2004,,,,AGC/ATC,512,512,Ser/Ile,Objective: To determine the drug resistance profiles and detect mutations present in the rpoB and katG genes as well as in the regulatory region of the inhA gene. Results:  3 new double mutations; 2 new novel mutations in single codons. 2 RMP-resistant strains contained no mutations. None of the RMP-sensitive isolates had mutations. 46 strains clustered into 14 groups with identical IS6110 RFLP patterns but direct links could not be established. Freq of mutations at codon 516 was high in Poland; could be due to geographic variations or a sample bias.,2001,105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible  4 INH-sensitive  3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113,Poland,real-time sequencing FRET,RRDR,R  MDR,N.S.,BACTEC 460,64/113,(1/0),rpoB: double mutation with 516 GAC/GGC,0,15184414,26,0,,,,,,
965,Rv0667,27,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,AGC/CGC,512,512,Ser/Arg,,,,,,,,,,,,,0,10645439,27,0,,,,,,
966,Rv0667,28,RIF,rpoB,,,Chan RCY JAC 2007,,,,AGC/GGC,512,512,Ser/Gly,,1994-2004,Consecutive isolates that exhibited resistance to one or more drugs. Grantham Hospital and Public Health Laboratory of Hong Kong,Hong Kong,PCR-SSCP  Sequencing,RRDR,,,Absolute concentration method,250,221,,0,17360809,28,0,,,,,,
967,Rv0667,29,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,CAA/TAA,513,513,Gln/STOP,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,>100 ug/ml,Proportion method,41/286,2/0,rpoB G507D  H526Y  S531F,0,19721079,29,0,,,,,,
968,Rv0667,30,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,CAA/AAT,513,513,Gly/Asn,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,>100 ug/ml,Proportion method,41/286,2/0,rpoB S512T  H526F  S531L,0,19721079,30,0,,,,,,
969,Rv0667,31,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAA/CTA,513,513,Gln/Leu,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,2/0,None described in the region sequenced.,1,8027320,31,15,,,,,,
970,Rv0667,32,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAA/AAA,513,513,Gln/Lys,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,1/0,None described in the region sequenced.,0,8027320,32,0,,,,,,
971,Rv0667,33,RIF,rpoB,,,Prammananan T CMI 2008,,,,CAA/GAA,513,513,Gln/Glu,,2003-2005,,Thailand,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,154/113,1/0,None described in the region sequenced.,0,18294243,33,0,,,,,,
972,Rv0667,34,RIF,rpoB,,,Kim BJ JCM 1997,,,,CAA/CCA,513,513,Gln/Pro,,Published 1997,Clinical isolates  both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58,South Korea,Sequencing,RRDR,R,N.S.,Absolute concentration method.,32/58,2/0,Location of double mutants not specified.,0,9003625,34,0,,,,,,
973,Rv0667,35,RIF,rpoB,,,Valim A JCM 2000,,,,CAA/CAC,513,513,Gln/His,,,,,,,,,,82/100,1/0,,0,10921994,35,0,,,,,,
974,Rv0667,36,RIF,rpoB,,,Secondary Publication: O'Sullivan DM JAntiChemo 2005,O'Sullivan DM JAntiChemo 2005,,,CAA/CGA,513,513,Gln/Arg,,,,,,,,,,,,,0,15814606,36,0,,,,,,
975,Rv0667,37,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,ins TTC,513,513-514,ins Phe,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,2/0,None described in the region sequenced.,0,8027320,37,0,,,,,,
976,Rv0667,38,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,ins TTC ATG,513,513-514,ins Phe Met,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,1/0,None described in the region sequenced.,0,8027320,38,0,,,,,,
977,Rv0667,39,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,del CAA TTC,513,513-514,del Gln Phe,,,,,,,,,,,,,0,10645439,39,0,,,,,,
978,Rv0667,40,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,del AA TTC ATG G,513,513-516,Gln/His and del Phe Met,,,,,,,,,,,,,0,10645439,40,0,,,,,,
979,Rv0667,41,RIF,rpoB,,,Valim A JCM 2000,,,,del TTC,514,514,del Phe,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,RHSZEth,N.S.,Proportion method,82/100,(1/0),Same isolate had deletions: 515 (ATG-Met)  516(GAC-Asp) and change in codon 513 CAA(Gln)/CAC(His),0,10921994,41,0,,,,,,
980,Rv0667,42,RIF,rpoB,,,Taniguchi H FEMS Micro 1996,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,TTC/TTG,514,514,Phe/Leu,Objective: To determine whether strains had mutations in regions other than the cluster I region or in other genes than the rpoB gene. Also to describe the relationship between the level of resistance ot RIF and mutational sites of the gene. Of Note:  2 mutations at 516 and 514 conferred low level resistance. Two explanations are possible: either there is a difference of amino acid change at codon 516 or there is a difference of other mutational sites harvored by the same strain.,Published  1996,39 clinical isolates (including MDR-TB strains) from Koga Hospital  Nougata central hospital  and Fukuoka-Higashi hospital. N=39,Japan,Sequencing,Whole gene,R,12.5 ug/ml,Proportion method  absolute concentration method,21/39,(1/0),,0,8870258,42,0,,,,,,
981,Rv0667,43,RIF,rpoB,,,Valim A JCM 2000,,,,TTC/GTC,514,514,Phe/Val,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,RHSZEth,N.S.,Proportion method,82/100,(1/0),Same isolate had change in codon 531 TCG(Ser)/TTG(Leu),0,10921994,43,0,,,,,,
982,Rv0667,44,RIF,rpoB,,,Cavusoglu C JCM 2002,,,,ins CGG,514,514-515,ins Arg,,Published 2002,41 RIF-resistant isolates from Reion Tuberculosis Laboratory and Ege University Mycobacteriology Laboratory. N=41,Turkey,Line probe assay  Sequencing,RRDR,R  RE   RHE  RH  RHES  RHS,N.S.,Proportion method,41/41,(1/0),,0,12454132,44,0,,,,,,
983,Rv0667,45,RIF,rpoB,,,Lipin MY CMI 2007,,,,del C AT,514,514-515,Phe/Leu and del Met,Mutations in the RRDR of the rpoB gene were identified in 200 (92%) of the MDR isolates - with the most frequent mutations being in codons 516  526  and 531  which were together found in 194 (89%) of the isolates. The paper also breaks down the mutations,1998-2001,MDR-TB isolates from pulmonary TB patients. Most patients were male (92%); mean age 43yrs; none were co-infected with HIV. N=217,Russia,Sequencing,RRDR,RHS  RHSK  RHSE,N.S.,Absolute concentration method.,217/217,1/0,None described in the region sequenced.,0,17403134,45,0,,,,,,
984,Rv0667,46,RIF,rpoB,,,Valim A JCM 2000,,,,del TTC ATG GAC,514,514-516,del Phe Met Asp,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,RHSZEth,N.S.,Proportion method,82/100,(1/0),Same isolate had change in codon 513 CAA(Gln)/CAC(His),0,10921994,46,0,,,,,,
985,Rv0667,47,RIF,rpoB,,,Hillemann D Int J Tuberc Lung Dis 2005,,,,ins TTC,515,515,ins Phe,,2004,92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152,Kazakhstan  Germany,real-time sequencing FRET,RRDR,MDR,N.S.,N.S.,92/152,(1/0),,0,16229229,47,0,,,,,,
986,Rv0667,48,RIF,rpoB,,,Sajduda A JCM 2004,,,,ATG/ATT,515,515,Met/Ile,,2003,105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible  4 INH-sensitive  3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113,Poland,real-time sequencing FRET,RRDR,R  MDR,N.S.,BACTEC 460,64/113,(8/0),rpoB: double mutation with 516 GAC/TAC,0,15184414,48,0,,,,,,
987,Rv0667,49,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,ATG/ATA,515,515,Met/Ile,,,,,,,,,,,,,0,10645439,49,0,,,,,,
988,Rv0667,50,RIF,rpoB,,,Valim A JCM 2000,,,,del ATG GAC CAG AAC,515,515-518,del Met Asp Gln Asn,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,RHSEZEth,N.S.,Proportion method,82/100,(1/0),,0,10921994,50,0,,,,,,
989,Rv0667,51,RIF,rpoB,,,Schilke K IntJTubLungDis 1999,,,,GAC/AAC,516,516,Asp/Asn,,Published  1999,87 MDR strains from 12 hospitals in Southern African regions + 13 RIF-resistant strains of M. africanum + 3 RIF-resistant strains of M. tuberculosis from Sierra Leone and Uganda + 2 RIF-resistant strains of M. tuberculosis from Namibia. N=105,South Africa,Sequencing,RRDR,MDR,N.S.,N.S.,105/105,(1/0),,0,10423225,51,0,,,,,,
990,Rv0667,52,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,GAC/CAC,516,516,Asp/His,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,50-75 ug/ml,Proportion method,41/286,3/0,rpoB D516H  H526R,0,19721079,52,0,,,,,,
991,Rv0667,53,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,GAC/GTC,516,516,Asp/Val,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,1/0,None described in the region sequenced.,1,8027320,53,15,,,,,,
992,Rv0667,54,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,GAC/GAG,516,516,Asp/Glu,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,2/0,Also mutated at Leu436Pro.,0,8027320,54,0,,,,,,
993,Rv0667,55,RIF,rpoB,,,Hillemann D Int J Tuberc Lung Dis 2005,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,GAC/GGC,516,516,Asp/Gly,,2004,92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152,Kazakhstan  Germany,real-time sequencing FRET,RRDR,MDR,N.S.,N.S.,92/152,(1/0),,0,16229229,55,0,,,,,,
994,Rv0667,56,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,GAC/GCC,516,516,Asp/Ala,,,,,,,,,,,,,0,10645439,56,0,,,,,,
995,Rv0667,57,RIF,rpoB,,,Sajduda A JCM 2004,,,,GAC/GTG,516,516,Asp/Val,,2004,105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible  4 INH-sensitive  3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113,Poland,real-time sequencing FRET,RRDR,R  MDR,N.S.,BACTEC 460,64/113,(1/0),None,0,15184414,57,0,,,,,,
996,Rv0667,58,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,GAC/TAC,516,516,Asp/Tyr,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,2/0,Also mutated at Leu436Pro.,1,8027320,58,15,,,,,,
997,Rv0667,59,RIF,rpoB,,,Hillemann D Int J Tuberc Lung Dis 2005,,,,GAC/TTC,516,516,Asp/Phe,,2004,92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152,Kazakhstan  Germany,real-time sequencing FRET,RRDR,MDR,N.S.,N.S.,92/152,(1/0),,0,16229229,59,0,,,,,,
998,Rv0667,60,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,del GAC CAG,516,516-517,del Asp Gln,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,2/0,None described in the region sequenced.,0,8027320,60,0,,,,,,
999,Rv0667,61,RIF,rpoB,,,Xueqiong W MolBiotech 2009,,,,GAC/CAC,517,517,Gln/His,,2002-2005,,China,Sequencing,RRDR,RSE,N.S.,Absolute concentration method,112/148,1/0,rpoB N518D,0,18600483,61,0,,,,,,
1000,Rv0667,62,RIF,rpoB,,,Mani C JCM 2001,,,,del GAC,517,517,del Gln,,Published 2001,RIF-R (n=44) and RIF-S (n=6) isolates from 50 patients. Total N=50,India,Sequencing,RRDR,R,>128ug/ml,Proportion method,44/50,1/0,None described in the region sequenced.,0,11474030,62,0,,,,,,
1001,Rv0667,63,RIF,rpoB,,,Sajduda A JCM 2004,,,,CAA/CTA,517,517,Gln/Leu,,2005,105 drug resistant strains (83 INH-resistant and 64 RMP-resistant) + 8 controls (H37Rv-susceptible  4 INH-sensitive  3 RMP-sensitive); Isolated from TB patients during second national survey of drug resistance in Poland; provided by National Tuberculosis Reference Laboratory in Warsaw. N=113,Poland,real-time sequencing FRET,RRDR,R  MDR,N.S.,BACTEC 460,64/113,(1/0),None,0,15184414,63,15,,,,,,
1002,Rv0667,64,RIF,rpoB,,,Hillemann D AAC 2005,,,,del CAG AAC,517,517-518,del Gln Asn,,2001,113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113,Germany,real-time sequencing,RRDR,MDR,N.S.,,103/113,(1/0),katG 315 AGC-ACC/Ser-Thr,0,15728936,64,0,,,,,,
1003,Rv0667,65,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,del CAG AAC,517,517-518,del Gln Asn,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,1/0,None described in the region sequenced.,0,8027320,65,0,,,,,,
1004,Rv0667,66,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,del G AAC AA,517,517-519,Gln/His and del Asn Asn,,,,,,,,,,,,,0,10645439,66,0,,,,,,
1005,Rv0667,67,RIF,rpoB,,,Wang Q JProtRes 2007,,,,AAC/TAC,518,518,Asn/Tyr,,Published 1997,,China,Sequencing,Whole gene,R,N.S.,Proportion method  absolute concentration method,112/30,1/0,,0,17970586,67,0,,,,,,
1006,Rv0667,68,RIF,rpoB,,,Siddiqi N AAC 2002,,,,AAC/ACC,518,518,Asn/Thr,,1995-1998,126 clinical isolates that were drug resistant. N=126,India,Sequencing,RRDR,RHO  ROS   RO  RH,N.S.,Proportion method,94/126,(6/0),1) rpoB dual mutaton with L511L; katG and inhA NM; gyrA A90A  S95T 3) rpoB dual mutation with R528P; gyrA S95T; rpsL NM; 4) rpoB dual mutaton with L511V; gyrA S95T; 5) gyrA S95T; 6) gyrA NM; 7) rpoB dual mutation with D516V; katG and inhA R463L,0,11796356,68,0,,,,,,
1007,Rv0667,69,RIF,rpoB,,,Hillemann D AAC 2005,,,,AAC/ATC,518,518,Asn/Ile,,2001,113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113,Germany,real-time sequencing,RRDR,MDR,N.S.,,103/113,(1/0),None,0,15728936,69,0,,,,,,
1008,Rv0667,70,RIF,rpoB,,,Kim BJ JCM 1997,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,AAC/CAC,518,518,Asn/His,,Published 1997,Clinical isolates  both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58,South Korea,Sequencing and PCR-SSCP,RRDR,R,N.S.,Absolute concentration method.,32/58,1/0,Location of double mutants not specified.,0,9003625,70,0,,,,,,
1009,Rv0667,71,RIF,rpoB,,,Chan RCY JAC 2007,,,,AAC/GAC,518,518,Asn/Asp,,1994-2004,Consecutive isolates that exhibited resistance to one or more drugs. Grantham Hospital and Public Health Laboratory of Hong Kong,Hong Kong,PCR-SSCP  Sequencing,RRDR,,,Absolute concentration method.,250,221,,0,17360809,71,0,,,,,,
1010,Rv0667,72,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,AAC/AAG,519,519,Asn/Lys,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,50 ug/ml,Proportion method,41/286,2/0,rpoB L511V  Q513E  H526R,0,19721079,72,0,,,,,,
1011,Rv0667,73,RIF,rpoB,,,Heym B Lancet 1994,,,,del AAC,519,519,del Asn,,1991-1992,39 drug-resistant isolates analyzed: 16 strains resistant to H  1 control - fully susceptible  15 strains from other French hospitals but where susceptibility testing was done at the Pitie-Salpetriere lab. Taken from survey from 1991-1992 of drug resistance among isolates received for testing at Pietie-Salpetriere Hospital. N=39,Russia  Netherlands,PCR-SSCP,,MDR,10-100ug/ml,Proportion method,13/39,(2/0),1) katG mutation present; inhA no mutation present; 2) katG no mutation present,0,7914261,73,0,,,,,,
1012,Rv0667,74,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CTG/ATG,521,521,Leu/Met,,,,,,,,,,,,,0,10645439,74,0,,,,,,
1013,Rv0667,75,RIF,rpoB,,,Taniguchi H FEMS Micro 1996,,,,CTG/CCG,521,521,Leu/Pro,,Published  1998,39 clinical isolates (including MDR-TB strains) from Koga Hospital  Nougata central hospital  and Fukuoka-Higashi hospital. N=39,Japan,Sequencing,Whole gene,R,< 0.39 ug/ml,Proportion method  absolute concentration method,21/39,(0/1),,0,8870258,75,30,,,,,,
1014,Rv0667,76,RIF,rpoB,,,Secondary Publication: O'Sullivan DM JAntiChemo 2005,O'Sullivan DM JAntiChemo 2005,,,CTG/CTA,521,521,Leu/Leu,,,,,,,,,,,,,0,15814606,76,0,,,,,,
1015,Rv0667,77,RIF,rpoB,,,Bodmer T JAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,TCG/TTG,522,522,Ser/Leu,,Published  1998,122 clinical isolates from patients from diverse geographical locations (Telenti et al  1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36,N.S.,PCR-SSCP,RRDR,R,8ug/ml,BACTEC 460,26/36,(1/0),,1,7759399,77,30,,,,,,
1016,Rv0667,78,RIF,rpoB,,,Yuen LK JCM 1999,O'Sullivan DM JAntiChemo 2005,,,TCG/CAG,522,522,Ser/Gln,Objective: To develop a better understanding of the epidemiology and molecular biology of RIF-resistant strains in Australia. Of note: 522 TCG/CAG has not been previously reported. Cluster A represented Timorese patients were genetically related to each other. Highly probable that the patients were already infected prior to arriving in Australia.,1990-1997,50 clinical isolates collected from different reference laboratories in Australia: 17 RIF sensistive; 33 RIF resistant. N=50,Timor,Sequencing,RRDR,RH,32-256 ug/ml,Resistance ratio method   BACTEC 460  E-test,33/50,(2/0),None,0,10565894,78,0,,,,,,
1017,Rv0667,79,RIF,rpoB,,,Secondary Publication: O'Sullivan DM JAntiChemo 2005,O'Sullivan DM JAntiChemo 2005,,,TCG/TGG,522,522,Ser/Trp,,,,,,,,,,,,,0,15814606,79,15,,,,,,
1018,Rv0667,80,RIF,rpoB,,,El Baghdadi J IJTLD 2003,,,,CCC/ACC,523,523,Gly/Trp,,1996-2001,122 isolates from 112 different patients; 42 Mtb isolates analyzed (37 resistant  5 sensitive). N=122,Morocco,Sequencing,RRDR,RHS,N.S.,Resistance ratio method,101/122,(1/0),,0,12870687,80,0,,,,,,
1019,Rv0667,81,RIF,rpoB,,,Pozzi G JCM 1999,,,,GGG/TGG,523,523,Gly/Trp,,Published April 2000,MDR isolates from three clinical microbiology laboratories; 37 isolates  proven to be from different patients  analyzed for this study. N=37,Italy,Sequencing,RRDR,RH  RHS  RHSCip  RHSAmi  RHSZ  RHSZAmi  RHSCZ,8-128ug/ml,Absolute concentration method,37/37,(1/0),Triple mutation with GAC516TAC and ACC525ATC,0,10074552,81,0,,,,,,
1020,Rv0667,82,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,GGG/GCG,523,523,Gly/Ala,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,>100 ug/ml,Proportion method,41/286,25/0,rpoB T508A or S531L or L511V  or H526R,0,19721079,82,0,,,,,,
1021,Rv0667,83,RIF,rpoB,,,Valim A JCM 2000,,,,TTG/TGG,524,524,Leu/Trp,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,MDR,N.S.,Proportion method,82/100,(1/0),Same isolate had changes in codons 525 ACC(Thr)/CCC(Pro); 526 CAC(His)/CTG(Leu); 527 del AAG(Lys),0,10921994,83,0,,,,,,
1022,Rv0667,84,RIF,rpoB,,,Zenteno-Cuevas R MemInstOswaldCruz 2009,,,,TTG/TCG,524,524,Leu/Ser,,2007,,Mexico,Sequencing,RRDR,HR,N.S.,BACTEC 460,15/25,1/0,rpoB S531L,0,19547874,84,0,,,,,,
1023,Rv0667,85,RIF,rpoB,,,Valim A JCM 2000,,,,ACC/CCC,525,525,Thr/Pro,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,MDR,N.S.,Proportion method,82/100,(1/0),Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 526 CAC(His)/CTG(Leu); 527 del AAG(Lys),0,10921994,85,0,,,,,,
1024,Rv0667,86,RIF,rpoB,,,Pozzi G JCM 1999,,,,ACC/ATC,525,525,Thr/Ile,,Published April 2001,MDR isolates from three clinical microbiology laboratories; 37 isolates  proven to be from different patients  analyzed for this study. N=37,Italy,Sequencing,RRDR,RH  RHS  RHSCip  RHSAmi  RHSZ  RHSZAmi  RHSCZ,8-128ug/ml,Proportion method,37/37,(1/0),Triple mutation with GAC516TAC and GGG523TGG,0,10074552,86,0,,,,,,
1025,Rv0667,87,RIF,rpoB,,,Bahrmand AR JCM 2009,,,,CAC/TTC,526,526,His/Phe,,2005-2006,286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran  Zabol province  Afghanistan border.,Iran,Sequencing,411bp fragment of rpoB,41R  37MDR,>100 ug/ml,Proportion method,41/286,2/0,rpoB S512T  G513N  S531L,0,19721079,87,0,,,,,,
1026,Rv0667,88,RIF,rpoB,,,Ramaswamy SV J Med Micro 2004,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/AAC,526,526,His/Asn,(445 in ref),1996-2001,Subset of 186 strains initially isolated from patients who attended the Jose E. Gonzalez University Hospital TB clinic. N=37,Mexico,Sequencing,,RHSE,N.S.,Proportion method,37/50,(1/0),rpoB: Double mutation with 435 GAC/GAG; embB: 306 ATG/ATA1,1,14729930,88,15,,,,,,
1027,Rv0667,89,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/GAC,526,526,His/Asp,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,8/0,None described in the region sequenced.,1,8027320,89,15,,,,,,
1028,Rv0667,90,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/TAC,526,526,His/Tyr,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,39/0,None described in the region sequenced.,1,8027320,90,15,,,,,,
1029,Rv0667,91,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/ACC,526,526,His/Thr,,,,,,,,,,,,,0,10645439,91,0,,,,,,
1030,Rv0667,92,RIF,rpoB,,,Prammananan T CMI 2008,,,,CAC/AGC,526,526,His/Ser,,2003-2005,,Thailand,Sequencing,Whole gene,MDR,N.S.,Proportion method,154/113,1/0,rpoB 515 ATG/CTG,0,18294243,92,0,,,,,,
1031,Rv0667,93,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/GGC,526,526,His/Gly,,,,,,,,,,,,,0,10645439,93,0,,,,,,
1032,Rv0667,94,RIF,rpoB,,,Kim BJ JCM 1997,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/TGC,526,526,His/Cys,,Published 1997,Clinical isolates  both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58,South Korea,PCR-SSCP  Sequencing,RRDR,R,N.S.,Absolute concentration method.,32/58,2/0,Location of double mutants not specified.,0,9003625,94,0,,,,,,
1033,Rv0667,95,RIF,rpoB,,,Kim BJ JCM 1997,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/CGC,526,526,His/Arg,,Published 1997,Clinical isolates  both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58,South Korea,PCR-SSCP  Sequencing,RRDR,R,N.S.,Absolute concentration method.,32/58,1/0,Location of double mutants not specified.,1,9003625,95,15,,,,,,
1034,Rv0667,96,RIF,rpoB,,,Bodmer T JAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/CCC,526,526,His/Pro,,Published  2001,122 clinical isolates from patients from diverse geographical locations (Telenti et al  1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36,N.S.,PCR-SSCP,RRDR,R,8ug/ml,BACTEC 460,26/36,(2/0),,0,7759399,96,0,,,,,,
1035,Rv0667,97,RIF,rpoB,,,Valim A JCM 2000,,,,CAC/CTG,526,526,His/Leu,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,RHSEZEth,N.S.,Proportion method,82/100,(1/0),Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 525 ACC(Thr)/CCC(Pro); 527 del AAG(Lys),0,10921994,97,0,,,,,,
1036,Rv0667,98,RIF,rpoB,,,Sheng J JApplMicro 2008,,,,CAC/CTT,526,526,His/Leu,,2002-2003,56 isolates from patients with pulmonary TB in Zhejiang province,China,PCR-SSCP   Sequencing,RRDR,R,N.S.,Agar proportion method,49/56,1/0,None in rpoB,0,18422555,98,0,,,,,,
1037,Rv0667,99,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/CTC,526,526,His/Leu,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,2/0,None described in the region sequenced.,1,8027320,99,15,,,,,,
1038,Rv0667,100,RIF,rpoB,,,Kapur V JCM 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/CAA,526,526,His/Gln,,Published 1994,Clinical isolates  both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128,USA,Sequencing,Whole gene,R,N.S.,Proportion method  BACTEC,121/128,1/0,Also mutated at Ser456Cys.,0,8027320,100,0,,,,,,
1039,Rv0667,101,RIF,rpoB,,,Bodmer T JAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CAC/CAG,526,526,His/Gln,,Published 2003,122 clinical isolates from patients from diverse geographical locations (Telenti et al  1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36,N.S.,PCR-SSCP,RRDR,R,>8ug/ml,BACTEC 460,26/36,(2/0),Double mutation with 498 Val/Ala,0,7759399,101,0,,,,,,
1040,Rv0667,102,RIF,rpoB,,,Siddiqi N AAC 2002,O'Sullivan DM JAntiChemo 2005,,,AAG/AAT,527,527,Lys/Asn,,1995-1998,126 clinical isolates that were drug resistant. N=126,India,Sequencing,RRDR,HRH,40 ug/ml,Proportion method,94/126,(2/0),1) katG or inhA R463L; 2) katG or inhA R463L  rpoB dual mutation with L521L,0,11796356,102,0,,,,,,
1041,Rv0667,103,RIF,rpoB,,,Valim A JCM 2000,,,,del AAG,527,527,del Lys,,1996-1998,100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100,Brazil,Sequencing,RRDR,RHSEZEth,N.S.,Proportion method,82/100,(1/0),Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 525 ACC(Thr)/CCC(Pro); 526 CAC(His)/CTG(Leu),0,10921994,103,0,,,,,,
1042,Rv0667,104,RIF,rpoB,,,Williams D AAC 1994,,,,AAG/CAG,527,527,Lys/Gln,,Published 1995,110 RIF-resistant and 10 RIF-susceptible strains from different geographic regions across the world. N=120,USA,PCR-HDF   Sequencing,RRDR,RHEEt,N.S.,Proportion method,108/120,(1/0),Double mutation with 526 (His),0,7840574,104,0,,,,,,
1043,Rv0667,105,RIF,rpoB,,,Siddiqi N AAC 2002,,,,CGC/CAC,528,528,Arg/His,,1995-1998,126 clinical isolates that were drug resistant. N=126,India,Sequencing,RRDR,HR  ROS,64-128 ug/ml,Proportion method,94/126,(2/0),1) rpoB dual mutation with H526Y; gyrA S95T; rpsL NM;  2) rpoB 1 dual mutation with with S531W; katG and inhA R463L  Inh (C/T),0,11796356,105,0,,,,,,
1044,Rv0667,106,RIF,rpoB,,,Siddiqi N AAC 2002,O'Sullivan DM JAntiChemo 2005,,,CGC/CCC,528,528,Arg/Pro,,1995-1998,126 clinical isolates that were drug resistant. N=126,India,Sequencing,RRDR,ROS  RHO  RHS  RH,40-64 ug/ml*,Proportion method,94/126,(4/0),1) rpoB dual mutation with N518T; gyrA S95T; rpsL NM; 2) katG or inhA NA; gyrA S95T; 3) katG or inhA R463L; rpsL K121K;  4) katG or inhA R463L; rpoB dual mutation with H526Y,0,11796356,106,0,,,,,,
1045,Rv0667,107,RIF,rpoB,,,Zenteno-Cuevas R MemInstOswaldCruz 2009,,,,CGC/CCT,528,528,Arg/Pro,,2007,,Mexico,Sequencing,RRDR,HRSEZ,N.S.,BACTEC 460,15/25,1/0,None,0,19547874,107,0,,,,,,
1046,Rv0667,108,RIF,rpoB,,,Wang Q JProtRes 2007,,,,TCG/TAG,538,538,Leu/STOP,,Published 1997,,China,Sequencing,Whole gene,R,N.S.,Proportion method  absolute concentration method,112/30,1/0,,0,17970586,108,0,,,,,,
1047,Rv0667,109,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,TCG/CAG,531,531,Ser/Gln,,,,,,,,,,,,,0,10645439,109,0,,,,,,
1048,Rv0667,110,RIF,rpoB,,,Donabella V Am J Respir Cell Mol Biol 1994,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,TCG/TTG,531,531,Ser/Leu,,Published 1994,,USA,Sequencing,RRDR,R,N.S.,,(1/9),(1/0),,1,7946393,110,30,,,,,,
1049,Rv0667,111,RIF,rpoB,,,Bodmer T JAC 1995,,,,TCG/TGG,531,531,Ser/Trp,,Published 2005,122 clinical isolates from patients from diverse geographical locations (Telenti et al  1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36,N.S.,PCR-SSCP,RRDR,R,8ug/ml,BACTEC 460,26/36,(1/0),,1,7759399,111,15,,,,,,
1050,Rv0667,112,RIF,rpoB,,,Bodmer T JAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,TCG/TAT,531,531,Ser/Tyr,,Published 2006,122 clinical isolates from patients from diverse geographical locations (Telenti et al  1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36,N.S.,PCR-SSCP,RRDR,R,>8ug/ml,BACTEC 460,26/36,(1/0),,0,7759399,112,0,,,,,,
1051,Rv0667,113,RIF,rpoB,,,Hillemann D AAC 2005,,,,TCG/TTT,531,531,Ser/Phe,,2001,113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113,Germany,real-time sequencing,RRDR,MDR,N.S.,,103/113,(2/0),katG 315 AGC-ACC/Ser-Thr,0,15728936,113,0,,,,,,
1052,Rv0667,114,RIF,rpoB,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,TCG/TGT,531,531,Ser/Cys,,,,,,,,,,,,,0,10645439,114,0,,,,,,
1053,Rv0667,115,RIF,rpoB,,,Moghazeh SL AAC 1996,Ramaswamy S Musser JM Tubercle lung Dis 1998,,,CTG/CCG,533,533,Leu/Pro,,1992-1995,RIF-R clinical isolates from strain database. N=24,USA,Sequencing,N.S,R,>32ug/ml,Proportion method,24/24,1/0,None described in the region sequenced.,1,8913484,115,30,,,,,,
1054,Rv0667,116,RIF,rpoB,,,Valim A JCM 2000,,,,CTG/CCT,533,533,Leu/Pro,,1996-1998,100 isolates from different regions of Brazil: 20 samples (19 RIF-resistant; 1 RIF-susceptible) from Sao Paulo. N=100,Brazil,Sequencing,RRDR,RH  RHS,N.S.,Proportion method,82/100,(2/0),Same isolate had double mutation: 526 CAC(His)/CTG(Leu),0,10921994,116,0,,,,,,
1055,Rv0667,117,RIF,rpoB,,,Tracevska T JCM 2002,,,,CCC/TCC,535,535,Pro/Ser,Objective: To characterize the rpoB and katG gene mutations that are dominant in the Latvian isolates of MDR-TB by commercial Line Probe Assay (LiPA)  direct sequencing of PCR products  single-strand conformation polymorphism (SSCP) and PCR-restriction fragment length polymorphism analyses.,1999-2000,70 patients admitted to State Centre for Tuberculosis and Lung Diseases with clinical symptoms of lung or renal TB or TB meningitis. 25-60 yrs old; 2/3 male. 19 drug-susceptible; 34 MDR isolates were analyzed by LiPA. N=70,Latvia,Line probe assay  Sequencing,RRDR,R  RH,N.S.,Absolute concentration method  BACTEC,51/70,(4/0),Double mutation with D516Y,0,12354882,117,0,,,,,,
1056,Rv0667,118,RIF,rpoB,,,Prammananan T CMI 2008,,,,CCC/CAC,535,535,Pro/His,,2003-2005,,Thailand,Sequencing,Whole gene,MDR,N.S.,Proportion method,154/113,1/0,rpoB 526 CAC/AGC His/Ser,0,18294243,118,0,,,,,,
1057,Rv0667,119,RIF,rpoB,,,Wang Q JProtRes 2007,,,,CTG/CCG,538,538,Leu/Pro,,Published 1997,,China,Sequencing,Whole gene,R,N.S.,Proportion method  absolute concentration method,112/30,1/0,,0,17970586,119,30,,,,,,
1058,Rv0667,120,RIF,rpoB,,,Prammananan T CMI 2008,,,,GAG/GGG,541,541,Glu/Gly,,2003-2005,,Thailand,Sequencing,Whole gene,MDR,N.S.,Proportion method,154/113,1/0,rpoB 526 CAC/TAC His/Tyr,0,18294243,120,0,,,,,,
1059,Rv0667,121,RIF,rpoB,,,Pozzi G JCM 1999,,,,GAG/GAT,541,541,Glu/Gly,,Published 2002,MDR isolates from three clinical microbiology laboratories; 37 isolates  proven to be from different patients  analyzed for this study. N=37,Italy,Sequencing,RRDR,RH  RHS  RHSCip  RHSAmi  RHSZ  RHSZAmi  RHSCZ,32-128 ug/ml,Proportion method,37/37,(1/0),Triple mutation with CAC526GAC and TCG553GCG,0,10074552,121,0,,,,,,
1060,Rv0667,122,RIF,rpoB,,,Aslan G JpnJInfectDis 2008,,,,CTG/ATG,545,545,Leu/Met,,2003-2006,Isolates from patients in Mersin University hospital in southern Turkey,Turkey,Sequencing,RRDR,R or MDR,N.S.,BACTEC 460,19/41,3/0,rpoB S531A  katG S315T,0,18653964,122,0,,,,,,
1061,Rv0667,123,RIF,rpoB,,,Pozzi G JCM 1999,,,,TCG/GCG,553,553,Ser/Ala,,Published 2003,MDR isolates from three clinical microbiology laboratories; 37 isolates  proven to be from different patients  analyzed for this study. N=37,Italy,Sequencing,RRDR,RH  RHS  RHSCip  RHSAmi  RHSZ  RHSZAmi  RHSCZ,32-128 ug/ml,Proportion method,37/37,(1/0),Triple mutation with CAC526GAC and GAG541GAT,0,10074552,123,0,,,,,,
1062,Rv0667,124,RIF,rpoB,,,Ramaswamy SV J Med Micro 2004,,,,ATC/GTC,561,561,Ile/Val,(480 in ref) Objective: To identify resistance-associated mutations in this geographic area. Results: All 37 isolates resistant to INH; 36 resistant to RIF; 1 susceptible to RIF. 25 were resistant to STR; 18 resistant to EMB.13 resistant to ALL and 16 resistant to 3 drugs. Many are new mutations.,1996-1998,Subset of 186 strains initially isolated from patients who attended the Jose E. Gonzalez University Hospital TB clinic + 13 pan-susceptible isolates. N=50,Mexico,Sequencing,RRDR,RHSE,N.S.,Proportion method,37/50,(1/0),rpoB: Double mutation with 450 TCG/TTG; embB: 306 ATG/ATA,0,14729930,124,0,,,,,,
1063,Rv0667,125,RIF,rpoB,,,Heep M JCM 2001,,,,ATC/ACC,561,561,Ile/Thr,,1997,80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98,Germany,Sequencing,RRDR,N.S.,N.S.,Proportion method,111/111,(1/0),Double mutation with S456L,0,11136757,125,0,,,,,,
1064,Rv0667,126,RIF,rpoB,,,Hauck Y JAC 2009,,,,GAA/GGA,562,562,Glu/Gly,,Published 2009,126 RIF resistant isolates were recovered from 142 patients by the reference centre for mycobacteria of the Service de Sant des Armes in a total of 18 countries. This mutation confer low level RIF resistance,Various,Sequencing,RRDR,R,<1 ug/ml,MGIT 960,122/122,1/0,rpoB P564L,0,19520715,126,0,,,,,,
1065,Rv0667,127,RIF,rpoB,,,Hauck Y JAC 2009,,,,CCT/CTT,564,564,Pro/Leu,,Published 2009,126 RIF resistant isolates were recovered from 142 patients by the reference centre for mycobacteria of the Service de Sant des Armes in a total of 18 countries. This mutation confer low level RIF resistance,Various,Sequencing,RRDR,R,<1 ug/ml,MGIT 960,122/122,1/0,rpoB E562G,0,19520715,127,0,,,,,,
1066,Rv0667,128,RIF,rpoB,,,Heep M JCM 2001,,,,CTG/GTG,571,571,Leu/Val,,1997,80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98,Germany,Sequencing,RRDR,RHEZ,N.S.,Proportion method,111/111,(2/0),Double mutation with D441Y,0,11136757,128,0,,,,,,
1067,Rv0667,129,RIF,rpoB,,,Yuen LK JCM 1999,O'Sullivan DM JAntiChemo 2005,,,ATC/TTC,572,572,Ile/Phe,Objective: To develop a better understanding of the epidemiology and molecular biology of RIF-resistant strains in Australia Of note: 572 ATC/TTC lies outside of the 69 bp region.,1990-1997,51 clinical isolates collected from different reference laboratories in Australia: 17 RIF sensistive; 33 RIF resistant. N=50,Vietnam,Sequencing,RRDR,RHE,> 256 ug/ml,Resistance ratio method  BACTEC 460  E-test,33/50,(1/0),None,0,10565894,129,0,,,,,,
1068,Rv0667,130,RIF,rpoB,,,Chan RCY JAC 2007,,,,TCG/TTG,574,574,Ser/Leu,,1994-2004,250 resistant isolates (resistant to 5 anti-tiuberculosis drugs) - none had apparent clonal features + 50 susceptible controls + 2 reference strains: ATCC 27294 H37Rv and ATCC 25117 H37Rag. N=302 isolates,Hong Kong,PCR-SSCP  Sequencing,RRDR,RHEZ,>64 ug/ml,Absolute concentration method.,221/250,1,katG 311 Asp/Gly,0,17360809,130,30,,,,,,
1069,Rv0667,131,RIF,rpoB,,,Prammananan T CMI 2008,,,,TCG/GCG,622,622,Ser/Ala,,2003-2005,,Thailand,Sequencing,Whole gene,MDR,N.S.,Proportion method,154/113,1/0,rpoB 531 TCG/TTG ser/Leu,0,18294243,131,0,,,,,,
1070,Rv0667,132,RIF,rpoB,,,Heep M JCM 2001,,,,CGC/TGC,633,633,Arg/Cys,,1997,80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98,Germany,Sequencing,RRDR,RH,N.S.,Proportion method  BACTEC 460,111/111,(1/0),Double mutation with S456L,0,11136757,132,0,,,,,,
1071,Rv0667,133,RIF,rpoB,,,Heep M JCM 2001,,,,GAG/GAT,672,672,Glu/Asp,,1997,80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98,Germany,Sequencing,RRDR,RH  RHE  RHZ  RHEZ,N.S.,Proportion method  BACTEC 460,111/111,(7/0),Double mutation with S456W,0,11136757,133,0,,,,,,
1072,Rv3795,1,RIF,embB,,,Shi R AAC 2007,,,,TAT/CAT,333,333,Tyr/His,This mutation did not confer EMB resistance but were found in RIF and INH resistant isolates,,74 clinical isolates from Beijing Tuberculosis Resaerch Institute. N=74,China,Sequencing,N.S,RHS,50-250 ug/ml,Proportion method,24/74 but not clear about differences between mutations,,,0,17846128,134,0,,,,,,
1073,Rv3795,2,RIF,embB,,,Shi R AAC 2007,,,,TAT/GAT,319,319,Tyr/Asp,This mutation did not confer EMB resistance but were found in RIF and INH resistant isolates,,74 clinical isolates from Beijing Tuberculosis Resaerch Institute. N=74,China,Sequencing,N.S,RH,50-250 ug/ml,Proportion method,24/74 but not clear about differences between mutations,,,0,17846128,135,0,,,,,,
1074,Rv1908c,1,INH,katG,,,Baker LV AAC 2005,,,-1,ins C,-1,,Frameshift,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array  Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,CCC-CCG substitution at nt 723  Pro-Pro,0,15793126,136,0,,,,,,
1075,Rv1908c,2,INH,katG,,,Gagneux S PLOS Path 2006,,,1,GTG/TTG or GTG/CTG,1,1,Val/Leu,,,,,,,,,,,,,0,16789833,137,0,,,,,,
1076,Rv1908c,3,INH,katG,,,Heym B MolMicro 1995,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,2,GTG/GCG,1,1,Val/Ala,,1995,Isolates from patients of Pitie Salpietre hospital in France during 1991-92,Russia,PCR-SSCP  Sequencing,Whole gene,MDR,1,Proportion method,34/37,1/0,,0,7746145,138,0,,,,,,
1077,Rv1908c,4,INH,katG,,,Cockerill FR JID 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,4,CCC/TCC,2,2,Pro/Ser,no consistent correlation b/w loss of catalase activity and increasing INH inhibitory concentration,1995,clinical strains of mtb,USA  Japan,Sequencing,Whole gene,,0.12,Proportion method,40071,1/0,Ala65Thr  Ala66Pro  Met126Ile  Ala243Ser  Asn258Ser  Ala264Thr  Tyr337Phe,0,7798673,139,0,,,,,,
1078,Rv1908c,5,INH,katG,,,Siddiqi N AAC 2002,Hazbon MH AAC 2006,,30,del C,10,10,TRUNC 26aa,,1995-1998,North India hospitals National Mycobacterium Repository,India,Sequencing,nt 3-239 & 1187-1600,H HRO HR HROS,10ug/ml R  1ug/ml I  2ug/ml O 2ug/ml S,Proportion method,74/126,6/0,R463L KatG  S95T gyrA  H526R rpo  H526Y rpo  D516V rpo  S531L rpo  D94A gyrA  K121K rpsL,0,11796356,140,0,,,,,,
1079,Rv1908c,6,INH,katG,,,Cockerill FR JID 1995,,,,del 8bp,10,10,Frameshift,,1995,Isolates from the Mayo Clinic,USA,Sequencing,Whole gene,H,>32ug/ml,Proportion method,40071,1/0,Ala424Val and Ala550Asp in katG.,0,7798673,141,0,,,,,,
1080,Rv1908c,7,INH,katG,,,Siddiqi N AAC 2002,Hazbon MH AAC 2006,,31,ACC/GCC,11,11,Thr/Ala,,1995-1998,North India hospitals National Mycobacterium Repository,India,Sequencing,3-239 1187-1600,H R,10ug/ml R  1ug/ml I,Proportion method,74/126,1/0,R463L KatG  D516G rpo,0,11796356,142,0,,,,,,
1081,Rv1908c,8,INH,katG,,,Siddiqi N AAC 2002,Hazbon MH AAC 2006,,34,ACC/CCC,12,12,Thr/Pro,,1995-1998,North India hospitals National Mycobacterium Repository,India,Sequencing,nt 3-239 1187-1600,H,1ug/ml I,Proportion method,74/126,1/0,R463L KatG,0,11796356,143,0,,,,,,
1082,Rv1908c,9,INH,katG,,,Cockerill FR JID 1995,,,50,AGC/AAC,17,17,Ser/Asn,,1995,Isolates from the Mayo Clinic,USA,Sequencing,Whole gene,H,0.12-1ug/ml,Proportion method,40071,,Gly19Asp  Gln224Glu  Ala243Ser  Ala550Asp,0,7798673,144,10,,,,,,
1083,Rv1908c,10,INH,katG,,,Cockerill FR JID 1995,,,56,GGC/GAC,19,19,Gly/Asp,,1995,Isolates from the Mayo Clinic,USA,Sequencing,Whole gene,H,0.12ug/ml,Proportion method,40071,0/1,Pro2Ser  Ser17Asn  Gln224Glu  Ala243Ser  Ala550Asp,0,7798673,145,10,,,,,,
1084,Rv1908c,11,INH,katG,,,Ramaswamy SV J Med Micro 2004,,,85-1059,del,29,29-353,Truncation,,1996-1998,Jose Gonzalez hospital Mexico,Mexico,Directed Oligonucleotide array  Sequencing,codon 228-357,H R E,>=1% growth 0.2ug/ml I  40ug/ml R  4ug/ml S  2ug/ml E,Proportion method,37/50,1/0,nt 1238; T-C rrs,0,14729930,146,0,,,,,,
1085,Rv1908c,12,INH,katG,,,Siddiqi N AAC 2002,,,98,ins A,33,33,Truncation,,1995-1998,North India hospitals National Mycobacterium Repository,India,Sequencing,nt 3-239 & 1187-1600,HR HRS,10ug/ml R  1ug/ml I,Proportion method,74/126,4/0,S531W rpo  H526L rpo  R463L KatG  D516G rpo  H526R rpo,0,11796356,147,0,,,,,,
1086,Rv1908c,13,INH,katG,,,Siddiqi N AAC 2002,Hazbon MH AAC 2006,,103,AAC/GAC,35,35,Asn/Asp,,2002,Clinical isolates from patients referred to hospital.,India,Sequencing.,237bp + 414bp fragments,I IRSO,>1ug/ml,Proportion method,74/126,2/0,One mutant at katG Arg463Leu; both mutant at rpoB Asp516Val.,0,11796356,148,0,,,,,,
1087,Rv1908c,14,INH,katG,,,Siddiqi N AAC 2002,,,109,del G,37,37,TRUNC 45aa,,1995,North India hospitals National Mycobacterium Repository,India,Sequencing,nt 3-239 & 1187-1600,HRO HR,10ug/ml R  1ug/ml I 2ug/ml O,Proportion method,74/126,2/0,S531W rpo  S95T gyrA  L511L H526R rpo,0,11796356,149,0,,,,,,
1088,Rv1908c,15,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,114,TGG/TGA,38,38,Trp/STOP,,,,,,,,,,,,,0,16870753,150,0,,,,,,
1089,Rv1908c,16,INH,katG,,,Sekigushi J JCM 2007,,,143,CTG/CAG,48,48,Leu/Gln,,2007,Japan & Poland,Japan,Sequencing,Whole gene,,,Proportion method  BACTEC,38/138,1/0,-15C/T upstream of mabA,0,17596354,151,0,,,,,,
1090,Rv1908c,17,INH,katG,,,Baker LV AAC 2005,,,149,del A,50,50,Frameshift,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array  Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,ahpC-34A,0,15793126,152,0,,,,,,
1091,Rv1908c,18,INH,katG,,,Pretorius GS AAC 1995,,,157-168,del CCGTCGCTGACC,52,52-57,del Ala Val Ala Asp Pro,,1995,South Africa Switzerland  USA,USA,PCR-SSCP  Sequencing,1-221  202-338  319-558  541-741  722-942  923-1140  1120-1342  1323-1526  1507-1718  1699-1915  1896-2115  2096-2310,HR,1.0 ug/ml,Proportion method,39/69,1/0,,0,8619582,153,0,,,,,,
1092,Rv1908c,19,INH,katG,,,Siddiqi N AAC 2002,,,181,GCG/ACG,61,61,Ala/Thr,,1995-1998,North India hospitals National Mycobacterium Repository,India,Sequencing,nt 3-239 & 1187-1600,HRO,10ug/ml R  1ug/ml I  2ug/ml O,Proportion method,74/126,1/0,R463L KatG  S95T gyrA  S531L rpo,0,11796356,154,0,,,,,,
1093,Rv1908c,20,INH,katG,,,Siddiqi N AAC 2002,,,185,ins C,62,62,Truncation,,1995-1998,North India hospitals National Mycobacterium Repository,India,Sequencing,nt 3-239 & 1187-1600,HRS HO HR,10ug/ml R  1ug/ml I 2ug/ml O,Proportion method,74/126,3/0,S531W rpo  K121K rpsL  S95T gyrA H526R rpo,0,11796356,155,0,,,,,,
1094,Rv1908c,21,INH,katG,,,Rouse DA AAC 1995,Hazbon MH AAC 2006,,189,GAC/GAA,63,63,Asp/Glu,Catalase-negative clinical isolate.,1995,Clinical isolates.,USA  South Korea,PCR-SSCP  Sequencing,Whole gene,H,50ug/ml,Absolute concentration method.,26/26,1/0,,0,8585728,156,0,,,,,,
1095,Rv1908c,22,INH,katG,,,Marttila HJ AAC 1996,Ramaswamy S Musser JM Tubercle lung Dis 1998,,195,ins CCCC,65,65,Frameshift,,1989-1995,Finland,Finland,Sequencing,Whole gene,H,1ug/ml,Disk elution method,54/56,1/0,,0,8878604,157,0,,,,,,
1096,Rv1908c,23,INH,katG,,,Cockerill FR JID 1995,,,193,GCC/ACC,65,65,Ala/Thr,,1995,Isolates from the Mayo Clinic,USA,PCR  RFLP   Sequencing.,Whole gene,H,0.25ug/ml,Proportion method,40071,0/1,Ala66Pro and others in katG.,0,7798673,158,0,,,,,,
1097,Rv1908c,24,INH,katG,,,Cockerill FR JID 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,196,GCG/CCG,66,66,Ala/Pro,,1995,Isolates from the Mayo Clinic,USA,Sequencing,Whole gene,H,0.25ug/ml,Proportion method,40071,0/1,Ala65Thr  Met126Ile  Ala243Ser  Asn258Ser  Ala264Thr  Tyr337Phe,0,7798673,159,0,,,,,,
1098,Rv1908c,25,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,212,ATC/AAC,71,71,Ile/Asn,,,,,,,,,,,,,0,10645439,160,0,,,,,,
1099,Rv1908c,26,INH,katG,,,Chan RCY JAC 2007,,,,GAC/GGC,72,72,Asp/Gly,Error? Codon 71 is Ile. Codons 72 and 74 are both Asp  nt code GAC (mutate to GGC for Asn).,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,161,0,,,,,,
1100,Rv1908c,27,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,214,GAC/AAC,72,72,Asp/Lys,,,,,,,,,,,,,0,16870753,162,0,,,,,,
1101,Rv1908c,28,INH,katG,,,Siddiqi N AAC 2002,,,?,GAC/AAC,73,73,Asp/Asn,Error? Codon 73 is Val. Codons 72 and 74 are both Asp  nt code GAC (mutate to AAC for Asn).,1995,North India hospitals National Mycobacterium Repository,India,Sequencing,nt 3-239 & 1187-1600,H,1ug/ml I,Proportion method,74/126,1/0,R463L KatG,0,11796356,163,0,,,,,,
1102,Rv1908c,29,INH,katG,,,Chan RCY JAC 2007,,,220,GAC/TAC,74,74,Asp/Tyr,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,164,0,,,,,,
1103,Rv1908c,30,INH,katG,,,Chan RCY JAC 2007,,,221,GAC/GGC,74,74,Asp/Gly,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,165,0,,,,,,
1104,Rv1908c,31,INH,katG,,,Chan RCY JAC 2007,,,252,ATG/ATA,84,84,Met/Ile,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,166,0,,,,,,
1105,Rv1908c,32,INH,katG,,,Gagneux S PLOS Path 2006,,,253,ACC/CCC,85,85,Thr/Pro,,,,,,,,,,,,,0,16789833,167,0,,,,,,
1106,Rv1908c,33,INH,katG,,,Marttila HJ AAC 1998,,,263,CAG/CGG,88,88,Gln/Arg,,,,,,,,,,,,,0,9736581,168,0,,,,,,
1107,Rv1908c,34,INH,katG,,,Cockerill FR JID 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,270,TGG/TGA,90,90,Trp/STOP,no consistent correlation b/w loss of catalase activity and increasing INH inhibitory concentration,1995,clinical strains of mtb,USA  Japan,Sequencing,Whole gene,,>32; catalase 5 mm,Proportion method,40071,1/0,none,0,7798673,169,0,,,,,,
1108,Rv1908c,35,INH,katG,,,Ramaswamy SV AAC 2003,,,271,TGG/CGG,91,91,Trp/Arg,Codon 91 is TGG=Trp; mutation is Trp/Arg  most likely via TGG/CGG.,,38 epidemiologically unrelated INH-monoresistant and 86 INH-susceptible isolates,USA  Mexico,Sequencing,,,2,BACTEC radiometric method; E-test,38/121,1/0,D3G (srmR homolog),0,12654653,170,0,,,,,,
1109,Rv1908c,36,INH,katG,,,Gagneux S PLOS Path 2006,,,281,GAC/GGC,94,94,Asp/Gly,,,,,,,,,,,,,0,16789833,171,0,,,,,,
1110,Rv1908c,37,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,281,GAC/GCC,94,94,Asp/Ala,,,,,,,,,,,,,0,10645439,172,0,,,,,,
1111,Rv1908c,38,INH,katG,,,Chan RCY JAC 2007,,,?,GGC/TGC,96,96,Gly/Cys,Error? Codon 64 is Tyr; there is no Gly or GGC in vicinity on katG.,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,173,0,,,,,,
1112,Rv1908c,39,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,296,GGG/GAG,99,99,Gly/Glu,,,,,,,,,,,,,0,10645439,174,0,,,,,,
1113,Rv1908c,40,INH,katG,,,Rouse et al MM 1996,Hazbon MH AAC 2006,,311,CGG/CTG,104,104,Arg/Leu,site directed mutagenesis to create mutants.,1996,INH-resistant clinical isolates and in vitro mutants of katG in mtb,,,,,>500,N.S.,n/a,100 fold reduction in peroxidase activity,,0,8939440,175,0,,,,,,
1114,Rv1908c,41,INH,katG,,,Gagneux S PLOS Path 2006,,,311,CGG/CAG,104,104,Arg/Gln,,,,,,,,,,,,,0,16789833,176,0,,,,,,
1115,Rv1908c,42,INH,katG,,,Gagneux S PLOS Path 2006,,,317,GCG/GTG,106,106,Ala/Val,,,,,,,,,,,,,0,16789833,177,0,,,,,,
1116,Rv1908c,43,INH,katG,,,Gagneux S PLOS Path 2006,,,319,TGG/CGG or TGG/AGG,107,107,Trp/Arg,,,,,,,,,,,,,0,16789833,178,0,,,,,,
1117,Rv1908c,44,INH,katG,,,Baker LV AAC 2005,Hazbon MH AAC 2006,,321,TGG/TGA,107,107,Trp/STOP,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,ahpC-30T,0,15793126,179,0,,,,,,
1118,Rv1908c,45,INH,katG,,,Rouse et al MM 1996,Hazbon MH AAC 2006,,322,CAC/GAC,108,108,His/Asp,site directed mutagenesis to create mutants.,1996,INH-resistant clinical isolates and in vitro mutants of katG in mtb,,,,,,N.S,n/a,,,0,8939440,180,0,,,,,,
1119,Rv1908c,46,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,322 324,CAC/GAA or CAC/GAG,108,108,His/Glu,No single mutation turns His into Glu. Has to be CAC/GAA or CAC/GAG (2 nts changed each).,,,,,,,,,,,,0,10645439,181,0,,,,,,
1120,Rv1908c,47,INH,katG,,,Rouse DA AAC 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,324,CAC/CAG,108,108,His/Gln,site directed mutagenesis ,1995,Washington D.C  Bethesda  South Korea,USA  South Korea,PCR-SSCP  Sequencing,Whole gene,H,50,Absolute concentration method,26/26,1/0,,0,8585728,182,0,,,,,,
1121,Rv1908c,48,INH,katG,,,Gagneux S PLOS Path 2006,,,326,GCT/GTT,109,109,Ala/Val,,,,,,,,,,,,,0,16789833,183,0,,,,,,
1122,Rv1908c,49,INH,katG,,,Wei CJ AAC 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,,329,GCC/GTC,110,110,Ala/Val,site directed mutagenesis ,2003,,,,,H,,,,,,0,12543676,184,0,,,,,,
1123,Rv1908c,50,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,del,113,113,Frameshift?,Primary paper not found.,,,,,,,,,,,,0,10645439,185,0,,,,,,
1124,Rv1908c,51,INH,katG,,,Lavender C AAC 2005,,,350,GAC/GCC,117,117,Asp/Ala,,2001-2003,Victorian Infectious Diseases Reference Laboratory,Australia,Sequencing,Whole gene,HR,0.4 ug/ml I,BACTEC,52/104,1/0,,0,16189082,186,0,,,,,,
1125,Rv1908c,52,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,del,120,120,Frameshift?,Primary paper not found.,,,,,,,,,,,,0,10645439,187,0,,,,,,
1126,Rv1908c,53,INH,katG,,,Heym B MolMicro 1995,Musser Clin Microb Rev 1995,,358-369,del,120,120-123,del,,1995,Isolates from Pitries hospital in France 1991-92,Yugoslavia,PCR-SSCP  Sequencing,Whole gene,H,,Proportion method,34/37,2/0,,0,7746145,188,0,,,,,,
1127,Rv1908c,54,INH,katG,,,Gagneux S PLOS Path 2006,,,361,GGC/TGC,121,121,Gly/Cys,,,,,,,,,,,,,0,16789833,189,0,,,,,,
1128,Rv1908c,55,INH,katG,,,Marttila HJ AAC 1998,,,362,GGC/GTC,121,121,Gly/Val,,1993-1995,Clinical isolates,Russia,Sequencing.,Whole gene,HR,N/A,Proportion method,24/27,1/0,Asp516Val in rpoB,0,9736581,190,0,,,,,,
1129,Rv1908c,56,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,del,122,122,Frameshift?,Primary paper not found.,,,,,,,,,,,,0,10645439,191,0,,,,,,
1130,Rv1908c,57,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,del,123,123,Frameshift?,Primary paper not found.,,,,,,,,,,,,0,10645439,192,0,,,,,,
1131,Rv1908c,58,INH,katG,,,Ramaswamy SV AAC 2003,,,372,ins G,124,124,Frameshift,,,38 epidemiologically unrelated INH-monoresistant and 86 INH-susceptible isolates,USA  Mexico,Sequencing,,,>256,BACTEC 460  E-test,38/121,1/0,G-9A (oxyR-ahpC),0,12654653,193,0,,,,,,
1132,Rv1908c,59,INH,katG,,,Chan RCY JAC 2007,,,373,GGC/TGC,125,125,Gly/Cys,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,194,0,,,,,,
1133,Rv1908c,60,INH,katG,,,Heym B MolMicro 1995,Musser Clin Microb Rev 1995,,373-375,ins CAT,125,125,ins His,Error? Review paper says insertion was CAT  Ile - but CAT codes for His. Can't access primary paper (French).,1995,Isolates from Pitries hospital in France 1991-92,Yugoslavia,PCR-SSCP  Sequencing,Whole gene,H,,Proportion method,34/37,1/0,,0,7746145,195,0,,,,,,
1134,Rv1908c,61,INH,katG,,,Cockerill FR JID 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,378,ATG/ATT  ATG/ATC or ATG/ATA,126,126,Met/Ile,Multiple mutations are possible  could not verify the actual mutation of these isolates after contact with the authors. No consistent correlation b/w loss of catalase activity and increasing INH inhibitory concentration,1995,clinical strains of mtb,USA  Japan,Sequencing,Whole gene,,.025; catalase 14 mm,Proportion method,40071,1/0,A65T; A66P; A243S; N258S; A264T; Y337F,0,7798673,196,0,,,,,,
1135,Rv1908c,62,INH,katG,,,Chan RCY JAC 2007,,,380,CAG/CCG,127,127,Gln/Pro,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,197,0,,,,,,
1136,Rv1908c,63,INH,katG,,,Fang Z JCM 1999,Hazbon MH AAC 2006,,384,CGG/CCG,128,128,Arg/Pro,,1990-1997,Scottish Mycobacterial refererence lab,United Kingdom,PCR-SSCP  Sequencing,2268-2288&2595-2615   2781-2801&3115-3135  3366-3386& 3633-3653  3661-3681& 3973-3993,H E R P Rifa Cip Ami S Proth,,BACTEC 460,10/715,1/0,Leu511Pro rpoB,0,10074516,198,0,,,,,,
1137,Rv1908c,64,INH,katG,,,Hazbon MH AAC 2006,,Ramaswamy S Musser JM Tubercle lung Dis 1998,412,AAC/CAC,138,138,Asn/His,,2006,Australia  Colombia India  Mexica  New York city  Spain & Texas,USA  Spain,HP asay  molecular beacon assay   Sequencing,,H,0.2ug/ml proportion method  0.1 for BACTEC methods,Proportion method  BACTEC MGIT 960  BACTEC 460,403/1111,1/0,,0,11158123,199,0,,,,,,
1138,Rv1908c,65,INH,katG,,,Hazbon MH AAC 2006,,,412,AAC/GAC,138,138,Asn/Asp,,2006,Australia  Colombia India  Mexica  New York city  Spain & Texas,USA  Spain,HP asay  molecular beacon assay   Sequencing,,H,0.2ug/ml proportion method  0.1 for BACTEC methods,Proportion method  BACTEC MGIT 960  BACTEC 460,403/1111,2/0,,0,11158123,200,0,,,,,,
1139,Rv1908c,66,INH,katG,,,Hazbon MH AAC 2006,,Ramaswamy S Musser JM Tubercle lung Dis 1998,413,AAC/AGC,138,138,Asn/Ser,,2006,Australia  Colombia India  Mexica  New York city  Spain & Texas,USA  Spain,HP asay  molecular beacon assay   Sequencing,,H,0.2ug/ml proportion method  0.1 for BACTEC methods,Proportion method  BACTEC MGIT 960  BACTEC 460,403/1111,1/0,,0,11158123,201,0,,,,,,
1140,Rv1908c,67,INH,katG,,,Morlock GP AAC 2003,,,413,AAC/ACC,138,138,Asn/Thr,,2003,USA Russia  Brazil,USA  Russia  Brazil,Sequencing,Whole gene,H,>32ug/ml,Microplate alamar blue assay method,17/41,1/0,,0,14638486,202,0,,,,,,
1141,Rv1908c,68,INH,katG,,,Wei CJ AAC 2003,Ramaswamy S Musser JM Tubercle lung Dis 1998,,415,GCC/CCC,139,139,Ala/Pro,site directed mutagenesis ,2003,,,,,,,,,,,0,12543676,203,0,,,,,,
1142,Rv1908c,69,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,418-419?,AGC/GCC?,140,140,Ser/Ala,Primary paper not found. Has to be a double nt mutation (AGC/GCC) if residues correct.,,,,,,,,,,,,0,10645439,204,0,,,,,,
1143,Rv1908c,70,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,419,AGC/AAC,140,140,Ser/Asn,Primary paper not found.,2006,Australia  Colombia India  Mexica  New York city  Spain & Texas,USA  Spain,HP asay  molecular beacon assay   Sequencing,,,0.2ug/ml proportion method  0.1 for BACTEC methods,Proportion method  BACTEC MGIT 960  BACTEC 460,403/1111,9/0,,0,10645439,205,10,,,,,,
1144,Rv1908c,71,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,418,AGC/GGC,140,140,Ser/Gly,Primary paper not found.,,,,,,,,,,,,0,16870753,206,0,,,,,,
1145,Rv1908c,72,INH,katG,,,Hai Hua Lin TubercRespirDis 2007,,,420,AGC/AGA,140,140,Ser/Arg,,2004,,South Korea,Sequencing,Whole gene,MDR,N.S.,N.S,29/29,1/0,katG N238K,0,2007582629,207,10,,,,,,
1146,Rv1908c,73,INH,katG,,,Sekigushi J JCM 2007,,,423,TTG/TTC,141,141,Leu/Phe,,2007,Japan & Poland,Japan  Poland,Sequencing,Whole gene,,,Proportionmethod  BACTEC MGIT 960,38/138,2/0,,0,17596354,208,0,,,,,,
1147,Rv1908c,74,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,425,GAC/GCC,142,142,Asp/Ala,,,,,,,,,,,,,0,10645439,209,0,,,,,,
1148,Rv1908c,75,INH,katG,,,Gagneux S PLOS Path 2006,,,428,AAG/ACG,143,143,Lys/Thr,,,,,,,,,,,,,0,16789833,210,0,,,,,,
1149,Rv1908c,76,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,443,CTG/GCG,148,148,Leu/Ala,,,,,,,,,,,,,0,10645439,211,0,,,,,,
1150,Rv1908c,77,INH,katG,,,Rouse et al MM 1996,Hazbon MH AAC 2006,,443,CTG/CGG,148,148,Leu/Arg,site directed mutagenesis to create mutants.,1996,INH-resistant clinical isolates and in vitro mutants of katG in mtb,,,,,,N.S.,n/a,,,0,8939440,212,0,,,,,,
1151,Rv1908c,78,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,See Note,CCG/GCG?? See Note,150,150,Leu/Ala Error? See Note,Error?? Residue 150 is Pro (CCG); mutation could be Pro/Ala (CCG/GCG).,,,,,,,,,,,,0,10645439,213,0,,,,,,
1152,Rv1908c,79,INH,katG,,,Marttila HJ AAC 1998,,,464,TAC/TCC,155,155,Tyr/Ser,Paper doesn't confirm nts but says it is a point mutation  and this is the only single point mutation that works.,1993-1995,Russia,Russia,Sequencing.,Whole gene,HRSK,1 ug/ml I  5 ug/ml R,Proportionmethod,24/27,1/0,Arg463Leu katG      Ser 531Leu rpoB,0,9736581,214,0,,,,,,
1153,Rv1908c,80,INH,katG,,,Gagneux S PLOS Path 2006,,,464,TAC/TGC,155,155,Tyr/Cys,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,3,0,16789833,215,0,,,,,,
1154,Rv1908c,81,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,479,TCA/TTA,160,160,Ser/Leu,,,,,,,,,,,,,0,10645439,216,0,,,,,,
1155,Rv1908c,82,INH,katG,,,Gagneux S PLOS Path 2006,,,484,GCG/ACG,162,162,Ala/Thr,,,,,,,,,,,,,0,16789833,217,0,,,,,,
1156,Rv1908c,83,INH,katG,,,Cockerill FR JID 1995,,,506,GGC/GCC,169,169,Gly/Ala,,1995,Isolates from the Mayo Clinic,USA,Sequencing.,Whole gene,H,1ug/ml,Proportion method,40071,1/0,Pro2Ser  Ser17Asn  Met126Ile   Gln224Glu  Ala264Val  Ala281Val  Try337Cys  Arg463Leu,0,7798673,218,0,,,,,,
1157,Rv1908c,84,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,Ramaswamy S Musser JM Tubercle lung Dis 1998,514,GCG/ACG,172,172,Ala/Thr,,2006,Australia  Colombia India  Mexica  New York city  Spain & Texas,USA  Spain,HP asay  molecular beacon assay   Sequencing,,H,0.2ug/ml proportion method  0.1 for BACTEC methods,Agar Proportion method  BACTEC MGIT 960  BACTEC 460,403/1111,2/0,,0,16870753,219,0,,,,,,
1158,Rv1908c,85,INH,katG,,,Chan RCY JAC 2007,,,515,GCG/GTG,172,172,Ala/Val,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,220,0,,,,,,
1159,Rv1908c,86,INH,katG,,,Chan RCY JAC 2007,,,528,ATG/ATA,176,176,Met/Ile,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,3,0,17360809,221,0,,,,,,
1160,Rv1908c,87,INH,katG,,,Secondary Publication: Hazbon MH AAC 2006,Hazbon MH AAC 2006,,539,ACG/AAG,180,180,Thr/Lys,,,,,,,,,,,,,0,16870753,222,0,,,,,,
1161,Rv1908c,88,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,See Note,ACG/???,180,180,Thr/Cys,Primary paper not found. Has to be a triple nt mutation if residues correct.,,,,,,,,,,,,0,10645439,223,0,,,,,,
1162,Rv1908c,89,INH,katG,,,Chan RCY JAC 2007,,,557,GGC/GTC,186,186,Gly/Val,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,224,0,,,,,,
1163,Rv1908c,90,INH,katG,,,Chan RCY JAC 2007,,,556-557,GGC/CAC,186,186,Gly/His,Error? CAC codes for His not Tyr. This would be a double nt mut for His (GGC/CAC)  triple nt for Tyr (TAC or TAT).,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,225,0,,,,,,
1164,Rv1908c,91,INH,katG,,,Baker LV AAC 2005,,,571,TGG/CGG,191,191,Trp/Arg,,1998,records from National  laboratory Myco resistance network database,United Kingdom,Directed Oligonucleotide array   Sequencing,Whole gene,H HS HE HSE MDR,ratio>=4,Resistance ratio method,202/378,1/0,,0,15793126,226,0,,,,,,
1165,Rv1908c,92,INH,katG,,,Chan RCY JAC 2007,,,572,del G,191,191,Frameshift,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,227,0,,,,,,
1166,Rv1908c,93,INH,katG,,,Morlock GP AAC 2003,,,583,G/A,195,195,Glu/Lys,,2003,USA Russia  Brazil,USA,Sequencing,Whole gene,Eth,1,Microplate alamar blue assay,17/41,0/1,nt 280 T/G inh ORF,0,14638486,228,0,,,,,,
1167,Rv1908c,94,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,Hazbon MH AAC 2006,594,TGG/TGA,198,198,Trp/STOP,,,,,,,,,,,,,0,10645439,229,0,,,,,,
1168,Rv1908c,95,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,598,AAG/TAG,200,200,Lys/STOP,,,,,,,,,,,,,0,10645439,230,0,,,,,,
1169,Rv1908c,96,INH,katG,,,Abe C JCM 2008,,,,,204,204,Trp/Arg,,Published in 2008,,Japan,Sequencing,Whole gene,H,,MGIT 960,96/96,1/0,,0,18508939,231,0,,,,,,
1170,Rv1908c,97,INH,katG,,,Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998,Ramaswamy S Musser JM Tubercle lung Dis 1998,,?,ins,217,217,Frameshift?,Primary paper not found.,,,,,,,,,,,,0,10645439,232,0,,,,,,
1171,Rv1908c,98,INH,katG,,,Chan RCY JAC 2007,,,654,AAC/AAA,218,218,Asn/Lys,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,233,0,,,,,,
1172,Rv1908c,99,INH,katG,,,Cockerill FR JID 1995,Ramaswamy S Musser JM Tubercle lung Dis 1998,,670,CAG/GAG,224,224,Gln/Glu,no consistent correlation b/w loss of catalase activity and increasing INH inhibitory concentration,1995,clinical strains of mtb,USA  Japan,Sequencing,Whole gene,,1; catalase 8 mm,Proportionmethod,,1/0,Pro2Ser  Ser17Asn  Met126Ile  Gly169Ala  Ala264Val  Ala281Val  Try337Cys  Arg463Leu,0,7798673,234,0,,,,,,
1173,Rv1908c,100,INH,katG,,,Cockerill FR JID 1995,,,670,CAG/GAG,224,224,Gln/Glu,,1995,Isolates from the Mayo Clinic,USA,Sequencing,Whole gene,H,<0.12-1ug/ml,Proportion method,,39815,Ala424Glu  Pro429Ser,0,7798673,235,0,,,,,,
1174,Rv1908c,101,INH,katG,,,Ghiladi RA J Am Chem Soc 2005,,,686,TAC/TTC,229,229,Tyr/Phe,LAB MUTATION,,,,,,,,,,,,0,16173777,236,0,,,,,,
1175,Rv1908c,102,INH,katG,,,Chan RCY JAC 2007,,,689,GTG/GCG,230,230,Val/Ala,,1994-2004,All isolates exhibiting resistance to one or more drugs R I E P O from Grantham Hospital and Public Health Laboratory of Hong Kong.,Hong Kong,PCR-SSCP  Sequencing,Whole gene,N.S.,,Absolute concentration method,250,241,1,0,17360809,237,0,,,,,,
1198,MTB000019,1,AMI,rrs,,,Maus CE AAC 2005 Aug,,,1401,A/G,1401,,rRNA gene,Sequential mutant selection in vitro implicates rrs mutations as molecular basis of resistance to each of the four drugs tested: Kamycin  amikacin  capreomycin  and viomycin. Testing of 16 clinical isolates shows rrs and tlyA mutations responsible for r,Published 2005,M.tb laboratory strains used for in-vitro selection of mutants; clinical isolates obtained from CDC. N=16,USA,Sequencing,Whole gene,KAmiCap,K >80ug/ml  Ami >64ug/ml  CAP 20-80ug/ml,N.S.,16/16,11/0,9 isolates had no additional mutaitons; one had a mutation at rrs A514C; and one had a mutation at rrs A514C and T1239C.,0,16048924,1170,0,,,,,,
2202,Rv0667,1,RIF,rpoB,1,CJ,Heep M AAC 2000,O'Sullivan DM JAntiChemo 2005,,,GTC/TTC,146,146,Val/Phe,Comparison of equivalent mutation conferring RIF-resistance in Mtb and H. pylori,Published 2003,6 isolates from Japan for which MICs of rifampin were elevated but with wild-type sequence in the rpoB cluster region. N=6,Japan,Sequencing,Whole gene,R,1-4  8-32 ug/ml,N.S.,(6/6 || 3 high level of resistance / 6 total),(3/0),,0,10722516,1,0,,,,,,
2203,Rv0667,2,RIF,rpoB,0,CJ,Taniguchi H FEMS Micro 1996,,,,GCG/GTG,381,381,Ala/Val,,Published 1997,39 clinical isolates (including MDR-TB strains) from Koga Hospital  Nougata central hospital  and Fukuoka-Higashi hospital. N=39,Japan,Sequencing,Whole gene,R,200 ug/ml,Proportion method  absolute concentration method,21/39,(1/0),,0,8870258,2,0,,,,,,
